


&/,1,&$/678'<[ZIP_CODE]&2/
$'28%/(%/,1'3/$&(%2& [ZIP_CODE]//('5$1'2 0,=('75,$/
72678'<7+(9,$6.,10,/. ()),&$&<$1'6$)(7<)25
75($7,1*,J(0(',$7('&2:Â¶60,/.$//(5*<,1&+,/'5(1
0,/(6678'<

3URWRFRO1XPEHU 0,/(69
,1'1XPEHU  ,1'
,QYHVWLJDWLRQDO3URGXFW 9LDVNLQ0LON'%9
,QGLFDWLRQ ,PPXQRJOREXOLQ(,J(PHG LDWHG&RZÂ¶V0LON$OOHUJ\
3KDVH 3KDVH
6SRQVRU '%97(&+12/2*,(6
DYHQXH3LHUUH%URVVROHWWH
0RQWURXJH 
)UDQFH
,QWHUQHW ZZZGEYWHFKQRORJLHVFRP

&RQWUDFW5HVHDUFK
2UJDQL]DWLRQ6\QHRV+HDOWKIRUPHUO \,1&5HVHDUFK//&
%HHFKOHDI&RXUW
6XLWH 
5DOHLJK1& 
8QLWHG6WDWHV

3URWRFRO9HUVLRQDQG'DWH ,QLWLDO3URWRFRO)LQDO9HUVLRQ-XQH
$PHQGPHQW )LQDO9HUVLRQ 1RYHP EHU
$PHQGPHQW)LQDO9HUVLRQ-XO\
$PHQGPHQW )LQDO9HUVLRQ 6HSWHPEHU 
$PHQGPHQW )LQDO9HUVLRQ'HFHPEHU 
$PHQGPHQW)LQDO 9HUVLRQ 0D\
$PHQGPHQW )LQDO9HUVLRQ -XQH

&21),'(17,$/
7KLVSURWRFROPD\QRWEHUHSURGXFHGRUFRPPXQLFDWHGWRDWKLUG SDUW\ZLWKRXW
WKHZULWWHQSHUPLVVLRQRI'%97HFKQRORJLHV '%9[COMPANY_003]
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 2 of 170 
This page intentionally left blank  
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 4 of 170 
PROTOCOL SYNOPSIS  
 
Protocol 
Number:  MILES  (V135 -201) 
Title:  A Double -Blind, Placebo -Controlled Randomized Trial to Study the 
Viaskin MILk Efficacy and Safety for Treating IgE -Mediated Cowâ€™s 
Milk Allergy in Children (MILES  Study)  
Investigational 
Product:  Viaskin Milk  (DBV135)  
Indication : Immunoglobulin E ( IgE)-mediated cowâ€™s milk allergy  
Number of 
Study Centres : Seventeen  sites in North America ([LOCATION_002] and Canada)  
Phase:  Phase 1/2 
Objectives:  The objectives of this study are : 
â€¢ To evaluate the safety and efficacy of Via skin Milk after 
12 months of epi[INVESTIGATOR_24873] ( EPIT ) 
treatment, for desensitizing IgE -mediated cowâ€™s milk -allergic 
children.  
â€¢ To assess the long -term safety and efficacy of up to 48 
months of tr eatment with Viaskin Milk.  
â€¢ To assess the safety and the therapeutic benefit of the most 
effective tested dose of Viaskin Milk over 24 months of 
treatment.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 5 of 170 
Study Design:  This is a multi -center , double -blind, placebo -controlled, randomized 
trial to study the safety and efficacy of Via skin Milk applied 
epi[INVESTIGATOR_322159] 2  to 17 years  of age  with 
IgE-mediated cowâ€™s milk allergy (CMA) . Viaskin Milk is a patch 
containing an ex tract of cowâ€™s milk proteins. Subjects will receive  
blinded  treatment  for 1 year at one of the 3 doses of Viaskin Milk : 
[ADDRESS_397614] dose of Viaskin Milk , 500 Âµg, 
and continue treatment in an open -label  manner for up to a 
maximum of 3 additional years.   
Following results of the 12 -month blinded period, all eligible 
subjects who wish to continue participation in the study will  switch  
from Viaskin Milk 500  Âµg to Viask in Milk 300 Âµg for 24 months of 
treatment.  
The study will be conducted at 17 sites in the U nited States  and 
Canada , with selected Investigator s and staff experienced in the 
diagnosis and management of CMA and anaphylaxis , and who are 
capable of performing  a double -blind placebo -controlled food 
challenge (DBPCFC) in children  (2 to 11  years old) and adolescents 
(12 to 1 7 years old) . 
Eligible subjects with confirmed IgE -mediated CMA will perform a 
first DBPCFC at screening with escalating doses of cowâ€™s milk 
proteins . Subjects showing a positive DBPCFC at screening, 
defined as the appearance of objective signs or symptoms to an 
eliciti ng dose of cowâ€™s milk proteins  â‰¤300  mg (a pproximately  9.4 mL 
of cowâ€™s milk) will be randomized in the study.  
The study will be divided into 2 consecutive parts (Part  A and 
Part B) for randomization of the su bjects to treatment.  
Part A will evaluat e the saf ety of 3  escalating doses of Viaskin Milk 
(150 Âµg, 300  Âµg, and 500  Âµg of cowâ€™s milk proteins ) versus  placebo  
in successive cohorts of subjects before proceeding to Part B . In 
each cohort, evaluation of safety will be based on safety data 
collected and analyzed from subjects treated for [ADDRESS_397615] 3  weeks of treatment, Part A subjects will 
not discontinue treatment but instead will continue treatment up to 
Month 12, at which time  subjects  will undergo a second D BPCFC.  
Part B is designed to evaluate the efficacy and safety of the 3  doses 
of Viaskin Mil k (150 Âµg, 300  Âµg, and 500  Âµg of cowâ€™s milk protein , 
assessed  to be safe from Part A) versus  placebo . Subjects will be 
randomized to receive a 12  month treatment (blinded treatment 
period), at which time a second DBPCFC will be performed.  The 
efficacy of V iaskin Milk will be assessed based on data po oled from 
subjects in both Part  A and Part  B, treated up to Month  12. 
After the Month  [ADDRESS_397616] 
DBPCFC was to  be performed at Month  24. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 6 of 170 
 After Month 24, eligible subjects from Part A or Part B were t o be 
proposed to enter the study extension to receive 2 additional years 
of EPIT with open -label Viaskin Milk at 500  Âµg. For subjects 
entering the study extension , a fourth and fifth DBPCFC were  to be 
performed at Month  36 and Month  48, respectively. Following 
results of the 12 -month blinded period, DBPCFC procedures were 
stopped while the subjects were still receiving Viaskin Milk 500  Âµg. 
After implementation of Protocol Amendment 5 , all subjects will 
recei ve Viaskin Milk 300 Âµg for 24 months , independently of the 
duration of previous treatment with Viaskin Milk 500  Âµg. For 
subjects switching to Viaskin Milk 300  Âµg, a n optional  DBPCFC may 
be performed after 12 and /or [ADDRESS_397617] . 
A final End -of-Study (EOS) visit will be performed for all subjects 
when they complete the study. The EOS visit was to take place 
[ADDRESS_397618] cowâ€™s milk -free diet with no consumption of 
dairy products or baked milk products until their EOS  visit (except 
during the DBPCFC s). 
Number of 
Subjects:  Approximately 194 subjects (18 subjects in P art A and 1 76 subjects 
in Part  B) will be randomized to treatment in thi s study.  
The number of subjects continuing  beyond the Month  24 visit and/or 
in the treatment period  with Viaskin Milk 300  Âµg will depend on the 
study extension  eligibility criteria and the willingness of subjects t o 
continue  in the study . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 8 of 170 
Study 
Population : The inclusion  and exclusion  criteria for study entry are listed below.  
Inclusion Criteria:  
1. Signed Informed Consent Form (ICF) by 
[CONTACT_7078](s)/guardian(s) of subjects and informed assent form 
(IAF) for subjects â‰¥[ADDRESS_397619] cowâ€™s milk -free diet, with 
no consumption of dairy or baked milk products.   
5. Cowâ€™s milk sIgE level at screening â‰¥10  kU/L  
6. Positive Skin Prick Test (SPT) to cowâ€™s milk with a largest 
wheal diameter â‰¥6  mm. 
7. Positive DBPCFC at screening w ith an eliciting dose 
â‰¤300  mg cowâ€™s milk proteins (approximately â‰¤9.4  mL of 
cowâ€™s milk).  
8. Negative urine pregnancy test for female subjects of 
childbearing potential.  Female subjects of childbearing 
potential must agree and commit to use effective  medical  
methods of contraception for the entire duration of their 
participation in the study. Sexual abstinence will be 
accepted as an effective method of contraception for girls 
below 15  years of age.  
9. Ability to perform spi[INVESTIGATOR_322160] (2005) for 
subjects â‰¥6  years  old. Ability to perform peak expi[INVESTIGATOR_10229] 
(PEF) measurements  for subjects â‰¥ 5 years  old. Subjects 
<[ADDRESS_397620] documented inability to 
adequately perform spi[INVESTIGATOR_322161] m only the PEF 
evaluation. Subjects <5 years of age may be enrolled if they 
had no clinical features of moderate or severe persistent 
asthma severity (as defined by [CONTACT_941] 2007 National Heart, 
Lung, and Blood Institute [NHLBI]  Guidelines) within 1 year 
before Visit  1. 
10. Subjects and/or parents/guardians willing to comply with all 
study requirements during participation in the study . 
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
6WXG\
3RSXODWLRQ
FRQWLQXHG ([FOXVLRQ&ULWHULD
 +LVWRU\RIVHYHUHDQDSK\OD[L VWRFRZ
VPLONUHVXOWLQJLQ
K\SRWHQVLRQK\SR[LDRUQHXURO RJLFDOFRPSURPLVHFROODSVH
ORVVRIFRQVFLRXVQHVVR ULQFRQWLQHQFHRUUHTXLULQJPHFKDQLFDO
YHQWLODWLRQ
 3UHJQDQF\RUODFWDWLRQ
 6SLURPHWU\IRUFHGH[SLUDWRU\YROXPHLQ VHFRQG)(9 
RIWKHSUHGLFWHGYDOXHDW 9LVLWIRUVXEMHFWVÂ• \HDUVDQGDEOH
WRSHUIRUPWKHVSLURPHWU\RU3() RISUHGLFWHGYDOXHDW
9LVLWIRUVXEMHFWVSH UIRUPLQJRQO\WKH3() PHDVXUHPHQWV
$Q\FOLQLFDOIHDWXUHVRIPRGHUDWHRUVHYHUHSHUVLVWHQWDVWKPD
VHYHULW\DVGHILQHGE\WKH1+/%,JXLGHO LQHVDQGKLJK
GDLO\GRVHVRILQKDOHGF RUWLFRVWHURLGVVHH $SSHQGL[ 
 .QRZQDOOHUJ\WRWKH9 LDVNLQSDWFKPDWHULDOV RUH[FLSLHQWVRUWR
DQ\RIWKHFRPSRQHQWVRIWKHIRRGFKDOOHQJHIRUPXODV RWKHU
WKDQWKHFRZÂ¶VPLONSURWHLQV
$OOHUJ\RUNQRZQKLVW RU\RIUHDFWLRQWR PHGLFDO
GUHVVLQJZLWKQRSRVVLELOLW\W RXVHDQDOWHUQDWLYHDGKHV LYH
GUHVVLQJDXWKRUL]HGE\WKHV SRQVRULQUHSODFHPHQW 
 6XEMHFWVKDYLQJREMHFWLYHV\PSWRPV WRWKHSODFHERIRUPXOD
OHDGLQJWRVWRSSLQJWKHFKDOOHQJHGXULQJWKHVFUHHQLQJ
'%3&)&
6HYHUHUHDFWLRQGXULQJWKHVFUHHQLQJ'%3&)&GHILQHGDVQHHG
IRULQWXEDWLRQDQGRUK\SRWH QVLRQSHUVLVWLQJDIWHU HSLQHSKULQH
DGPLQLVWUDWLRQDQ GRUWKHQHHGIRU! GRVHVRIHSLQHSKULQH
 6\PSWRPDWLFDOOHUJ\WRSROOHQVZLWK V\PSWRPVGXULQJWKHSROOHQ
VHDVRQWKDW PLJKWLQWHUIHUHZLWKWKHV\PSWRPVREVHUYHGGXULQJ
WKH'%3&)&LIWKH'%3&)&LVSHUIRUPHGGXULQJWKHSROOHQ
VHDVRQ6FUHHQLQJRIVXFKVXEM HFWVVKRXOGEHPDGHRXWRIWKH
SROOHQVHDVRQ
,QDELOLW\WRGLVFRQWLQXHVKRUWDFWLQJDQWLKLVWDPLQHVIRU GD\VRU
ORQJDFWLQJDQWLKLVWDPLQHVIRUWR GD\VGHSHQGLQJRQWKH
KDOIOLIHEHIRUHWKH '%3&)& 
8VHRIV\VWHPLFORQJDFWLQJFRUWLFRVWHURLGVZLWKLQ ZHHNV
EHIRUH9LVLWDQGRUXVHRIV\VWHPLFVKRUWDFWLQJ
FRUWLFRVWHURLGVZLWKLQZHHNV EHIRUH9LVLWRUXVHRI V\VWHPLF
ORQJDFWLQJRUVKRUW DFWLQJFRUWLFRVWHURLGVGXULQJVFUHHQLQJ
XQOHVVXVHGWRWUHDWV\PSWRPVW ULJJHUHGE\WKH'%3&)& RU
WULJJHUHGE\DFFLGHQWDODOOHUJHQFRQVXPSWLRQLQWKH ODWWHUFDVH
'%3&)&PXVWWKHQEHVFKH GXOHGDIWHUDPLQLPXP RI
ZDVKRXWGD\VC
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 10 of 170 
Study 
Population 
(continued):  12. Subjects with asthma conditions meeting  1 or several criteria 
below: 
â€¢ Uncontrolled persistent asthma (as defined by [CONTACT_941] 
2007 NHLBI guidelines) or subject is being treated 
with a combination therapy of medium or high daily 
dose of inhaled corticosteroid with a long acting 
inhaled Î²2 -agonist. Intermittent asthmatic subjects 
who require intermittent use of inhaled 
corticosteroids for rescue are permitted.  
â€¢ At least 2 systemic corticosteroid courses for asthma 
within 1  year before  Visit 1 or 1 oral corticosteroid 
course for asthma within  3 months before  Visit 1, or 
during screening  (unless used to treat symptoms 
triggered by [CONTACT_322242]) . 
â€¢ Prior intubation /mechanical ventilation due to asthma 
within 2  years before  Visit 1, or during screening.  
13. Upper respi[INVESTIGATOR_322162] 7  days of 
DBPCFC (DBPCFC must then be rescheduled  at least 7 days 
after resolution o f these conditions ). 
14. Any history of milk immunotherapy (eg , oral immunotherapy, 
sublingual immunotherapy or specific oral tolerance induction).  
15. Prior  history of any other food allergen immunotherapy (eg , oral 
immunotherapy, sublingual immunotherapy or specific oral 
tolerance induction) within [ADDRESS_397621] be discontinued at the time 
of Visit  1. 
17. Use of any anti -IgE drug (e g, omalizumab), any 
immunomodulatory therapy, or any biological agent therapy 
(eg, anti-tumor necrosis factor drugs) within 1  year before  
Visit 1, or during screening.  
18. Generalized dermatologic diseases ( eg, severe atopic 
dermatitis, uncontrolled generalized eczema, icthyosis vulgaris) 
with no intact zones to apply the Viaskin patch , or urticarial and 
mast cell disorders such as chr onic idiopathic urtica ria. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 11 of 170 
Study 
Population 
(continued):  19. Subject and/or subjectâ€™s parents/guardians with obvious 
excessive anxiety and unlikely to cope with the conditions of a 
food challenge.  
20. Past or current disease, including but not limited to active 
eosinophilic gastrointestinal disorders, autoimmune disorders, 
immunodeficiency, malignancy, uncontrolled disease 
(hypertension, diabetes, psychiatric disorder, cardiac disease), 
or other disorders (eg, liver, gastrointestinal, kidney, 
cardiovascular, pulmo nary disease or blood disorder) which in 
the opin ion of the Investigator or the s ponsor may affect the 
subjectâ€™s participation in the study or place the subject at 
increased risk.  
21. Subjects and/or parents/guardians unable to use the 
epi[INVESTIGATOR_107528] -injecto r properly in spi[INVESTIGATOR_322163].  
22. Contraindicated condition for the use of epi[INVESTIGATOR_238].  
23. Use of any investigational drug or device, or participation in 
another interventional clinical stu dy within 3 months before 
Visit 1. 
24. Subjects receiving  beta-blockers or angiotensin converting -
enzyme inhibitors.  
25. Subjects unable to follow the protocol requirements.  
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 12 of 170 
Eligibility  
Criteria for  
Study 
Extension  with 
Viaskin Milk 
500 Âµg (Month s 
24 to 48) :  
 The inclusion and exclusion criteria for entry  in the study exten sion 
up to Month  48 are listed below.  
Inclusion Criteria:  
1. Signed study extension ICF by [CONTACT_7078]( s)/guardian(s) of 
subjects and informed assent form  for subjects â‰¥[ADDRESS_397622] 2 years in MILES, including a 
complete documented DBPCFC at Month  24. 
Note: following results of the 12 -month blinded period, Month 
24 DBPCFC should not be  performed anymore. Inclusion 
criterion #2 becomes  â€œSubjects who completed the first 2 years 
in MILESâ€  
3. Negative urine pregnancy test at Month [ADDRESS_397623] cowâ€™s milk -
free diet, with no consumption of dairy or baked milk products 
during participation in the study (except during the DBPCFC s). 
5. Subjects and/or parents/guardians willing to  comply with all 
study requirements during participation in the study  extension . 
 
Exclusion Criteria:  
1. Any n ew disorder or disease that may affect the subjectâ€™s 
participation in the study, or place the subject at increased risk, 
or for which epi[INVESTIGATOR_322164] . 
2. Poor c ompliance in patch application  (below 80% ), defined as 
patch not applied at all  for >73 days (either consecutive or not) 
during  the second year of participation in MILES . 
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 13 of 170 
Eligibility  
Criteria for  the 
switch to 
Viaskin Milk 
300 Âµg: Inclusion Criteria:  
1. Signed ICF by [CONTACT_7078](s)/guardian(s) of subjects and informed 
assent form for subjects â‰¥[ADDRESS_397624] cowâ€™s milk -
free diet, with no consumption of dairy or baked milk products 
during participation in the stud y (except during the DBPCFCs).  
4. Subjects and/or parents/guardians willing to comply with all 
study requirements during participation.  
 
Exclusion Criteria:  
1. Any new disorder or disease that may affect the subjectâ€™s 
participation in the study, or place the sub ject at increased risk, 
or for which epi[INVESTIGATOR_322165].  
2. Poor compliance in patch application (below 80%) during the 
previous  year of participation in MILES.  
 
Primary 
Endpoint:  The primary efficacy endpoint will be the percentage (%) of subjects 
who are treatment responders aft er the first [ADDRESS_397625] 
one of the following criteria:  
â€¢ A â‰¥10 -fold increase in the Cumulative Reactive Dose (CRD) 
of cowâ€™s milk proteins at the Month  [ADDRESS_397626] 144  mg of 
cowâ€™s milk proteins (approximately 4.5  mL of milk)  
â€¢ A CRD of cowâ€™s milk proteins â‰¥1444  mg (approximately 
45 mL of milk ) at the Month  12 DBPCFC.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 14 of 170 
Secondary 
Endpoints:  Secondary Efficacy Endpoints  up to Month 12 (double -blind, 
placebo -controlled treatment period) : 
â€¢ The mean and median CRD of cowâ€™s milk proteins at 
Month  12 and change from baseline.  
â€¢ The change from baseline value in levels of sIgE and 
allergen -specific immunoglobulin G4 (sIgG4) to cowâ€™s milk at 
all timepoints evaluated up to Month  12. 
â€¢ The change from baseline value in levels of sIgE and sIgG4 
to caseins, Î± -lactalbumin, and Î² -lactoglobulin at all 
timepoints evaluated up to Month  12.  
â€¢ The change from baseline in SPT wheal at all timepoints 
evaluated up to Month  12. 
â€¢ The change in the severity of symptoms elicited during the 
milk DBPCFC from baseline to Month  12.  
â€¢ The change from baseline in Quality of Li fe (QoL) 
assessments at Month  12. 
Endpoints after Month 12 (open -label treatment periods with 
Viaskin Milk 500  Âµg up to 48 months  and Viaskin Milk 300 Âµg 
for 24 months) : 
â€¢ The percentage (%) of subjects who are treatment 
responders over the course of open -label treatment with 
Viaskin Milk 500  Âµg and 300 Âµg .  
â€¢ The CRD of cowâ€™s milk proteins over the course of open -
label treatment with Viaskin Milk 500  Âµg and 300 Âµg . 
â€¢ The levels of sIgE to cowâ€™s milk over the course of open -
label treatment with Viaskin Milk 500  Âµg and 300 Âµg . 
â€¢ The levels of sIgG4 to cowâ€™s milk proteins over the course of 
open -label treatment with Viaskin Milk 500 Âµg.  
â€¢ The levels of sIgE and sIgG4 to caseins, Î± -lactalbumin, and 
Î²-lactoglobulin over the course of open -label treatment with 
Viaskin Milk  500 Âµg and 300 Âµg .  
â€¢ The SPT wheal over the course of open -label treatment with 
Viaskin Milk 500  Âµg and 300 Âµg . 
â€¢ The severity of symptoms elicited during the milk DBPCFC 
over the course of open -label treatment with Viaskin Milk 
500 Âµg and 300 Âµg  
â€¢ The QoL ass essments over the course of open -label 
treatment with Viaskin Milk 500  Âµg and 300 Âµg . 
Sponsor: DBV Technologies  
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential Page 15 of 170 
Safety Endpoints:  
â€¢Adverse Events (AEs) and Treatment -Emergent Adverse
Events (TEAEs) by [CONTACT_9313] , preferred term ,
maximum severity , and relatedness  to the investigational
product .
â€¢Serious Adverse Events (SAEs) and Treatment -Emergent
Serious Adverse Events (TESAEs) by [CONTACT_9313] ,
preferred term , severity , and relatedness  to the
investigational product .
â€¢TEAEs leading to study di scontinuation, and relatedness  to
the investigational product .
â€¢Incidence, duration , and maximum severity of local
cutaneous reactions , as assessed by [CONTACT_423] .
â€¢Severity of local cutaneous reactions , as assessed by [CONTACT_33316].
â€¢Adverse Events of Spec ial Interest (AESI) including
systemic allergic symptoms  and local AESI
â€¢Frequency and severity of symptoms elicited during the
DBPCFC.
â€¢Vital signs, physical examinations , and laboratory data .
â€¢Spi[INVESTIGATOR_322166].
Exploratory Endpoint s: 
â€¢The change from baseline in ep igenetic modifications at
Month  12, if evaluated
â€¢Epi[INVESTIGATOR_322167] -label
treatment with Viaskin Milk 500  Âµg and 300 Âµg, if evaluated .
â€¢The r elationship between the presence of filaggrin
mutations , safety, and response to treatment .
â€¢The change from baseline value in  levels of s IgE to peanut,
egg, house dust mite , and grass pollen .
â€¢Enumeration and characterization of reactions triggered by
[CONTACT_322243]â€™s milk (in any form) during
the study.
â€¢Analysis of â€œr isk-taking behaviorâ€ of subjects (voluntary milk
consumption) during the study .
â€¢Planned  management of the  subject after termination of the
study.
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397627]  ................................ ................  25 
3.1.2  Part A  ................................ ................................ ...........................  26 
3.1.3  Part B  ................................ ................................ ...........................  26 
3.1.4  Open -label treatment periods with Viaskin Milk 500 Âµg and 
Viaskin Milk 300  Âµg ................................ ................................ ....... 27 
3.1.5  Summary Study Design Flow Charts  ................................ ............  28 
3.2 Discussion of Study Design  ................................ ................................ ........  33 
4 Selection of Subjects and Criteria for Withdrawal  ................................ .............  33 
4.1 Number of Planned Subjects  ................................ ................................ ....... 33 
4.2 Eligibility Criteria for Study Enrollment  ................................ ......................  33 
4.2.1  Inclusion Criteria  ................................ ................................ ...........  33 
4.2.2  Exclusion Criteria  ................................ ................................ ..........  34 
4.3 Eligibility Criteria for Study Extension (Months 24 to 48)  ..........................  36 
4.3.1  Inclusion Criteria  ................................ ................................ ...........  36 
4.3.2  Exclusion Criteria  ................................ ................................ ..........  36 
4.4 Eligibility criteria for the switch to Viaskin Milk 300 Âµg  .............................  37 
4.4.1  Inclusion Criteria  ................................ ................................ ...........  37 
4.4.2  Exclusion Criteria  ................................ ................................ ..........  37 
4.5 Removal of Subjects from Therapy or Assessments  ................................  37 
5 Investigational Products  ................................ ................................ ......................  38 
5.1 Drug Substance  ................................ ................................ ............................  38 
5.2 Investigational Products Administered  ................................ ......................  38 
5.3 Investigational Products Storage  ................................ ................................  39 
5.4 Packaging and Labelling  ................................ ................................ .............  39 
6 Administration of Study Treatments  ................................ ................................ ... 39 
6.1 Method of Assigning Subjects to Treatment Groups  ................................  39 
6.2 Selection of Doses in the Study  ................................ ................................ .. 39 
6.3 Administration of Study Treatments to Subjects  ................................ ....... 40 
6.3.1  Blinded Treatment Period  ................................ .............................  41 
6.3.2  Open -label Treatment Period  ................................ ........................  42 
6.4 Blinding  44 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 17 of 170 
6.5 Prior and Concomitant Therapy  ................................ ................................ .. 44 
6.5.1  Prior and Concomitant Therapy Records and 
Recommendations  ................................ ................................ ........  44 
6.5.2  Prohibited Concomitant Treatments and Procedures:  ...................  45 
6.5.3  Permitted Concomitant Treatments and Procedures:  ....................  [ADDRESS_397628] Disposition  ................................ ................................ ..... 109 
8.1.4  Demographic and Other Baseline Characteristics  .......................  109 
8.1.5  Concomitant Medications  ................................ ............................  109 
8.1.6  Efficacy  ................................ ................................ .......................  109 
8.1.7  Safety Variables  ................................ ................................ ..........  113 
8.1.8 Exploratory Variables  ................................ ................................ .. 116 
8.2 Interim Analyses  ................................ ................................ .........................  117 
8.3 Determination of Sample Size  ................................ ................................ ... 117 
8.4 Randomization Procedures  ................................ ................................ ....... 118 
Random Sequencing of the Challenge Formulas During the DBPCFC  ........  118 
9 Quality Assurance and Quality Control  ................................ ............................  119 
9.1 Audit and Inspection  ................................ ................................ ..................  119 
9.2 Monitoring  ................................ ................................ ................................ ... 119 
9.3 Data Management and Coding  ................................ ................................ .. 119 
10 Records and Supplies  ................................ ................................ ........................  120 
10.1  Drug Accountability  ................................ ................................ ...................  120 
10.2 Financing and Insurance  ................................ ................................ ...........  121 
11 Ethics  ................................ ................................ ................................ ..................  122 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397629] Confidentiality  ................................ ................................ ...............  123 
12 Study Administration, Reporting and Publication, Including Archiving  ........  124 
12.1  Study Administration  ................................ ................................ .................  124 
12.2 Reporting and Publication, Including Archiving  ................................ ...... 125 
13 References  ................................ ................................ ................................ ..........  126 
14 Appendices  ................................ ................................ ................................ .........  128 
14.1  Investigator Signature [CONTACT_3490]  ................................ ................................ ...... 129 
14.2  Oral Food Challenge Symptom Score Sheets  ................................ ..........  130 
14.3  Quality of Life Questionnaire Forms  ................................ .........................  134 
14.3.1  Food Allergy Quality of Life Questionnaire -Child Form 
(FAQLQ -CF) ................................ ................................ ...............  134 
14.3.2  Food Allergy Quality of Life Questionnaire -Teenager Form 
(FAQLQ -TF)................................ ................................ ................  139 
14.3.3  Food Allergy Quality of Life Questionnaire â€“ Parent Form 
for Children (FAQLQ -PF) ................................ ............................  144 
14.3.4  Food Allergy Quality of Life Questionnaire â€“ Parent Form 
for Teenagers (FAQLQ -PFT)  ................................ ......................  150 
14.4  Anaphylaxis Staging System  ................................ ................................ ..... 156 
14.5  Anaphylaxis Emergency Action Plan  ................................ ........................  157 
14.6  Inhalation Corticosteroid Dose Conversion Table by [CONTACT_71329]  ...... 158 
14.7  Wash -Out Periods for Short -Acting and Long -Acting Antihistamines 
Based on Terminal Elimination Half -Life ................................ ..................  160 
14.8  Declaration of Helsinki  ................................ ................................ ...............  161 
14.9  Reference Safety Information for the Cowâ€™s Milk Food Challenge in 
the MILES study  ................................ ................................ .........................  170 
 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397630] OF ABBREVIATIONS  
ACE = Angiotensin -Converting Enzyme  
AE = Adverse Event  
AESI  = Adverse Event of Special Interest  
ALT = Alanine Aminotransferase  
ANCOVA  = Analysis of Covariance  
AST = Aspartate Aminotransferase  
BDRM  = Blinded Data Review Meeting  
BMI = Body Mass Index  
BUN  = Blood Urea Nitrogen  
Â°C = Degrees Celsius  
CFR = Code of Federal Regulations  
cGCP  = Current Good Clinical Practice  
CMA  = Cowâ€™s Milk Allergy  
CSR  = Clinical Study Report  
CRD  = Cumulative Reactive Dose  
CRO  = Contract Research Organization  
CTD  = Cumulative Tolerated Dose  
DBPCFC  = Double -Blind Placebo -Controlled Food Challenge  
DBV = DBV Technologies  
DSMB  = Data and Safety Monitoring Board  
eCRF  = Electronic Case Report Form  
EDC  = Electronic Data Capture  
EDS = Epi[INVESTIGATOR_322168] D elivery System  
EOS  = End-of-Study  
EPIT  = Epi[INVESTIGATOR_322169] = Early Termination  
FAS = Full Analysis Set  
FDA = Food and Drug Administration  
FEV 1 = Forced Expi[INVESTIGATOR_1814] 1 Second  
FAIM  = Food A llergy Independent Measure  
FAQLQ -CF = Food Allergy Quality of Life Questionnaire â€“ Child Form  
FAQLQ -PF= Food Allergy Quality of Life Questionnaire â€“ Parent Form  
FAQLQ -PFT=  Food Allergy Quality of Life Questionnaire â€“ Parent Form 
Teenagers  
FAQLQ -TF = Food Allergy Quality of Life Questionnaire â€“ Teenager Form  
FU = Follow -up 
GMP  = Good Manufacturing Practice  
GSP  = Global Safety and Pharmacovigilance  
h = Hour(S)  
IAF = Informed Assent Form  
ICF = Informed Consent Form  
ICH = International Conference on Harmonisation  
IgE = Immunoglobulin E  
IgG4  = Immunoglobulin G4  
IP = Investigational Product  
IRB = Institutional Review Board  
ITT = Intent -to-Treat  Set 
i.v. = Intravenous  
IWRS  = Interactive Web Response System  
LOCF  = Last Observation Carried Forward  
MedDRA     = Medical Dictionary for Regulatory Activities  
MMRM       =                 M ixed Model Repeated Measures  
n = Number of subjects with an observation  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 20 of 170 
N = Number o f subjects in the dataset or population  
NHLBI  = National Heart , Lung , and Blood Institute  
OFC  = Oral Food Challenge  
OLS = Open -label Set  
PC = Placebo Controlled  
PEF = Peak Expi[INVESTIGATOR_322170] = Per Protocol Set  
QA = Quality Assurance  
QoL = Quality of Life  
RBC  = Red Blood Cell  
SAE = Serious Adverse Event  
SAP = Statistical Analysis Plan  
SD = Standard Deviation  
sIgE = Allergen -Specific Immunoglobulin E   
sIgG4  = Allergen -Specific Immunoglobulin G4  
SOC  = System Organ Class  
SOP  = Standard Operating Procedure  
SPT = Skin P rick Test  
SS = Safety Set  
S[LOCATION_003]R  = Suspected Unexpected Serious Adverse Reaction  
TEAE  = Treatment -Emergent Adverse Event  
TESAE  = Treatment -Emergent Serious Adverse Event  
WBC = White Blood C ell 
WHO Drug  = World Health Organisation  Drug Dictionary  
WMA  = World Medical Association  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397631] up to 6% of young 
children  and 3 to 4% of adults , and appears to have an increasing prevalence .1,2 
Allergic reactions to food can result from  different immunologic mechanisms including 
immunoglobulin E ( IgE)-mediated reactions (acute onset), non -IgE cell -mediated 
reactions (delayed or chronic onset) or a combination of both. Food allerg ies lead  to a 
large variety of clinical symptoms involving the skin , and/or the gastrointestinal and 
respi[INVESTIGATOR_322171] , and the cardiovascular system . Of these  food allergy  symptoms , 
those  described as anaphylactic shock can be life -threatening and require  a rapid 
admission to an emergency room.  
Cowâ€™s milk allerg y (CMA) is the most common food allergy in infants and young 
children, with an incidence of approximately 2 to 3% in developed countries .3,[ADDRESS_397632] shown that the prognosis for developi[INVESTIGATOR_322172]â€™s milk is good, 
with a majority of pa tients outgrowing their CMA by [CONTACT_14898] [ADDRESS_397633] that the resolution rate of CMA is approximately  
50% by 5  years  of ag e.8,9 The low levels of allergen -specific IgE (sIgE) to cowâ€™s milk 
and milk skin prick test (SPT) wheal size have been shown to be good predictors of 
resolution , while high levels of cowâ€™s milk sIgE have been shown to be predictors of 
persistence of C MA.,,[ADDRESS_397634] avoidance of the 
responsible allergen(s). This is especially challenging for cowâ€™s milk , which is widely 
included  in many dairy products, and also in smaller amounts in other manufactured 
food products. Consequently, th e risk of accidental allergic reactions in children allergic 
to cowâ€™s milk represents a major health concern, and the frequency of accidental 
exposure, some leading to severe reactions, could reach 40% in children over a 
12-month peri od.[ADDRESS_397635] of oral immunotherapy or sublingual 
immunotherapy for the treatment of CMA; these studies have shown some efficacy in 
increasing the quantity of cowâ€™s milk consumed.12,13 However, occurrences of local 
adverse events ( AEs), as well as systemic, potentially serious reactions during the 
course of oral immunotherapy are common.,[ADDRESS_397636] in some cases within 1 week off 
therapy. Thus, developi[INVESTIGATOR_322173] a clear unmet medical need.  
DBV Technologies (DBV) is developi[INVESTIGATOR_007] a novel product for the treatment of CMA. The  
investigational product , Viaskin Milk (DBV  135) consists of an epi[INVESTIGATOR_322174] a patch (Viaskin delivery system) , containing a solid deposit of 
formulated milk protein extract . Epi[INVESTIGATOR_24873] (EPIT), consisting of 
repeat ed applications of the patch containing the allergen to intact skin, is a novel 
method under investigation for the treatment of foo d allergies . 
The rationale for testing EPIT in humans for the treatment of CMA is based on the 
following:  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 22 of 170 
1. EPIT has shown evidence of clinical benefit in animal and early human studies, 
especially in the pediatric population  with CMA . 
2. EPIT provides a ready -to-use and easy -to-administer form of allergen 
immunotherapy, particularly well -adapted to the pediatric p opulation.  
3. EPIT can directly target the immunocompetent cells (such as the Langerhans 
and Dendritic cells) in a nonvascularized environment (ie , the epi[INVESTIGATOR_49196]).  
EPIT is expected to have a better safety profile than the other forms of immunotherapy 
due to t he slow delivery of large allergenic macromolecules in the epi[INVESTIGATOR_322175], 
hence reducing notably the risk of systemic distribution of the allergen.  EPIT has been 
shown to be well tolerated and could represent a very promising approach for the 
treatment of CMA.  
1.2 Nonclinical Studies  
Several nonclinical studies support the clinical development of Viaskin Milk . These 
include  an efficacy study in milk -sensitized mice, toxicolo gy studies (including 
repeat -dose, genotoxicity and tolerance studies), as well as biocompatibility studies 
performed with the Viaskin alone.   
The overall results of the studies support the conclusion that no toxic effects are 
expected with Viaskin Milk. Details regarding nonclinical studies with Viaskin Milk  are 
available in the Investigatorâ€™s Brochure .15  
1.3 Clinical Studies  
A brief summary of clin ical study information for Viaskin Milk is included below. Refer to 
the Viaskin Milk (DBV 135) Investigatorâ€™s Brochure  for additional d etails re garding 
clinical studies with Viaskin Milk . 
A pi[INVESTIGATOR_2268] 3 -month clinical study entitled â€œEfficacy of a new epi[INVESTIGATOR_322176]â€™s milk tolerance in children with cowâ€™s milk protein allergy: a pi[INVESTIGATOR_11480]â€ has been completed (study #SV 782). The clinical study report (CSR) of this 
pi[INVESTIGATOR_322177] .[ADDRESS_397637]Â® 
diagno stic product.  Diallertest is a ready -to-use cowâ€™s milk allergen atopy patch test 
that has been made available by [CONTACT_322244] 
[ADDRESS_397638] kit includes one control patch and one 
allergen patch containing 500 Âµg of skimmed cowâ€™s milk powder (approximately 150 Âµg 
cowâ€™s milk protein).  
Children aged between 3 months to 15 years and with cowâ€™s milk protein sIgE 
>0.35  kU/L a nd/or a positive SPT  to cowâ€™s milk protein plus an oral milk challenge were 
eligible for  participation in the study. If the oral cowâ€™s milk challenge was positive at a 
dose <10 mL, the subjects were randomized (1:1) to receive active treatment  patch 
(containing 1 mg of cowâ€™s milk powder)  or placebo . Each patch was applied on the 
posterior tru nk in the inter -scapular space of the children for 48 hours, 3 times a week. 
The total duration of the blinded therapy was 3  month s, followed by [CONTACT_3440] -label 
dosing up to an additional 6  months. The primary efficacy criterion was the maximal 
cumulative tolerated dose (CTD) of cowâ€™s milk (in  mL) after 3  months of  the blinded 
treatment . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 23 of 170 
The mean  age ï‚± standard deviation ( SD) of the subjects enrolled in this study was 
3.82 ï‚± 2 years (range:  from 10 months to 7 years  and 8 months). A total of 9  children  
treated with the active patch and 7  children treated with placebo were incorporated in 
the per protocol analysis. An oral food challenge with cowâ€™s m ilk was performed at 
baseline (Day 0) and after 3  months (D ay 90) of blinded treatment. The maxim al CTD 
of milk increased from a mean  ï‚± SD of 1.77  ï‚± 2.98 mL at Day 0 to 23.61  ï‚± 28.61  mL at 
Day 90 in the active treatment group; in the active gro up, CTD slightly decreased in 
1 patient and increased by >10-fold in 2 patients and >100-fold in 3  patients a fter the 
EPIT treatment. T he mean CTD did not change in the placebo group (4.36  ï‚± 5.87 mL 
at Day 0 to 5.44  ï‚± 5.88 mL at Day 90). Although this preliminary study failed to 
demonstrate a statistically significant improvement of the CTD (likely due to the limited 
number of subjects  and short duration of the treatment period ), subjects  treated  with 
the active patch demonstrated increased tolerance to milk exposure.  
No child required interruption of treatment because of an AE and none received 
epi[INVESTIGATOR_238]. No serious adverse events  (SAEs)  were reported during the trial. Overall, 
repeated application of the active patch was safe and well tolerated  in this study .  
In summary, the results of the pi[INVESTIGATOR_322178]â€™s milk EPIT demonstrate d a 
favorable  safety pro file, a clear trend toward clinical efficacy , and suggest ed that longer  
treatment periods might be appropriate.   
1.4 Study Rationale  
This study is designed to evaluate the safety and efficacy of repeated doses of Viaskin 
Milk delivered epi[INVESTIGATOR_322179] -mediated CMA. The goal s 
of developi[INVESTIGATOR_322180] : 
â€¢ To protect subjects with IgE -mediated CMA from the risk of severe reactions, in 
particular severe anaphylactic reactions, in case of accidental exposure to cowâ€™s 
milk. 
â€¢ To permit or accelerate the re -introduction of cowâ€™s milk and other dairy 
products into the diet of cowâ€™s milk -allergic subjects.  
2 Study Objectives  
The objectives of this study are : 
1. To evaluate the safety and efficacy of Via skin Milk to induce desensitiz ation to 
cowâ€™s milk in IgE-mediated cowâ€™s milk -allergic children  after [ADDRESS_397639] effective tested 
dose of Viaskin Milk over 24 months of treatment.  
3 Investigational Plan  
3.1 Overall Study Design and Plan  
This is a multi -center , double -blind, placebo -controlled, randomized trial to study the 
safety and efficacy of Via skin Milk applied epi[INVESTIGATOR_322181]: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397640] of cowâ€™s milk proteins. The placebo treatment will consist of a Viaskin patch 
containing a similar formulat ion without cow â€™s milk proteins. The study will be  
conducted at 17 sites in the [LOCATION_002] and Canada , with selected Investigator s and 
staff experienced in the diagnosis and management of CMA and anaphylaxis , and who 
are capable of performing a double -blind placebo -controlled food challenge (DBPCFC) 
in children  (2 to 11 years old) , adolescents (12 to 17 years old) . 
Eligible subjects with confirmed IgE -mediated CMA will perform a first DBPCFC at 
screening with escalating doses of cowâ€™s milk proteins. Subj ects showing a positive 
DBPCFC at screening, defined as the appearance of objective signs or symptoms to 
an eliciting dose of cowâ€™s milk proteins â‰¤300  mg (approximately 9.4  mL of cowâ€™s milk) 
will be randomized in the study.  
Double -blind, placebo -controlled  treatment period up to Month 12  
The study was divided in to 2 consecutive parts  for randomization of the subjects to 
treatment : Part A and Part  B. Part A  initially permit ted an evaluation of  the safety of 
3 escalating doses of Viaskin Milk  (150 Âµg, 300  Âµg, and 500  Âµg cowâ€™s milk proteins ) 
versus  placebo  in successive cohorts of subjects before proceeding to Part B . Part B 
permit ted an evaluation of the efficacy and safety of the 3 safe dose s of Viaskin Milk  
(150 Âµg, 300  Âµg and 500  Âµg of cowâ€™s milk protein , as assessed from the safety data in 
Part A subjects ) versus  placebo . The efficacy of Viaskin Milk was assessed based on 
data pooled from subjects in both Part A and Part B. Details of subject enrol lment and 
the treatments administered for each par t of the study are provided in Section  3.1.2  for 
Part A and in Section  3.1.3  for Part  B.  
In both Part  A and Part  B of the study , subjects  were  randomized to receive treatment 
with Viaskin Milk versus  placebo for 12 months (blinded treatment period) , at which 
time a second DBPCFC was performed. The primary  analysis of this study was 
conducted after data h ave been collected up to Month  [ADDRESS_397641] dose  selected (500 Âµg of cowâ€™s milk protein), based on safety data in Part A 
subjects. A third D BPCFC was to be performed at Month 24.  
After Month 24, all eligible subjects from Part A and Part B were to be proposed to 
enter the study extension to receive 2 additional years of EPIT with open -label Viaskin 
Milk at 500  Âµg (see eligibility criteria i n Section  4.3). For subjects entering the study 
extension , the fourth and fifth DBPCFC s were to be performed at Month  [ADDRESS_397642] effective tested dose was 
the Viaskin Milk 300  Âµg, and that this dose was safe1. Given that all subjects were 
currently receiving the 500 -Âµg dose , all subjects will switch from Viaskin Milk 500  Âµg to 
                                                
1 Refer to the Investigatorâ€™s Brochure  of Viaskin Milk  for details about results of the 12 -month 
blinded  period.  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
9LDVNLQ0LONÂ—JIRUPRQW KVLQGHSHQGHQWO\ RIWKHGXUDWLR QRISUHYLRXVWUHDWPHQW
ZLWK9LDVNLQ0LONÂ—J
6XEMHFWVZLOOFRQWLQXHWRUHFHLYH9LDVNLQ0LONÂ—JXQWLOWKH \FDQVZLWFKWR9LDVNLQ
0LONÂ—J1R'%3&)&VDUHWREHSHUIRUPHGZKLOHWKHVXEMHFWV DUHVWLOOUHFHLYLQJ
9LDVNLQ0LONÂ—J2QFHWKHU HJXODWRU\DSSURYDOVDUHUHFHLYHG DQGWKH9LDVNLQ0LON
Â—JLVDYDLODEOHDWWKHLQY HVWLJDWLRQDOVLWHVVXEMHFWVZLOO FRPHIRUDVZLWFKYLVLWWR
UHFHLYH9LDVNLQ0LONÂ—JIRUDGGLWLRQDOPRQWKV$'%3&)& FDQEHSHUIRUPHG
DIWHUDQGRUPRQWKVRIWUHDWPHQWZLWK9LDVNLQ0LONÂ—J EXWZLOOEHRSWLRQDO
7KHVXEMHFWVZKRGHFOLQHWRFRQ WLQXHLQWKHVWXG\WRUHFHLYH9L DVNLQ0LONÂ—JZLOOEH
GLVFRQWLQXHGDQGZLOOSHUIRUPDQ(26RUDQHDUO\WHUPLQDWLRQ( 7YLVLWVHH 6HFWLRQ

$ILQDO(QGRI6WXG\(26YLVLWZLOOEHSHUIRUPHGIRUDOOVXEM HFWVZKHQWKH\FRPSOHWH
WKHVWXG\)RUVXEMHFWVZKRFRPSOHWHWKHVWXG\DW0RQWKRIW KHRSHQODEHOWUHDWPHQW
SHULRGZLWK9LDVNLQ0LONÂ—JWK H(26YLVLWZLOOWDNHSODFH GD\VÂ“GD\VDIWHU9LVLW
)RUVXEMHFWVZKRZLOOVZLWFKWR9LDVNLQ0LONÂ—JWKLV( 26IROORZXSYLVLWZLOOWDNH
SODFHZHHNVDIWHUWKHHQGRIWKHWUHDWPHQWSHULRG
$OOVDIHW\DQGHIILFDF\GDWDFROOHFWHGGXULQJWKHHQWLUHVWXG\ ZLOOEHUHSRUWHGLQDILQDO
&65
6XEMHFWVDUHWRUHPDLQRQDFRZÂ¶V PLONIUHHGLHWZLWKQRFRQVXP SWLRQRIGDLU\SURGXFWV
RUEDNHGPLONSURGXFWVGXULQJWKHLUHQWLUHSDUWLFLSDWLRQLQWKH VWXG\H[FHSWGXULQJ
'%3&)&SURFHGXUHV$QDQDS K\OD[LVHPHUJHQF\SODQZLOOEHGHVLJQHGIRUWKLVVWXG\
DQGSURYLGHGWRWKHVXEMHFWVVHH $SSHQGL[ IRUDQH[DPSOH $QHSLQHSKULQHDXWR 
LQMHFWRU ZLOODOVREHJLYHQWRHDFKVXEMHFW
DW9LVLWWREHXVHGDFFRUGLQJ WKHDQDSK\OD[LVHPHUJHQF\SODQ 
7KHWRWDOGXUDWLRQRIWKHVWXG \ZLOOEHDSSUR[LPDWHO\\HDUV 7KHWRWDOGXUDWLRQRI
SDUWLFLSDWLRQLQWKHVWXG\ZLOOGLIIHUIRUHDFKVXEMHFWGHSHQG LQJRQZKHQWKH\VZLWFKWR
9LDVNLQ0LONÂ—JDQGFRXOG EHXSWRDSSUR[LPDWHO\\HDUV 
)ORZFKDUWVVX[COMPANY_003]UL]LQJWKHSURFHVV RIHQUROOPHQWLQWRHDFKSDU WRIWKHVWXG\DQGWKH
RYHUDOOVWXG\GHVLJQDUHSUHVHQWHGL Q6HFWLRQ 
 'DWDDQG6DIHW\0RQLWRULQJ%RDUG
$QLQGHSHQGHQW'DWDDQG6DIHW\ 0RQLWRULQJ%RDUG'60%FRPSRVHG RIH[SHUWVLQ
IRRGDOOHUJ\DQGLQWKHPHWKRGRORJ\RIFOLQLFDOWULDOVZLOOEH IRUPHGWRPRQLWRUWKHVDIHW\
GDWDIRUWKLVVWXG\7KLV'60%ZLOOEHLQGHSHQGHQWRIWKHVSRQV RUDQGZLOOUHYLHZ
VDIHW\GDWDIURPWKHVWXG\DW VSHFLILHGLQWHUYDOVGXULQJWKHVW XG\DQGRQDQ DGKRF
EDVLVDVGHHPHGQHFHVVDU\E\WK H'60%&KDLURUZKHQFRQYH\HGE \WKHVSRQVRU
7KH'60%ZLOOUHYLHZEOLQGHGGDWDEXWPD\KDYHDFFHVVWRXQEOL QGHGGDWDDVGHHPHG
QHFHVVDU\E\WKH'60%PHPEHUV
7KHGDWDUHYLHZE\WKH'60%PHPEHUVZLOOHQVXUHWKDWVDIHW\RI 9LDVNLQ0LONDWD
VSHFLILFGRVHLVDVVHVVHGEHIRUHHVFDODWLQJWRWKHQH[WKLJKHVW GRVHRI9LDVNLQ0LONLQ
3DUW$RIWKHVWXG\7KH'60%PHPEHUVZLOODOVRUHYLHZWKHFXPX ODWLYHVDIHW\GDWD
FROOHFWHGIURPDOOVXEMHFWVLQ3DUW $WRGHWHUPLQHWKH9LDVNLQ 0LONVDIHW\SURILOHDWHDFK
RIWKHGRVHOHYHOVHYDOXDWHGL Q3DUW$WRKHOSWKHVSRQVRULQ VHOHFWLQJWKHGRVHVWREH
XVHGLQ3DUW%7KHUROHVUHVS RQVLELOLWLHVFRQVWLWXWLRQDQGR SHUDWLRQVRIWKH'60%ZLOO
EHGHVFULEHGLQWKH'60%&KDU WHUZKLFKZLOOEHUHYLHZHGDQGVL JQHGE\HDFKPHPEHU
RIWKH'60%CCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 26 of 170 
3.1.2  Part A    
In Part A  of the study , the safety of 3 escalating doses of Viaskin Milk , 150 Âµg, 300  Âµg, 
and 500  Âµg cowâ€™s milk proteins , will initially be assessed over a 3 -week treatment 
period . Subjects will be randomized into 3 successive cohorts of 6 subjects each to 
receive either Viaskin Milk or placebo in a 2:1 ratio.  
Cohort  1 (150 Âµg dose group ): a total of 6 subjects will be randomized (2:1 ratio) to 
receive either Viaskin Milk at  150 Âµg (n=4) or placebo (n=2). Safety d ata will be  
collected and  analyzed  after [ADDRESS_397643] dose of Viaskin 
Milk. 
Cohort  2 (300 Âµg dose group ): the screening of subjects in Cohort  [ADDRESS_397644] will be randomized and treated 
in this cohort before the review of the DSMB from the previous cohort has been 
completed  and the DSMB rec ommendation made . The same process as described 
above for Cohort  1 will be repeated : a total of 6  additional subjects will be randomized 
(2:1 ratio) to receive Viaskin Milk at 300 Âµg (n=4) or placebo (n=2). Safety data after 
[ADDRESS_397645] dose of Viaskin Milk.  
Cohort  3 (500 Âµg dose group ): the screening of subjects in C ohort [ADDRESS_397646] will be randomized and treated 
in this cohort before the review of t he DSMB from the previous cohort has been 
completed  and the DSMB recommendation made . The same process as described 
above for Cohorts  1 and 2  will be repeated : a total of 6  additional s ubjects will be 
randomized (2:1  ratio) to receive Viaskin Milk at 500 Âµg (n=4) or placebo (n=2). 
Safety data after 3 weeks of treatment will be collected and analy zed. In parallel, 
cumulative safety data from subjects in the previous Cohorts  1 and 2  will also be 
collected and made availa ble for review  by [CONTACT_4318].  The DSMB will assess 
whether this dose of 500 Âµg is also safe.  
All subjects in Part A will continue their blinded treatment  at their assigned initial dose 
of treatment  (150 Âµg, 300 Âµg, or 500 Âµg Viaskin Milk or placebo) up to Mo nth 12. 
3.1.3  Part B   
After t he analysis of the cumulative safety data of Part A subjects , the 3 doses of 
Viaskin Milk  (150 Âµg, 300  Âµg, and 500  Âµg of cowâ€™s milk protein ) were kept to study the 
efficacy of Viaskin Milk in a placebo -controlled dose -finding Part B of the study.  
The s creening of subjects in Part  B may start after enrollment  in Part A is complete ; 
however,  none of the  subject s screened in Part  B can be randomized and treated 
before the review of the safety data from Part A subjects has been completed by [CONTACT_322245] ( FDA).  
A pause in the randomization will allow for this safety review to occur and 
recommendations to be release d. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 27 of 170 
In Part B, approximately  176 additional subjects will be randomized (1:1 :1:1 ratio) to 
receive Viaskin Milk 150 Âµg (n=44) , Viaskin Milk 300 Âµg  (n=44) , Viaskin Milk 500 Âµg 
(n=44) , or placebo (n=44) up to Month  12. 
3.1.[ADDRESS_397647] dose selected (500  Âµg of cowâ€™s milk protein), based on the safety 
data of Part A subjects.  
Subjects who terminated the study at Month [ADDRESS_397648], the re-introduction of milk into the diet as early as possible (eg, 
baked milk products or dairy prod ucts) or the initiation of  different therapi[INVESTIGATOR_322182] a 
preferred option  for other subjects . For this purpose, all eligible subjects from Part A 
and Part B (see eligibility criteria  in Section  4.3) were proposed to enter into the 
open -label study extension, to receive [ADDRESS_397649] s who enter ed the study extension were to continue their treatment up to 
Month  48 and to perform additional DBPCFC s at Month 36 and at Month 48.  
Following results of the 12 -month blinded period , the DBPCFCs that were to be 
performed at Month 24, Month 36 and Month 48 should not be conducted while 
the subjects are still receiving Viaskin Milk 500  Âµg.  
Switch to Viaskin Milk 300  Âµg 
Following results of the 12 -month blinded  period , all eligible subjects will switch from 
Viaskin Milk 500  Âµg to Viaskin Milk 300  Âµg for 24 additional months, independently of 
the duration of  previous  treatment with Viaskin Milk 500  Âµg: 
â€¢ Subjects who will decline to switch to  Viaskin Milk 300  Âµg will be discontinued 
from the study and an ET visit or an EOS visit will be performed (see Section  
7.2.3 ); 
â€¢ Subjects who will switch to Viaskin Milk 300  Âµg will be treated for 24 additional 
months : 
o Until Visit S1 is performed and the subjects start with Viaskin Milk 
300 Âµg, they will continue to receive Viaskin Milk 500  Âµg. No DBPCFC 
should  be performed while the subjects are still receiving Viaskin Milk 
500 Âµg. 
o Subjects will then follow  a dedicated study flowchart  (see Table 6 and 
Table 7), 
o Optional DBPCFCs can be performed after 12 and /or 24 months of 
treatment , 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397650] comply with the standardized 
methodology defined in  Section [IP_ADDRESS] . Standardized milk and placebo 
food c hallenge formula and material as well as the Manual of 
Procedures will be provided to all sites  and must be used for conducting 
the food challenge.  
When performed, the results of these  food challenge(s) will be 
documented and reported in the e -CRF.  
o The EOS  visit will take place [ADDRESS_397651] 
cowâ€™s milk -free diet with no consumption of dairy products or baked milk products until 
their final study visit (except during DBPCFC). At the end of participation in the study, 
the re -introduction of milk products (eg, dairy products or baked milk products) into the 
subjectâ€™s diet, or the decision to keep the subject under a strict cowâ€™s milk -free diet will 
be left to the Investigatorâ€™s discretion.  
3.1.5  Summary Study Design Flow Charts  
[IP_ADDRESS]  Process Summary of Enrollment  
Figure 1 presents a summa ry of the enrollment  process into Part  A and Part  B of the 
study.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 30 of 170 
Figure 3 presents a summary of the study design for the open -label treatment period 
with Viaskin Milk 300  Âµg.
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 31 of 170 
Figure 2: Overview  of the Study Design  for Part A, Part B and the open -label treatment  period  with Viaskin Milk 500  Âµg as was planned before Protocol 
Amendment 5  
 
 
 
Abbreviations:  D=day; FU=follow -up; M=month; DBPCFC=Double -Blind Placebo  Controlled Food Challenge;  
 
Following results of the 12 -month blinded period, Month 24, Month 36 and Month 48 DBPCFCs should not be performed while the subjects are 
still receiving Viaskin Milk 500  Âµg. 
  

Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 32 of 170 
Figure 3. Overview of stud y design  for the open -label treatment period with Viaskin Milk 300  Âµg 
 
 
Abbreviations:  FU=follow -up; M=month; DBPCFC=Double -Blind Pl acebo Controlled Food Challenge.  

Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397652] in 
children and adolescent  subjects  with IgE-mediated CMA. Randomization and double -
blinding are used to minimize bias in treatment allocation and in the assessment of 
both safety and efficacy during the double -blind treatment period. Randomization and 
double -blinding also minimize s bias arising from the  expectations of subjects  and/or 
their parent(s)/guardian(s), the Investigator s, and from individuals who collect  the study  
data. 
An open -label extension at the highest safe dose based on the safety data collected 
during the Part A and B was initia ted. The selected dose before the  availability of  
efficacy data was the Viaskin Milk [ADDRESS_397653] efficacious dose was determined to be the Vias kin Milk 300  Âµg. This dose was 
shown to be safe. Consequently, all subjects will switch over to this dose for an 
additional treatment period  of 24 months . 
4 Selection of Subjects and Criteria for Withdrawal  
4.1 Number of P lanned Subjects  
Approximately 194 children and adolescent subjects will be rando mized in th is study , 
18 subjects in Part A and 1 76 subjects  in Part B.  The screen failure rate is anticipated 
to be around 35%, therefore  approximately 300 subjects may be screened in the study.  
4.2 Eligibility Criteria  for Study Enrol lment  
4.2.1  Inclusion Criteria  
1. Signed Informed Consent Form (ICF) by [CONTACT_7078](s)/guardian(s) of subjects and 
informed assent  form (IAF)  for subjects â‰¥[ADDRESS_397654] cowâ€™s milk -free diet, with no cons umption of 
dairy or baked milk products.   
5. Cowâ€™s milk sIgE level at screening â‰¥10 kU/L.  
6. Positive SPT to cowâ€™s milk with a largest wheal diameter â‰¥6  mm. 
7. Positive DBPCFC at screening with an eliciting dose â‰¤300 mg cowâ€™s milk 
proteins (a pproximately  â‰¤9.4 mL of cowâ€™s milk).  
8. Negative urine pregnancy test for female subjects of childbearing potential. 
Female subjects of childbearing potential must agree and commit to use 
                                                
2 Refer to the Investigatorâ€™s Brochure  of Viaskin Milk  for details about results of the 12 -month 
blinded  period.  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
HIIHFWLYHPHGLFDOPHWKRGVRIFRQ WUDFHSWLRQIRUWKHHQWLUHGXUDW LRQRIWKHLU
SDUWLFLSDWLRQLQWKHVWXG\ 6H[XDODEVWLQHQFHZLOOEHDFFHSWHG DVDQHIIHFWLYH
PHWKRGRIFRQWUDFHSWLRQIRUJL UOVEHORZ\HDUVRIDJH
 $ELOLW\WRSHUIRUPVSLURPHWU\SURFHGXUHVLQDFFRUGDQFHZLWK WKH$PHULFDQ
7KRUDFLF6RFLHW\JXLGHOLQHVIRUVXEMHFWVÂ•\HDUVROG$ELOLW\WRSHUIRUP
SHDNH[SLUDWRU\IORZ3()PHDVXUHPHQWVIRUVXEMHFWVÂ•\HDUVR OG6XEMHFWV
\HDUVRIDJHZKRKDYHGRFXPHQWHGLQDELOLW\WRDGHTXDWHO\SHU IRUP
VSLURPHWU\FDQSHUIRUPRQO\WKH3()HYDOXDWLRQ6XEMHFWV\HD UVRIDJHPD\
EHHQUROOHGLIWKH\KDGQRFOLQLFDOIHDWXUHVRIPRGHUDWHRUVHY HUHSHUVLVWHQW
DVWKPDVHYHULW\DVGHILQHGE\WKH1DWLRQDO+HDUW/XQJD QG%ORRG
,QVWLWXWH>1+/%,@*XLGHOLQHVZLWKLQ\HDUEHIRUH9LVLW
6XEMHFWVDQGRUSDUHQWVJXDUGLDQVZLOOLQJWRFRPSO\ZLWKDO OVWXG\UHTXLUHPHQWV
GXULQJSDUWL FLSDWLRQLQ WKHVWXG\
 ([FOXVLRQ&ULWHULD
 +LVWRU\RIVHYHUHDQDSK\OD[LV WRFRZÂ¶VPLONUHVXOWLQJLQK\S RWHQVLRQK\SR[LDRU
QHXURORJLFDOFRPSURPLVHFROOD SVHORVVRIFRQVFL RXVQHVVRULQF RQWLQHQFHRU
UHTXLULQJPHFKDQLFDOYHQWLODWLRQ
 3UHJQDQF\RUODFWDWLRQ
 6SLURPHWU\IRUFHGH[SLUDWRU\YROXPHLQVHFRQG)(9 RIWKHSUHGLFWHG
YDOXHDW9LVLWIRUVXEMHFWVÂ• \HDUVDQGDEOHWRSHUIRUPWKH VSLURPHWU\RU3()
RISUHGLFWHGYDOXHDW9LVLWI RUVXEMHFWVSHUIRUPLQJRQO\ WKH3()
PHDVXUHPHQWV
 $Q\FOLQLFDOIHDWXUHVRIPRGHUDWHRUVHYHUHSHUVLVWHQWDVWKP DVHYHULW\DV
GHILQHGE\WKH1+/%,JXLGHOLQH VDQGKLJKGDLO\GRVHVRILQKDOHG
FRUWLFRVWHURLGVVH H$SSHQGL[ 
 .QRZQDOOHUJ\WRWKH9LDVNLQ SDWFKPDWHULDOVRUH[FLSLHQWV RUWRDQ\RIWKH
FRPSRQHQWVRIWKHIRRGFKDOOHQJHIRUPXODVRWKHUWKDQWKHFRZÂ¶V PLONSURWHLQV
$OOHUJ\RUNQRZQKLVWRU\RIUHDFW LRQWR PHGLFDOGUHVVLQJ ZLWKQR
SRVVLELOLW\WRXVHDQ DOWHUQDWLYHDGKHV LYHGUHVVLQJDXWKRUL]HGE\WKHV SRQVRULQ
UHSODFHPHQW 
 6XEMHFWVKDYLQJREMHFWLYHV\PSWRPVWRWKHSODFHERIRUPXODOH DGLQJWRVWRSSLQJ
WKHFKDOOHQJHGXULQJWK HVFUHHQLQJ'%3&)&
 6HYHUHUHDFWLRQGXULQJWKHVFUHHQLQJ'%3&)&GHILQHGDVQHHG IRULQWXEDWLRQ
DQGRUK\SRWHQVLRQSHUVLVWLQJD IWHUHSLQHSKULQHDGPLQLVWUDWLRQ DQGRUWKHQHHG
IRU!GRVHVRIHSLQHSKULQH
 6\PSWRPDWLFDOOHUJ\WRSROOHQVZLWKV\PSWRPVGXULQJWKHSROO HQVHDVRQWKDW
PLJKWLQWHUIHUHZLWKWKHV\PSWRP VREVHUYHGGXULQJWKH'%3&)&L IWKH
'%3&)&LVSHUIRUPHGGXULQJWKHS ROOHQVHDVRQ6FUHHQLQJRIVXFK VXEMHFWV
VKRXOGEHPDGHRXWRIWKHSROOHQVHDVRQ
,QDELOLW\WRGLVFRQWLQXHVKRUW DFWLQJDQWLKLVWDPLQHVIRU GD\VRUORQJDFWLQJ
DQWLKLVWDPLQHVIRUWRGD\V GHSHQGLQJRQWKHKDOIOLIHEHI RUHWKH'%3&)&C
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 35 of 170 
11. Use of systemic long -acting corticosteroids within 12 weeks before  Visit 1 
and/or use of systemic short -acting corticosteroids within 4 weeks before  Visit 1 
or use of systemic long-acting or short -acting corticosteroids during screening 
(unless used to treat symptoms triggered by [CONTACT_322246] c onsumption; in th e latter case DBPCFC must then be 
scheduled after a minimum of 7 wash -out days ). 
12. Subjects with asthma conditions meeting 1 or several criteria below:  
â€¢ Uncontrolled persistent asthma (as defined by [CONTACT_941] 2007 NHLBI 
guidelines ) or subject is being treated with a combination therapy of 
medium or high daily dose of inhaled corticosteroid with a long acting 
inhaled Î²2 -agonist. Intermitten t asthmatic subjects who require 
intermittent use of inhaled corticosteroids for rescue are permitted.  
â€¢ At least 2 systemic corticosteroid courses for asthma within 1  year 
before  Visit 1 or 1 oral corticosteroid course for asthma within 3  months 
before  Visit 1, or during screening  (unless used to treat symptoms 
triggered by [CONTACT_322242]) . 
â€¢ Prior intubation /mechanical ventilation due to asthma within 2  years 
before  Visit 1, or during screening.  
13. Upper respi[INVESTIGATOR_322162] 7 d ays of DBPCFC 
(DBPCFC must then be rescheduled  at least 7 days after resolution of these 
conditions ). 
14. Any history of milk immunotherapy (eg , oral immunotherapy, sublingual 
immunotherapy or specific oral tolerance induction).  
15. Prior history of any other food  allergen immunotherapy (eg , oral 
immunotherapy, sublingual immunotherapy or specific oral tolerance induction) 
within [ADDRESS_397655] be 
discontinued at the time of Visit 1.  
17. Use of any anti -IgE drug (e g, omalizumab), any immunomodulatory therapy, or 
any biological agent therapy (eg , anti-tumor necrosis factor drugs) within 1  year 
before  Visit 1, or duri ng screening.  
18. Generalized dermatologic diseases ( eg, severe atopic dermatitis, uncontrolled 
generalized eczema, icthyosis vulgaris) with no intact zones to apply the 
Viaskin patch , or urticarial and mast cell disorders suc h as chronic idiopathic 
urtica ria. 
19. Subject and/or subjectâ€™s parents/guardians with obvious excessive anxiety and 
unlikely to cope with the conditions of a food challenge.  
20. Past or current disease, including but not limited to active eosinophilic 
gastrointestinal disorders, autoimmune disord ers, immunodeficiency, 
malignancy, uncontrolled disease (hypertension, diabetes, psychiatric disorder, 
cardiac disease), or other disorders (eg , liver, gastrointestinal, kidney, 
cardiovascular, pulmonary disease or blood disorder) which in the opi[INVESTIGATOR_1101] t he 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397656]â€™s participation in the study or 
place the subject at increased risk.  
21. Subjects and/or parents/guardians unable to use the epi[INVESTIGATOR_107528] -injector 
properly in spi[INVESTIGATOR_322183].  
22. Contraindicated condition for the use of epi[INVESTIGATOR_238].  
23. Use of any investigational drug or device, or participation in another 
interventional clinical study within 3 months before  Visit 1.  
24. Subjects receiving  beta-blockers or angiotensin converting -enzyme (AC E) 
inhibitors.  
25. Subjects unable to follow the protocol requirements.  
4.3 Eligibility Criteria for Study Extension (Month s 24 to 48)  
 Not applicable after subjects have switched to Viaskin Milk 300  Âµg. 
4.3.1  Inclusion Criteria  
1. Signed study extension ICF by [CONTACT_7078](s)/guardian(s) of subjects and informed 
assent form for subjects â‰¥[ADDRESS_397657] 2 years in MILES, including a complete 
documente d DBPCFC at Month 24.  
Note: following results of the 12 -month blinded period, Month 24 DBPCFC 
should not be performed anymore. Inclusion criterion #2 becomes  
â€œSubjects who completed the first 2 years in MILESâ€.  
3. Negative urine pregnancy test at Month [ADDRESS_397658] cowâ€™s milk -free die t, with no 
consumption of dairy or baked milk products during participation in the study 
(except during the DBPCFC s). 
5. Subjects and/or parents/guardians willing to comply with all study requirements 
during participation in the study  extension . 
4.3.[ADDRESS_397659]â€™s participation in the 
study, or place the subject at increased risk, or for which epi[INVESTIGATOR_322184].  
2. Poor compliance in patch application (below 80%), defined as patch not appl ied 
at all for  >73 days (either consecutive or not) during the second year of 
participation in MILES . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 37 of 170 
4.4 Eligibility criteria for the switch to Viaskin Milk 300 Âµg  
The following eligibility  criteria apply to the subjects who agree to switch to Viaskin Milk 
300 Âµg. 
4.4.1  Inclusion Criteria  
1. Signed ICF by [CONTACT_7078](s)/guardian(s) of subjects and informed assent form for 
subjects â‰¥[ADDRESS_397660] cowâ€™s milk -free diet, with no 
consumption of dairy or baked milk products during participation in the study 
(except during the DBPCFCs).  
4. Subjects and/or parents/guardians willing to comply with all study requirements 
during participation.  
4.4.[ADDRESS_397661]â€™s participation in the study, 
or place the subject at increased risk, or for whic h epi[INVESTIGATOR_322184].  
2. Poor compliance in patch application (below 80%)  during the previous  year of 
participation in MILES.  
 
4.[ADDRESS_397662] in this clinical study may be discontinued for any of the following reasons:  
â€¢ Adverse Event: a ny SAE, clinically significant AE, or severe laboratory 
abnormality . 
â€¢ Subject or parent(s)/guardian(s)  decision  (consent withdr awal) . 
â€¢ Investigator decision: o ccurrences of any medical condition or 
circumstances that expose the subject to substantial risk and/or do not allow 
the subject to adhere to the requirements of the protocol . 
â€¢ Pregnancy.  
â€¢ Noncompliance: subjectâ€™s failure to co mply with protocol requirements or 
study -related procedures.  
â€¢ Lost to follow -up: subjectâ€™s failure to return for scheduled visits despi[INVESTIGATOR_322185] . 
â€¢ Sponsor or regulatory authorit y decision: t ermination of the study by [CONTACT_103], FDA, or other regulatory authorities.  
â€¢ Death . 
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
6XEMHFWVDQGWKHLUSDUHQWVJXDUGLDQVDUHIUHHWRZLWKGUDZF RQVHQWIURPSDU WLFLSDWLQJ
LQWKHVWXG\DWDQ\WLPHZLWKRXW SUHMXGLFHWRIXUWKHUWUHDWPHQW 7KHUHDVRQVIRU
ZLWKGUDZDOZLOOEHGRFXPHQWHG6XE MHFWVZLWKGUDZLQJIURPWKHVW XG\VKRXOGFRPSOHWH
WKHHDUO\WHUPLQDWLRQVWXG\SURFHGXUHV 6HFWLRQ 
5HDVRQDEOHHIIRUWVZLOOEHPDGH WRFRQWDFWVXEMHFWVZKRDUHORV WWRIROORZXSDQGZLOO
EHGRFXPHQWHGLQWKHVXEMHFWÂ¶VILOH
6XEMHFWVZKRDUHZLWKGUDZQIURPWKHVWXG\ZLOOUHFHLYHVWDQGDUG RIFDUHDFFRUGLQJWR
WKHMXGJPHQWRIWKHWUHDWLQJSK\VLFLDQ
7KHVSRQVRUKDVWKHULJKWWRWHU PLQDWHWKHVWXG\ XQGHUVSHFLDO FLUFXPVWDQFHVWKDWPD\
EHUHODWHGWRWKHLQYHVWLJDWLRQDO SURGXFWRUWKHFRPSDQ\RUIRU DQ\RWKHUUHDVRQ,Q
WKHVHLQVWDQFHVWKH,QYHVWLJDWRU VDQGWKHUHJXODWRU\DXWKRULWL HVDQG,QVWLWXWLRQDO
5HYLHZ%RDUGV,5%VZLOOEHLQIRU PHGDERXWWKHUHDVRQRIVWXG\ WHUPLQDWLRQ
6WRSSLQJUXOHVIRUWKHVWXG\DUHSUHVHQWHGLQ 6HFWLRQ
 ,QYHVWLJDWLRQDO3URGXFWV
 'UXJ6XEVWDQFH
7KHGUXJVXEVWDQFHLVD QXQPRGLILHG DOOHUJHQH[WUDFW WKDWLVDO\RSKLOL]HGFRZÂ¶VPLON
SURWHLQVH[WUDFW 



 ,QYHVWLJDWLRQDO3 URGXFWV$GPLQLVWHUHG
7KHLQYHVWLJDWLRQDOSURGXFW 9LDVNLQ0LON '%9 SDWFKFRQVLVWVRIDQHSLFXWDQHRXV
GUXJGHOLYHU\V\VWHP ('6ZLWKWKHDSSHDUDQFHRI DSDWFKFRQWDLQLQJDVROLGGHSRVLW
RIFRZÂ¶VPLONSURWHLQV 
 


 


3ODFHERWUHDWPHQWZLOO FRQVLVWRID9LDVNLQ SDWFKZLWKDVLPLOD UIRUPXODWLRQWR9LDVNLQ
0LONEXWGHYRL GRIFRZÂ¶VPLONSURWHLQV  
 





CCI
CCI
CCI
CCI
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
 ,QYHVWLJDWL RQDO3URGXFWV6WRUDJH
7KHLQYHVWLJDWLRQDOSURGXFWVZLOOEHVWRUHGLQWKHUHIULJHUDWRU EHWZHHQÂƒ&WRÂƒ&
Âƒ)WRÂƒ)VHH863&RQWUROOHG5RRP7HPSHUDWXUH
6WRUDJHDWDPELHQWWHPSHUDWXUHIR UVKRUWDQGRULQWHUPLWWHQWSH ULRGVRIWLPHLQFOXGLQJ
WUDQVSRUWDWLRQLVSHUPLWWHG
 3DFNDJLQJDQG/DEHOOLQJ
$OOSDFNDJLQJDQGODEHOOLQJRSHUDWLRQVZLOOEHSHUIRUPHGDFFRUG LQJWR*03IRU
PHGLFLQDOS URGXFWVDQG WKHUHOHYDQWUHJXODWRU\UHTXLUHPHQWV  


2QHLQYHVWLJDWLRQDOSDWFKZLOOEHSODFHGLQDSRXFKDQGHDFK
SRXFKZLOOEH ODEHOOHG7KHODEHOOHGSRXFKHVZLOOEHSODFHGLQ ODEHOOHGWUHDWPHQWER[HV 
DQGVHYHUDOWUHDWPHQWER[HV PD\EHLQVHUWHGLQWRODEHO OHGWUHDWPHQWNLWV $OWHUQDWLYHO\ 
GHSHQGLQJ XSRQWKHVFKHGXOHRIYLVLW VWKHSRXFKHVZLOOEHSODFHGGLUHFWO\LQWRWKH
ODEHOOHGWUHDWPHQWNLWV LQZKLFKFDVHRQHWUHDWPHQWNLWZLOOUHSUHVHQWRQHWUHDWPHQW
ER[(DFKWUHDWPHQWNLWZLOOEHODEHOOHGZLWKDNLW QXPEHU6LWHVZLOOXVHWKH,QWHUDFW LYH
:HE5HVSRQVH6\VWHP,:56IRUNLWDVVLJQPHQWWRWKHVXEMHFWV DQGWKHQVLWH
SHUVRQQHOZLOOGLVSHQVHWKHLQGLYLGXDOWUHDWPHQWER[ WRWKHVXEMHFWVDWHDFKYLVLWZLWK D
VXIILFLHQW TXDQWLW\RI9LDVNLQ SDWFKHVWRFRYHUWKHSHULRGE HWZHHQWZRFRQVHFXWLYH
YLVLWV7KHODEHOOHGDQGSDFNDJHGLQYHVWLJDWLRQDOSURGXFWZLOO EHVWRUHGDFFRUGLQJWR
*03UHTXLUHPHQWVXQGHUWKHVW RUDJHFRQGLWLRQVHVWDEOLVKHGE\VW DELOLW\VWXGLHV
8SRQUHFHLSWRIDVKLSPHQWUHTXHVWWKHVWXG\GUXJZLOOEHVKLS SHGWRWKHFOLQLFDOVLWH
7KHSKDUPDFLVWZLOOUHFH LYHDQGVWRUHWKHLQYHVWLJDWLRQDOSURGX FWDVLQVWUXFWHGVHH
6HFWLRQXQWLOGLVSHQVDWLRQ $WWKHHQGRIWKHVWXG\WKHSKDUPDFLVWZLOOEH
UHVSRQVLEOHIRUGHVWUR\LQJD Q\XQXVHGLQYHVWLJDWLRQDOSURGXFWÂ± HLWKHUUHWXUQHGE\WKH
VXEMHFWVRUQRWGLVSHQVHGDWDOOÂ±DQGZLOOSURYLGHDFRUUHVSRQ GLQJFHUWLILFDWHRI
GHVWUXFWLRQ
 $GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV 0HWKRGRI$VVLJQLQJ6XEMHFWVWR7UHDWPHQW*URXSV
$OOVXEMHFWVZLOOEHDVVLJQHGDQLGHQWLILFDWLRQQXPEHUDW9LVLW 7KH,:56ZLOO
UDQGRPL]HDOOHOLJLE OHVXEMHFWVDQGDVVLJQWKHDSSURSULDWHWUHD WPHQWNLW,:56ZLOO
PDQDJHWKHLQYHQWRU\DQGDVVLJQPHQWRIWUHDWPHQWWRVXEMHFWVDW WKHNLWOHYHO7KHVLWH
SKDUPDFLVWVZLOOGLVSHQVHWKHGUX JSURGXFWDFFRUGLQJWRWKH,:5 6UHFRPPHQGDWLRQV
6XEMHFWVDWHDFKGRVHOHYHOZLOO EHUDQGRPO\DVVLJQHGWRUHFHLY HHLWKHU9LDVNLQ0LONRU
SODFHERDFFRUGLQJWRDFRPSXWHUJHQHUDWHGUDQGRPL]DWLRQFRGHWK DWZLOOEHSURGXFHG
E\DQXQEOLQGHGVWXG\VWDWLVWLFLDQDWWKH&RQWUDFW5HVHDUFK2UJ DQL]DWLRQ&52LQ
DFFRUGDQFHZLWKWKH6WDQGDUG2SHU DWLQJ3URFHGXUHV623VRIWKH &52,QDGGLWLRQ
WKHUDQGRPL]DWLRQWRWUHDWPHQWIRUVXEMHFWVUDQGRPL]HGLQ3DUW %ZLOOEHVWUDWLILHGE\
VLWHDQGE\DJHJURXSFKLOGUHQWR \HDUVROGDWWKHWLPHR I9LVLWDGROHVFHQWV
WR\HDUVROGDWWKHWLPHRI9LVLW
 6HOHFWLRQRI'RVHVLQWKH6WXG\
7KHRSWLPDO9LDVNLQ0LONFOLQ LFDOGRVHFRXOGQRWEHDQWLFLSDWHG DWWKHVWDUWRIWKHVWXG\
EXWWKHGRVHVWREHWHVWHGLQWKL VVWXG\ZHUHEDVHGRQWKHUHVX OWVREWDLQHGIURPWKH
SUHFOLQLFDOWR[LFLW\ORFDOWRO HUDQFHVWXGLHVWKDWZHUHSHUIRUPH GWRHYDOXDWHWKHWR[LFLW\RICCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397663] weeks of treatment as follows:  
â€¢ [ADDRESS_397664] week (from Day  1 to Day  7); 
â€¢ 12 hours of daily application during the second we ek (from Day  8 to Day  14); 
â€¢ [ADDRESS_397665] week (from Day  15) onwards.  
In case of severe local reactions, or if the subject present s an AE considered as a 
systemic â€œallergic reaction typeâ€ of any severity  and related to the study drug , the daily 
duration of patch appl ication can be adapted/reduced if the Investigator considers this 
could allow for  an optimal management of the safety of the subjects. The daily duration 
of patch application could then be progressively extended day by [CONTACT_322247] 
24-hours/day applica tion after the AE resolves or stabilizes.  In the rare event that 
Grade 4 local skin reactions occur, subjects should transiently discontinue patch 
application. Subjects should then visit the site for the next patch application and for 
adequate examination and treatment of the wounded zone (refer to  Section  [IP_ADDRESS] , 
Adverse Events of Special Interest to the Sponsor).  
The patches will be appl ied on the inter -scapular area o n the back of the children (2 to 
11 years old) and on the inner side of the arms for the adolescents  (12 to 17 years old)  
and former adolescents who become adults  (â‰¥18 years old) . Children who reach the 
age of 12 years during their  participation in the study may continue to apply the 
patches on their back, or switch to the arms.  For each site of application (arms or 
back), the specific place where the patch is applied will represent a zone : 6 zones in 
total will be  used and rotated for application of the patches . The application of the patch 
should start with Zone 1 on Day  1, then Z one 2 on Day  2, then Zone 3 on Day  3â€¦up to 
Zone 6 on Day  6. Then the patch will be applied back to Zone 1 on Day  7, Zone 2 on 
Day 8, etc. 
â€¢ For children (2 to 11 years old), the Zones  1, 2, and 3 will be located on 1 side 
of the spi[INVESTIGATOR_322186]  4, 5 and 6 will be located on the other side of the spi[INVESTIGATOR_050].  
â€¢ For adolescents (12 to 17 years  old) and former adolescents who become 
adults  (â‰¥18 years old) , the Zones  1, 2 and 3 will be located on 1 arm and 
Zones  4, 5, and 6 will be located on the other arm.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 43 of 170 
dose of Viaskin Milk  selected for Part B (500 Âµg of cowâ€™s milk protein ), based on safety 
data of Part A subjects . The Vi askin Milk open -label treatment period was to continue 
until Month  [ADDRESS_397666] weeks of treatment as follows:  
â€¢ [ADDRESS_397667] week  
â€¢ 12 hours of dai ly application during the second week  
â€¢ [ADDRESS_397668] week onwards  
At the time of Protocol  Amendment  5, all subjects were currently receiving active 
treatment with Viaskin Milk 500 Âµg. The switch to Viaskin Milk 300 Âµg will not 
require a  progressive  increase of application duration, and all subjects will be 
able to start with 24 hours of daily application of Viaskin Milk 300 Âµg . 
During the open -label treatment period s with Viaskin Milk 500  Âµg and Viaskin Milk 
300 Âµg, the daily duration of patch application could also be reduced/adapted and 
progressively extended up over a few days to reach the 24 -hours/day application in 
some specific cases , as described in the previous section,  if the Investigator considers 
this could allow for an optimal management of the safety of the subjects.  In the rare 
event that Grade [ADDRESS_397669]  to the location (back or arm) and zones  
together with  the recommendations for applying and removing the patch should 
continue as described above in the blinded  treatment period section  (refer to 
Secti on 6.3.1 ).  
If the patch was removed or has fallen off prematurely, the daily duration of application 
of the patch and the reason for early removal will be recorded in the subject diary 
cards. During the open -label treatment period s with Viaskin Milk [ADDRESS_397670] patch application was to be 
the day before the second Month  24 DBPCFC (day before Visit  17). For subjects who 
enter ed the study extension after Month  24, the open -label  treatment period was to 
continue with Viaskin Milk [ADDRESS_397671] patch 
application was to be on the day before the second Month  48 DBPCFC (day before 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 44 of 170 
Visit 23). The last application of Viaskin Milk [ADDRESS_397672] in the DBPCFC performed after 24 months of treatment:  
â€¢ If the subjects perform the DBPCFC, the last patch application will be the day 
before the  second day of the  DBPCFC /Visit S7;  
â€¢ If the subjects do not perform the DBPCFC, the last patch application will be 
the day before Month 24/Visit S6.  
6.[ADDRESS_397673] , Investigator , medical monitor, 
sponsor, and the entire study processing team will remain blinded to treatment  
assigned (refer to Section 6.1, Method of Assigning Subjects to Treatment Groups) to 
the subjects duri ng the 12-month double -blind treatment period and the blinding will 
remain until all 12-month data are collected .  
The appearance of Viaskin Milk and placebo  patches will be identical. During the 
blinded treatment period, a n Emergency Code Break procedure will be available to 
Investigator s via IWRS, to allow for unblinding a subject  or treatment kit , (ie, informing 
the Investigator  of the treatment group to which the subject has been assigned ). The 
blind for a specific subject can be broken by [CONTACT_322248]. If possible, t he 
medical monitor  at the CRO  and the sponsor should be consulted  before breaking the 
blind  and the Investigator  should always assess the relationship of the AE to the 
investigational product  before breaking the blind.  
Open -label treatment period with Viaskin Milk [ADDRESS_397674] been completed (Visit 13), all 
subjects we re to continue treatment until Month  [ADDRESS_397675] dose of Viaskin Milk selected for Part B (500 Âµg of cowâ€™s milk 
protein), based on safety data of Part  A subjects. Treatment with open -label Viaskin 
Milk 500  Âµg was to continue until Month  48 for subjects who enter the study extension.  
After the switch to Viaskin Milk 300  Âµg, subjects will receive th is treatment in an open -
label manner for 24 months.  
6.5 Prior and C oncomitant Therapy  
6.5.1  Prior and Concomitant Therapy R ecords  and Recommendations  
All prior medications used within 6 months prior to Visit 1 will be recorded on the 
electronic case report form ( eCRF ). All medications taken any time from the study start 
until the end of the study will be recorded on the eCRF.  
Application of a topi[INVESTIGATOR_322187] (eczematou s lesions, 
pruritus, edema, etc ) is allowed and will be recorded as concomitant medication. A 
topi[INVESTIGATOR_322188] 1% hydrocortisone or equivalent will be distributed to each 
randomized subject at discharge on Day  1 (Visit 4) . In case the 1% hydrocortisone 
topi[INVESTIGATOR_322189], a topi[INVESTIGATOR_322190] a more potent corticosteroid can be prescribed and locally applied.  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
2UDODQWLKLVWDPLQHRURUDOFRUWL FRVWHURLGVDUHDOORZHGWRWUHDW $(VGHWHUPLQHGDV
EHLQJDOOHUJLFUHDFWLRQVDQG VKRXOGEHUHFRUGHGDVFRQFRPLWDQW PHGLFDWLRQV7KHVH
WUHDWPHQWVVKRXOGEHOLPLWHGL QGXUDWLRQDQGVWRSSHGDVVRRQDV WKH$(VKDVKDYH
UHVROYHG7KH,QYHVWLJDWRUZLOOGHWHUPLQHWKHEHVWFKRLFHRIWU HDWPHQWVWKHGRVHDQG
WKHUHJLPHQDFFRUGLQJWRWKHVXEMH FWÂ¶VDJHDQGWKHW\SHDQGWK HGHJUHHRIVHYHULW\RI
WKHUHDFWLRQ&HWLUL]LQHLVUHFRPPHQGHGDVWKHRUDODQWLKLVWDPL QHRIFKRLFH
,QWUDPXVFXODUO\L QMHFWDEOHHSLQHSKULQH 
ZLOOEHGLVWULEXWHGWRHDFKVXEMHFWDWGLVFKDUJHRQ'D\ 9LVLW WREHXVHGLQ
FDVHRIV\P SWRPVRIDQDSK\OD[LV7KH,QYHVWLJDWRUZLOOH[SODLQWRWKHVXEM HFWDQGRU
SDUHQWVJXDUGLDQV DQGGRFXPHQW ZKHQDQGKRZWRVHOILQMHFWWKHHSLQHSKULQH
DFFRUGLQJWRWKH$QDSK\OD[ LV(PHUJHQF\$FWLRQ3ODQ VHH$SSHQGL[ZKLFKZLOO
DOVREHJLYHQWRWKHVXEMHFW7 KHLQWUDPXVFXO DUO\LQMHFWDEOHHS LQHSKULQHZLOOEHUHSODFHG
LIXVHGRULILWH[SLUHV$Q\XVH LHDGPLQLVWUDWLRQRILQMHF WDEOHHSLQHSKULQHZLWKLQ
PRQWKVSULRUWR9LVLWRUGXUL QJWKHVWXG\PXVWEHUHFRUGHG LQWRWKHH&5)
7KHDGPLQLVWUDWLRQRISULRUFRQFR PLWDQWPHGLFDWLRQVPXVWEHUHF RUGHGLQWKHH&5)WR
LQFOXGHWKHPHGLFDWLRQQDPHGRVDJ HDQGXQLWVURXWHVFKHGXOH VWDUWDQGVWRSGDWHV
ZKHQDSSOLFDEOHDQGLQGLFDWLRQIR UXVH*HQHULFQDPHVIRUFR QFRPLWDQWPHGLFDWLRQV
VKRXOGEHXVHGRUDOWHUQDWLYHO\7UDGHQDPHVVKRXOGEHXVHGLQW KHFDVHRIFRPELQHG
PHGLFDWLRQV
 3URKLELWHG&RQFRPLWDQW 7UHDWPHQWVDQG3URFHGXUHV
x $Q\LQYHVWLJDWLRQDOGUXJRUGHYLFHRWKHUWKDQ9LDVNLQ0LONRU SODFHER
x 6KRUWDFWLQJDQWLKLVWDPLQHVIRUWRGD\VDQGORQJDFWLQJDQ WLKLVWDPLQHVIRU
WRGD\VEHIRUHDQ\'%3&)&RU637SURFHGXUHVVHH $SSHQGL[
x /RQJDFWLQJ EDJRQLVWVHJIRUPRWHUROZLW KLQKRXUVEHIRUHDQ\'%3&)&
x 2PDOL]XPDERURWKHULPPXQRPRGXODWRU\DJHQWV
x %LRORJLFDOGUXJVLQFOXGLQJEX WQRWOLPLWHGWRDQWLERGLHV%FH OOVGHSOHWLQJDJHQWV
RUWXPRUQHFURVLVIDFWRULQKLELWRUV
x &DOFLXPFKDQQHOEORFNHUV
x %HWDEORFNHUVRU$&(LQKLELWRUV
x $Q\RWKHULPPXQRWKHUDS\WUHDWPHQ WHJIRRGDOOHUJHQ>V@RUDHU RDOOHUJHQ>V@
x %HIRUH3URWRFRO$PHQGPHQW$Q\IRRGFKDOOHQJHWRPLONRWKHU WKDQUHTXLUHG
DVSHUWKLVSURWRFRORUWRDQ\RWKHUIRRG
x $IWHU3URWRFRO$PHQGPHQW$Q\IRRGFKDOOHQJHWRPLONRWKHU WKDQSURSRVHG
DVSHUWKLVSURWRFRO
 3HUPLWWHG&RQFRPLWDQW7UHDWPHQWVDQG3URFHGXUHV
x 7RSLFDOFRUWLFRVW HURLGVWRWUHDWDQ\ORFDOFXWDQHRXV$(HJH F]HPDRU
HU\WKHPDSUXULWXVHGHPDUDVKHWF
x 2UDODQWLKLVWDPLQHVDQGRUDORULQKDOHGFRUWLFRVWHURLGVWRWUH DW$(VVHH
6HFWLRQ 5HVFXH0HGLFDWLRQ'XUDWLRQRIWUHDWPHQWVKRXOGEHOLPLWHG
DQGLGHDOO\VWRSSHGXSRQ$(UHVR OXWLRQ$QLQKDODWLRQFRUWLFRVW HURLGFRQYHUVLRQ
WDEOHLVLQFOXGHGL Q$SSHQGL[ 
x ,QWUDPXVFXODUO\LQM HFWDEOHHSLQHSKULQHCCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 46 of 170 
â€¢ Treatments (other than those described above) prescribed in case of any AE.  
â€¢ After Protocol Amendment 5: Any food challenge to any other food than milk  
required for the subjectâ€™s medical management will be permitted . Whether the 
subjectâ€™s medical condition  is still  compatible with their participation in the study 
should be assessed  by [CONTACT_2725]â€™ s medical monitor  
before the food challenge is performed . Note that the initiation of any other 
immunotherapy treatment remains prohibited during the participation of the 
subject in the MILES study (refer to Section 6.5.2 ).    
6.6 Treatment C ompliance  
Subjects and/or parent(s)/guardian(s) will receive diary cards to record the daily 
application of Viaskin patches (see Section [IP_ADDRESS]  for further details about  diary 
cards).  The duration of the patch application will be recorded every day from Day  1 
(Visit 4) up to Month  3 (Visit 9) on the subject diary cards.  After Month 3, the subjects 
will only record the days and time period s when the duration of the patch app lication 
did not follow the durations recommend ed in the protocol . During the period of [ADDRESS_397676] and/or parent(s)/guardian(s) will be 
collected periodically during the subjectâ€™s visit at sites and entered into the eCRF or the 
clinical database . 
It is the Investigator â€™s responsibility to correctly instruct subjects and/or 
parent(s)/guardian(s) on how to store and administer the investigational prod uct. At 
each visit, prior to dispensing a new investigational treatment  box, the compliance of 
the subject will be assessed by [CONTACT_322249] (even for a duration that is less than  the recommended duration), versus  the 
number of days in that time interval . An overall  compliance of â‰¥80% over the treatment 
period is sought. Subjects exhibiting a poor compliance ( <80%) should be counseled  
on the importance of a good compliance.  
The Investigator  or designated study perso nnel will maintain a log of all investigational 
product  dispensed (see Section 10.1, Drug A ccountability for details).  
6.7 Study Stoppi[INVESTIGATOR_322191], if any of the following occur:  
â€¢ Any death related to Viaskin dosing;  
â€¢ More than one Stage 3 anaphylaxis ( see Appendix 14.4, Anaphylaxis Staging 
System) related to Viaskin application (and not occu rring during the DBPCFC s); 
â€¢ More than 3 subjects requiring >1 injection of epi[INVESTIGATOR_322192] (and not occurring during the DBP CFCs). 
Upon safety review, 1 of the following outcomes will be determined:  
â€¢ Accrual into the study may cont inue without modification;  
â€¢ Accrual into the study may continue with modifications as recomm ended by [CONTACT_40746];  
â€¢ Accrual into the study should stop.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397677] (Viaskin Milk or p lacebo) will 
be [ADDRESS_397678] 
and second years after the switch to Viaskin Milk 300  Âµg, respectiv ely, as described in 
Section 7.4. A maximum of  7 site visits are planned, and a maximum of 5 phone calls 
will be held between scheduled site visits.  
The subjects and/or parent(s)/guardian(s) must be instructed that subjects  
should follow a strict cowâ€™s milk -free diet with no consumption of cowâ€™s milk, 
dairy products , or any baked milk products during their entire participation in the 
study.  
7.2.1  Pre-Treatment  Screening Period  
The screening period will include  3 pre-treatment visits (Visits 1 to 3) for all subjects . 
The duration of the screening period up to the first day of treatment with the study drug 
at Visit [ADDRESS_397679] be â‰¤60 days.  This gives enough tim e for the subjects to perform their 
3 pre-treatment visits and plan for the Visit 4 based on their schedule and siteâ€™s 
availabilit y. The screening period could however be shorter than 60 days. If applicable, 
subjects with abnormal laboratory assessments due  to concomitant transient disease 
(flu, viral illness , etc) can repeat their laboratory assessm ents or be rescheduled for 
laboratory asses sment at the discretion of the Investigator . 
[IP_ADDRESS]  Visit 1 (Screening Visit)  
The site staff must go into IWRS to register th e subject for Screening.  
Subjects will undergo the following procedures at this visit:  
Written and signed ICF/IAF will be obtained before any asses sments are made.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 48 of 170 
Written and signed genetic ICF/IAF for optional genetic analysis (epi[INVESTIGATOR_322193]) may be obtained only if subjects or  their parent(s)/guardian(s)  agree 
to participate in th ese analys es. 
All subjects will be assessed for eligibility against the in clusion and exclusion criteria  
and assigned a subject identification num ber. 
Qual ity of Life (QoL) Food Allergy Q oL Questionnaire  (FAQLQ )/Food Allergy 
Independent Measure  (FAIM ) forms20 (Appendix 14.3) will be completed by [CONTACT_423]  
(when applicable)  and parent(s)/guardian(s) before any procedures at this visit are 
performed.  The appropriate  QoL questionnaire forms to complete depend on the age of 
the subject  at the time of Visit [ADDRESS_397680]â€™s full medical history, including history of CMA  and any other type of 
allergy, if applicable.  
Prior medications (received within 6 months  prior to Visit 1) and ongoing  medications 
will be documented.  
Demographic data, including  date of birth , sex, ethnic origin, weight (kg), and height 
(cm) will be collected . 
A physical examination, including a complete skin examination,  will be performed and 
the results documented.  
Vital signs (heart rate , systolic and diastolic blood pressure, and respi[INVESTIGATOR_697] ) for 
subjects in a si tting position will be measured . 
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk  will be performed . 
Blood samples for hematology and  biochemistry laboratory tests, immunological 
markers (IgE, immunoglobulin G4 [ IgG4 ]) will be collected . 
Only f or subjects who signed the genetic ICF /IAF: a blood sample for filaggrin 
mutations may be collected ; only 1 sample for filaggrin mutations is to be collected 
during the s tudy, either at this visit or at other visits listed in Table  2, Table  3, Table  4, 
and Table  5. 
Only f or subjects who signed the genetic ICF /IAF: a blood samp le for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
AEs will be recorded  from the day of signing the ICF/ IAF. 
[IP_ADDRESS]  Visit 2  (First day of the Screening DBPCFC ) 
Visit 2 can be scheduled and conducted  as soon as the laboratory results from Visit  1 
are available and confirm the eligibility criteri on related to the cowâ€™s milk sIgE (ie, the 
sIgE must be â‰¥10 kU/L). This v isit [ADDRESS_397681] day of the scree ning 
DBPCFC.  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before  the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_119576]. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 49 of 170 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
PEF measurements  (depending on the subjectâ€™s age  and ability to perform these tests ) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
DBPCFC will be performed  and t he grading of each symptom will be made using the 
grading definition s in the Oral Food Challenge (OFC) symptom score sheet s 
(see Appendix  14.2). 
A minimum duration of  [ADDRESS_397682] 
is discharged from the site. The observation period can be extended beyond 
3 hours if deemed necessary by [CONTACT_12244] r. 
[IP_ADDRESS]  Visit 3  (Second day of the Screening DBPCFC ) 
Visit 3 corresponds to the second day of the screening DBPCFC. Visit 3 will be 
scheduled within 7  days after Visit 2 . However, Visit 3 may be scheduled up to a 
maximum of 14  days  after Visit  2 and documented in the eCRF, if either of the following 
occur: (1) the subject experiences reactions after the DBPCFC at Visit 2 that require 
more than 7  days to elapse before the next food challenge , or (2) any intercurrent  
disease preventin g the second day of the challenge to be conducted safely as planned; 
in this specific condition, the timeframe between the [ADDRESS_397683] be appropriately documented , or (3) the subjectâ€™s schedule or site 
logistics preve nt the second day of food challenge to be performed within [ADDRESS_397684] day.  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before  the DBPCFC and can be  repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737] . 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
PEF measurements  (depending on the subjectâ€™s age  and ability to perform these tests ) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheet s (see Appendix  14.2). 
A minimum duration of [ADDRESS_397685] dose of the 
challenge has been administered or the challenge stopped because of (a) clea r 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 50 of 170 
objective reaction(s) has (have) occurred , the order of the challenge formulas can be 
unblinded and the results of the challenge will be established  as described in 
Section  [IP_ADDRESS].[ADDRESS_397686] is confirmed at the end of Visit  3, and up to the day of Visit 4. 
7.2.2  Part A, Part B , 12-month open -label treatment with Viaskin Milk 500  Âµg and 
study extension   
The following visit  schedule  applies until Protocol Amendment 5  is approved and 
the subjects switch to Viaskin Milk 300  Âµg. However,  no further  DBPCFC should 
be conducted while the subjects are still receiving Viaskin Milk 500 Âµg .  
Refe r to Section 7.2.3  as soon as the Viaskin Milk 300  Âµg is available at the study site.  
[IP_ADDRESS]  Visit 4  (Day  1) 
Visit 4 (Day 1) should take place  within a maximum of 60 days after Visit 1 (screening 
visit). This visit corresponds to the first day of treatment.  
Subjects will undergo the following procedures at this visit:  
Subjects will be reassessed for eligibility against the in clusion and exclusion criteria  
before  proceeding to  allocation of a treatment kit . The site staff must login into IWRS to 
be allocated a randomization treatment kit for the subject.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rat e, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a si tting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained . 
Any AEs that have occ urred since the previous visit will be documented and any 
changes in medication s reported.  
One patch will be  taken from the Visit [ADDRESS_397687]â€™s ski n 
as described in  Section  6.3.  
For only Part  B subjects, t he Visit [ADDRESS_397688] and instructions will be given for completion.  
Epi[INVESTIGATOR_107528] -injector and the Anaphylaxis Emergency Action Plan (Appendix  14.5) 
will be dispensed and/or their utilization reviewed, as necessary.   
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397689] s can then be  discharged from the site  only after th is observation period . 
This period  can be extended beyond  3 or 6  hours if deemed necessary by [CONTACT_3786] . 
Vital sign s, PEF measurements, and the e xamination, grading, and photography of the 
area o f the skin where the  Viaskin patch  is appli ed will be performed  at the following 
timepoi nts: before application of the first patch , then  at 30  minutes, 1  hour, 2  hours, 
3 hours and 6  hours (when applicable) after application of the patch . Note: for subjects 
in Part  B, the 6 -hour timepoint is not required.  
Subjects and/or their parent(s)/guardian(s) will be instructed to use the diary card and 
to bring the card to the site at each subsequent visit. S ubjects and/or 
parent(s)/guardian(s) will be instructed to record any AEs and associated medications 
on the diary cards  and will als o be reminded to record the duration of application and 
reason (s) for early removal of the Viaskin patch , if the patch is removed before the 
recommended duration  of application . Any accidental cowâ€™s milk consumption (in any 
form) must also be documented on  the diary cards. At subsequent visits, the diary card 
will be reviewed and the data will be collected by [CONTACT_8786].  
[IP_ADDRESS]  Visit 5  (Day  2) (for Part A Subjects Only)  
This visit is required only for subjects enrolled in Part A  and will take place the day aft er 
Visit 4 .  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
A new patch will be  taken from the Visit [ADDRESS_397690]â€™s 
skin as described in Section  6.3. 
The Visit [ADDRESS_397691]  and instructions 
repeated/reminded if required . 
Review/reminder of the  utilization of the  epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), if required . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 52 of 170 
Subjects will be observed at site for a  minimum duration of 2  hours after 
application of the patch.  The observation period can b e extended beyond these 
2 hours if deemed necessary by [CONTACT_737] . 
[IP_ADDRESS]  Visit 6  (Day  8/Week 1  Â±2 days ) 
Visit 6 (Day 8/Week 1) will take place 7 days Â± 2 days after Visit 4 (Day  1).  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
PEF measurements  (depending on the su bjectâ€™s age  and ability to perform these tests ) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin  patch  
application will be performed.  
Diary card will be  checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The treatment box from the previous visit will be collected from the subject and drug 
accountability /compliance  will be assessed . 
The Visit [ADDRESS_397692] . 
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan (Appendix  14.5), as necessary.   
[IP_ADDRESS]  Visit 7 ( Day 22/Week 3  Â±3 days ) 
Visit 7 (Day 22 /Week 3) will take place 21 days Â± 3 days after  Visit 4 (Day 1) .  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (de pending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
Blood samples for hematology and  biochemistry laboratory tests, as well as for 
immunological markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected  at this visit  if not collected at Visit  1. 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397693] and drug 
accountability/compliance will be assessed . 
Site staff will login  into IWRS to be allocated an initial re -supply kit for the subject. The 
Visit [ADDRESS_397694] . 
Review/reminder of the u tilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196]-
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 8 (Week 6  Â±3 days ) 
Visit 8 (Week 6) will take place 6 weeks Â±3 days after  Visit 4 (Day 1) .  
Subjects will undergo the following procedures at this  visit: 
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
PEF measurements (depending  on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used f or Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397695] and drug 
accountability/compliance will b e assessed.  
The Visit [ADDRESS_397696] . 
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 9 ( Month 3  Â±7 days ) 
Visit 9 (Month 3) will take place 3 months Â±7 days after  Visit 4 (Day 1) .  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressu re, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hema tology , biochemistry laboratory tests, and immunological 
markers (IgE, IgG4)  will be collected.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 54 of 170 
Only f or subjects who signed the genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected  at this visit  if not collected at  a previous visit . 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397697] and drug 
accountability/compliance will be assessed.  
Site staff will login  into IWRS to be allocated an additional re -supply kit for the subject. 
The Visit [ADDRESS_397698] . 
Review/reminder of the  utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 10 ( Month 6  Â±7 days )  
Visit 10 (Month 6) will take place 6 months Â±7 days after  Visit 4 (Day 1) .  
Subjects will undergo th e following procedures at this visit:  
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk  will be performed.  
Blood samples for hematology , biochemistry laborator y tests, and immunological 
markers (IgE, IgG4)  will be collected.  
Only f or subjects who signed the genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected  at this visit  if not collected at a previous visit . 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397699] and drug 
accountability/compliance will be assessed.  
Site staff will login  into IWRS to be allocated an additional re -supply kit for the subject. 
The Visit [ADDRESS_397700].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary.  The expi[INVESTIGATOR_322197]: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397701], as necessary.  
[IP_ADDRESS]  Visit  11 (Month 9  Â±7 days ) 
Visit 11 (Month 9) will take place 9 months  Â±7 days after  Visit 4 (Day 1) .  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (h eart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the s kin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397702] and drug 
accountability/compli ance will be assessed.   
Site staff will login  into IWRS to be allocated an additional re -supply kit for the subject. 
The Visit [ADDRESS_397703].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the An aphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 12 ( Month 12  Â±7 days ; First Day of the Mont h 12 
DBPCFC ) 
Visit 12 (Month 12) will take place 12 months Â±7 days after  Visit 4 (Day 1) . Visit [ADDRESS_397704] day of the Month 12 DBPCFC.  
Subjects will undergo the following procedures at this visit:  
QoL questionnaire FAQLQ/FAIM forms (Append ix 14.3) will be completed by [CONTACT_1560] (when applicable) and parent(s)/guardian(s) before any procedures at this visit 
are performed.  The appropriate  QoL questionnaire forms to complete depend on the 
age of the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed 
before the DBPCFC and c an be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737] . 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and can be repeat ed 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 56 of 170 
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology , biochemistry laboratory tests,  and immunological 
markers (IgE, IgG4)  will be collected.  
Only for subjects who signed the genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected  at this visit if not collected at a previous v isit. 
Only for subjects who signed the genetic ICF /IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
DBPCFC will be performed and t he grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheet s (see Appendix  14.2). 
Any AEs that have occurred since the previous visit wil l be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/ reminded , if required . 
The Visit [ADDRESS_397705] and drug 
accountability/compliance will be assessed.  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan ( Appendi x 14.5) as necessary. The expi[INVESTIGATOR_322198]-injector will be checked and a new auto -injector should be dispensed to the 
subject, as necessary . 
A minimum duration of [ADDRESS_397706] day of the double -blind treatment period.  It is recommended that a patch not be 
applied on the day of the DBPCFC procedures at Visit  12 and subjects should be 
instructed to not apply any patch between Visit 12 and Visit 13.  
[IP_ADDRESS]  Visit 13  (Second day of the Month 12 DBPCFC)  
Visit [ADDRESS_397707] within 7 days after Visit 12 . However, Visit 13 may be scheduled up to a 
maximum of 14  days  after Visit  12 and documented in the eC RF, if either of the 
following occur: (1) the subject experiences reactions after the DBPCFC at Visit 12 that 
require more than 7  days to elapse before the next food challenge, or (2) any 
intercurrent  disease preventing the second day of the challenge to be conducted safely 
as planned; in this specific condition, the timeframe between the [ADDRESS_397708] be appropriately documented , or (3) the subjectâ€™s 
schedule or si te logistics prevent the second day of  food cha llenge to be performed 
within [ADDRESS_397709]  day.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 57 of 170 
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before  the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737] . 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and  can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheet s (see Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaski n patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
Site staff will login  into IWRS . The treatment kit  to be allocated at this Visit [ADDRESS_397710] . 
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397711] dose of the 
challenge has be en administered or the challenge stopped because (a) clear objective 
reaction(s) has (have) occurred , the order of the challenge formulas can be unbl inded 
and the results  of the challenge will be established  as described in Section  [IP_ADDRESS].[ADDRESS_397712] patch  of the open -label treatment 
up to a maximum of 7 days after Visit 13.  
[IP_ADDRESS]  Visit 14  (21 days Â±3 days  after Visit 13)  
Visit [ADDRESS_397713] 21 days Â±3 days after  Visit 13 . 
Subjects will undergo the following procedures at this visit:  
A physical examination,  including a complete skin examination, will be performed.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 58 of 170 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
PEF measurements (depending on the subjectâ€™s age and abili ty to perform these tests) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397714] and drug 
accountability/compliance will be assessed.   
The Visit [ADDRESS_397715] . 
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 15 ( Month 18  Â±14 days )  
Visit 15 (Month 18) will take place 6 months  Â±14 days after  Visit 13.  
Subjects will undergo the following procedures at this visit:  
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s  age and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, as well as 
immunological markers (IgE, IgG4) will be collected.  
Only for subjects who signed the  genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit . 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397716] and drug 
accountability/compliance will be assessed.  
Site staff will login  into IWRS to be allocated a re -supply open -label kit for the subject. 
The Visit [ADDRESS_397717].  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 59 of 170 
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
[IP_ADDRESS]  Visit 16 ( Month 24  Â±14 days ; First Day of the Mon th 24 
DBPCFC )  
Before implementation of Protocol Amendment 5  
Visit 16 (Month 24) will take place 12 months  Â±[ADDRESS_397718] been completed.  
Subjects will undergo the following procedures at this visit:  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1766] 
(when applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed.  The appropriate  QoL questionnaire forms to complete depend upon t he age 
of the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed 
before  the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessar y by [CONTACT_737] . 
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk  will be performed.  
Blood samples for hematology and  biochemistry laboratory tests,  and immunological 
markers (IgE, IgG4)  will be collected.  
Only for subjects who signed the genetic ICF /IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit . 
Only for subjects who signed  the genetic ICF /IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
DBPCFC will be performed  and the grading of each symptom will be made using the 
gradin g definitions in  the OFC symptom score sheet s (see Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medicat ions reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be checked and given back to the subject  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397719] and drug 
accountability/compliance will be assessed.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397720].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397721] 
is discharged from the site. The observation period can be extended beyond 
3 hours if deemed necessary by [CONTACT_737].  
After implementation of Protocol Amendment 5  
Until the  subjects can switch to Viaskin Milk 300  Âµg, the following will apply:  
â€¢ The Visit 16 will proceed without the procedures related to the DBPCFC;  
â€¢ Site staff will login into IWRS to be allocated  treatment kits fo r both Visit 16 and 
Visit 17;  
â€¢ Visit 17 will not be conducted . 
[IP_ADDRESS]  Visit 17  (Second day of the Month 24  DBPCFC)  - Not to be 
conducted after implementation of Protocol Amendment [ADDRESS_397722] within 7 days after Visit 16 . However, Visit 17 may be scheduled 
up to a maximum of 14  days  after Visit  16 and documented in the e CRF, if either of the 
following occur: (1) the subject experiences reactions after the DBPCFC at Visit 16 that 
require more than 7  days to elapse before the next food challenge, or (2) any 
intercurrent  disease preventing the second day of the challenge to be conducted safely 
as planned; in this specific condition, the timeframe between the [ADDRESS_397723] be appropriately documented , or (3)  the subjectâ€™s 
schedule or site logistics prevent the second day of food cha llenge t o be performed 
within [ADDRESS_397724]  day.  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before  the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737] . 
Vital signs (heart rate, systolic and diastolic blood pressure, and r espi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before  the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737] . 
PEF measurements (depending on the subjectâ€™s age and ability to perform these tes ts) 
will be obtained.  
DBPCFC will be performed  and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheet s (see Appendix  14.2). 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397725]  and instructions 
repeated/reminded , if required . 
The Visit [ADDRESS_397726] and drug 
accountabili ty/compliance will be assessed.   
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary.  The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397727] dose of the 
challenge has been administered or the challenge stopped because of (a) clear 
objective reaction(s) has (have) occurred, the order of the challenge formulas can be 
unblinded and the results  of the challenge will be established  as described in 
Section  [IP_ADDRESS].2  and recorded in the eCRF.  
After the second day of the Month  24 DBPCFC, eligible  subjects will be proposed 
to enter the study extension to receive 2 additional years of EPIT with open -label 
Viaskin Milk 500  Âµg.  Subjects who enter the study extension  will undergo the 
following additional procedures:  
Written and signed ICF/IAF to enter  study extension will be collected  at Visit [ADDRESS_397728] 14 days after 
Visit 17.  
[IP_ADDRESS]  Visit 18 (Month 30 Â±14 days )  
For the subjects who enter the study extension, a Visit 18 (Month  30) will take place 
18 months Â±14 days after Visit  13.  
Subjects will undergo the following procedures at this visit: 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 62 of 170 
SPT to cowâ€™s milk will be performed.   
Blood samples for hematology and  biochemistry laboratory tests, as well as 
immunological markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked a nd given back  to the subject and instructions 
repeated /reminded,  if required.  
The Visit [ADDRESS_397729] and drug 
accountability/compliance will be assessed.  
Site staff will login  into IWRS to be allocated a re-supply  open-label kit for the subject. 
The Visit [ADDRESS_397730].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) will be provided, as necessary. The expi[INVESTIGATOR_322199] -injector will be checked and a new auto -injector should be dispensed 
to the subject, as necessary.  
[IP_ADDRESS]  Visit 19 (Month 36 Â±14 days ; First day of the Month 36 
DBPCFC)   
Before implementation of Protocol Amendment 5  
For subjects who entered the study extension, Visit 19 (Month  36) will take place 24 
months Â±[ADDRESS_397731] been completed.  
Subjects will undergo the following procedures at this visit:  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1766] 
(when applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed. The appropriate  QoL questionnaire forms to complete  depend on the age of 
the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as jud ged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessar y by [CONTACT_737].  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, and immunological 
markers (IgE, IgG4) will be collected.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 63 of 170 
Only for subjects who signed the genetic ICF/IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit.  
Only fo r subjects who signed the genetic ICF/IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheets  (see Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if require d. 
The Visit [ADDRESS_397732] and drug 
accountability/compliance will be assessed.  
Site staff will login into IWRS to be allocated a small re-supply open -label kit to cover 
the period between both days of the DBPCFC . The Visit [ADDRESS_397733].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397734] 
is discharged from the site. The observation period may be extended beyond 
3 hours if deemed necessary by [CONTACT_737].  
After implementation of Protocol Amendment 5  
Until the subjects can switch to Viaskin Milk 300  Âµg, the following will apply:  
â€¢ The Visit 19 will proceed without the procedures related to the DBPCFC;  
â€¢ Site staff will login into IWRS to be allocated  treatment kits for both Visit 19 and 
Visit 20;  
â€¢ Visit 20 will not be conducted . 
 
[IP_ADDRESS]  Visit 20 (Second day of the Month 36 DBPCFC)  - Not to be 
conducted after implementation of Protocol Amendment [ADDRESS_397735] within 7  days 
after Visit 19. However, Visit 20 may be scheduled up to a maximum of 14  days  after 
Visit 19 and documented in the eCRF, if either of the following occur s: (1) the subject 
experiences reactions after the DBPCFC at Visit  19 that require more than 7  days to 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 64 of 170 
elapse before the next food challenge, or (2)  any intercurrent  disease preventing the 
second day of the challenge to be conducted safely as planned; in this specific 
condition, the timeframe between the [ADDRESS_397736] be appropriately documented, or (3)  the subjectâ€™s schedule or si te logistics 
prevent the second day of food challenge to be performed within [ADDRESS_397737] day.  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before the D BPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
DBPCFC will be performed and the grading of each symptom wi ll be made using the 
grading definitions in the OFC symptom score sheets (see Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documente d and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if r equired.  
The Visit [ADDRESS_397738] and drug 
accountability/compliance will be assessed.  
Site staff will login into IWRS to be allocated a re-supply  open -label kit for the subject. 
The Visit [ADDRESS_397739].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397740] dose of the 
challenge has been administered or the challenge stopped because of (a) clear 
objective reaction(s) has (have) occurred, the order of the challenge formulas can be 
unblinded and the results  of the challenge will be establish ed as described in 
Section  [IP_ADDRESS].2  and recorded in the eCRF.  
[IP_ADDRESS]  Visit 21 (Month 42 Â±14 days)  
For subjects who entered the study extension , Visit 21 (Month  42) will take place 30 
months  Â±14 days after  Visit 13.  
Subjects will undergo the following procedures at this visit:  
Weight (kg) and height (cm) will be measured.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 65 of 170 
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, as well as 
immunological markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of th e skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit [ADDRESS_397741] and drug 
accountability/compliance will be assessed.  
Site staff will login into IWRS to be allocated a  re-supply  open -label kit for the subject. 
The Visit [ADDRESS_397742].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5) as necessary. The expi [INVESTIGATOR_322198]-injector will be checked and a new auto -injector should be dispensed to the 
subject, as necessary.  
[IP_ADDRESS]  Visit 22 (Month 48 Â±14 days; First day of the Month 48 
DBPCFC)   
Before implementation of Protocol Amendment 5  
For subjects who entered th e study extension, Visit 22 (Month 48) will take place 36 
months  Â±[ADDRESS_397743] been completed.  
Subjects will undergo the following procedures at this visit:  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1766] 
(whe n applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed. The appropriate  QoL questionnaire forms to complete depend upon the age 
of the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physic al examination, including a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_31145]) for 
subjects in a sitting position will be measured  before the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 66 of 170 
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform th ese tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, and immunological 
markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for the analysis of 
filaggrin mutations may be collected at this visit if not collected at a previous visit.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed fo r female subjects with childbearing potential.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheets (see  Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit [ADDRESS_397744] and drug 
accountability/compliance will be assessed.  
Site staff will login into IWRS to be allocated a small re-supply open -label kit to cover 
the period between both days of the DBPCFC . The Visit [ADDRESS_397745].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -inject or and the Anaphylaxis 
Emergency Action Plan (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397746] 
is discharged from the site. The observation period may be extended beyond 
3 hours if deemed necessary by [CONTACT_737].  
After implementation of Protocol Amendment 5  
Until the subjects can switch to  Viaskin Milk 300  Âµg, the following will apply:  
â€¢ The Visit 22 will proceed without the procedures related to the DBPCFC;  
â€¢ Visit 23 will not be conducted . 
 
[IP_ADDRESS]  Visit 23 (Second day of the Month 48 DBPCFC)  - Not to be 
conducted after implementation of Protocol Amendment 5  
Visit 23 corresponds to the second day of the Month 48 DBPCFC.  It is recommended 
that a patch not be applied on that day as it will be the end of the open -label treatment 
period.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397747] within 7 days 
after Visit 22 . However, Visit 23 may be scheduled up to a maximum of 14  days  after 
Visit 22 and documented in the eCRF, if either of the following occur: (1) the subject 
experiences reactions after the DBPCFC at Visit 22 that  require more than 7  days to 
elapse before the next food challenge, or (2) any intercurrent  disease preventing the 
second day of the challenge to be conducted safely as planned; in this specific 
condition, the timeframe between the [ADDRESS_397748] be appropriately documented, or (3) the subjectâ€™s schedule or site logistics 
prevent the second day of food challenge to be performed within [ADDRESS_397749] day.  
Subjects will undergo the following procedures at this visit:  
A physical examination, including a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pressure, and r espi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
PEF measurements (depending on the subjectâ€™s age and ability to perform these tes ts) 
will be obtained.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheets (see  Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will b e checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit [ADDRESS_397750] and drug 
accountability/compliance will be assessed.  
Review/reminder of the utilization of the epi[INVESTIGATOR_22493] e auto -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397751] dose of the 
challenge has been administered or the challenge stopped because of (a) clear 
objective reaction(s) has (have) occurred, the order of the challenge formulas can be 
unblinded and the results  of the challenge will be established  as described in 
Section  [IP_ADDRESS].[ADDRESS_397752] 14 days after Visit 2 3. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 68 of 170 
[IP_ADDRESS]  Additional Phone Contacts  
In addition to the regular study visits at  site, the study personnel will contact [CONTACT_12912] /subjectsâ€™ guardians or parents  by [CONTACT_322250], especially 
skin-related symptoms , and concomitant treatments if a ny. 
â€¢ Individual phone contacts (PCs) are designated â€œPCâ€ followed by [CONTACT_322251] (e .g., â€œ9â€), followed by [CONTACT_110179] â€œaâ€ for the first phone 
call after that clinic visit, â€œbâ€ for the next phone call a fter that s ame clinic visit, 
and so forth ). During the first year of treatment , 7 PCs are scheduled at: Month 
2 (PC8a)  
â€¢ Month 4 (PC9a)  
â€¢ Month 5 (PC9b)  
â€¢ Month 7 (PC10a)  
â€¢ Month 8 (PC10b)  
â€¢ Month 10 (PC 11a) 
â€¢ Month 11 (PC 11b). 
The date s of these PC s during the first year of treatment will be calculated from the 
date of Visit 4 (Day 1), with a permitted window of ï‚± 7 days.  
During the second year of treatment, 4 additional phone contacts (PC s) are scheduled 
at: 
â€¢ Month 14 (PC14a)  
â€¢ Month 16 (PC14b)  
â€¢ Month 20  (PC15a)  
â€¢ Month 22 (PC 15b).  
The date s of these PC s during the second year of treatment will be calculated from the 
date of V isit 13 (start date of the open -label  treatment period), with a permitted window 
of ï‚± 7 days.  
For the subjects who enter in the study  extension,  4 additional phone contacts (PCs) 
are scheduled at:  
â€¢ Month 27  (PC17 a) 
â€¢ Month 33  (PC18 a) 
â€¢ Month 39  (PC20a)  
â€¢ Month 45  (PC21a)  
The dates of these PCs during the third and fourth year of treatment will be calculated 
from the date of Visit 13 (start dat e of the open -label treatment period), with a permitted 
window of ï‚±14 days.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397753] s not consent ing to switch to Viaskin Milk 300  Âµg, the following procedures 
should be performed:  
â€¢ EOS visit procedures (Table  3) if the subject has reached Month 24 of open -label 
treatment with Viaskin Milk 500  Âµg, 
â€¢ ET visit procedures  (Table  4 or Table  5) in all other cases.  
 
For the eligible subjects consenting to switch to Viaskin Milk 300  Âµg, the visit schedule 
and procedures are described in the sections below. V isit timepoints are in ref erence to 
the switch to Viaskin Milk 300  Âµg (e.g. â€œMonth 6â€ should be understood as â€œMonth 6 
following the switch  to Viaskin Milk 300  Âµgâ€). 
[IP_ADDRESS]  Visit S1 (Day 1)  
The subject  should be contact[CONTACT_322252] S1 (Day 1).  
Signed  written  ICF/IAF  for the switc h to Viaskin Milk 300  Âµg will be obtained before any 
assessments are made.  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1766] 
(when applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed. The appropriate  QoL questionnaire forms to complete depend upon the age 
of the subject  at the time of Visit [ADDRESS_397754] and drug accountability/compliance will be 
assessed.   
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] ( depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology, bio chemistry laboratory tests, and immunological 
markers (IgE, IgG4) will be collected , unless already d one within [ADDRESS_397755] and instructions will be given for completion.  
Epi[INVESTIGATOR_107528] -injector and the Anaphylaxis Emergency Action Plan (Appendix  14.5) 
will be dispensed and/or their utilization reviewed, as necessary.  The expi[INVESTIGATOR_322198]-injector will be checked and a new auto -injector should be dispensed to the 
subject, as necessary.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 70 of 170 
Only for subjects who signed the genetic ICF/IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
[IP_ADDRESS]  Visit S2 (Month 6 Â±14 days)  
Visit S2 (Month 6) will take place 6 months Â±14 days after  Visit S1 (Day 1) .  
QoL questionnaire FAQLQ/FAIM forms ( Appendix 14.3) will be completed by [CONTACT_1766] 
(when applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed. The appropriate  QoL questionnaire forms to complete depend upon t he age 
of the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_98157]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology, bio chemistry laboratory tests, and immunological 
markers (IgE, IgG4) will be collected.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for  Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit S1 treatment box es will be collected from the subject and drug 
accountability/compliance will be assessed.  
Site staff will login into IWRS to be allocated to be allocated open -label [ADDRESS_397756].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the  Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322198]-injector will be checked and a new auto-injector should be dispensed to the 
subject, as necessary.  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
[IP_ADDRESS]  Visit S3 (Month 12 Â±14 days ; First Day of the  optional  Month 
12 DBPCFC)  
Visit S3 (Month 12) will take place 12 months Â±14 days after  Visit S1 (Day 1) , for all 
subjects . Visit S3 corresponds to the first day of the optional Month [ADDRESS_397757] experienced a severe 
anaphylaxis  to cowâ€™s milk  during the MILES s tudy, whether or not occurring during the 
DBPCFC, no further DBPCFC should be conducted for this subject.  
If the subject decides to perform the DBPCFC, n o patch should be applied on that day 
until all DBPCFC procedures have been completed.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 71 of 170 
QoL questionnair e FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1560] (when applicable) and parent(s)/guardian(s) before any procedures at this visit 
are performed. The appropriate  QoL questionnaire forms to complete depend on the 
age of the subject  at the time of Visit 1 . 
Weight (kg) and h eight (cm) will be measured.  
A physical examination including a complete skin examination will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322200] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology, bio chemistry laboratory tests, and immunological 
markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and inst ructions 
repeated/reminded, if required.  
The Visit S2 treatment box es will be collected from the subject and drug 
accountability/compliance will be assessed. Site staff will login into IWRS to be 
allocated open-label [ADDRESS_397758].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan (Appendix  14.5) as necessary. The expi[INVESTIGATOR_322198]-injector will be checked and a new auto -injector should be dispensed to the 
subject, as necessary.  
Only for subjects performing the DBPCFC : the grading of each symptom will be 
made u sing the grading definitions in the OFC symptom score sheets 
(see Appendix  14.2). Physical examination and vital signs measurements can be 
repeated anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
AEs occurring during the DBPCFC should be collected.  
A minimum duration of [ADDRESS_397759] 
is discharged from the site. The observation period can be extended beyond 
3 hours if deemed necessary by [CONTACT_737].   
[IP_ADDRESS]  Visit S4 (Second day of the  optional  Month 12 DBPCFC ; only 
for subjects who performed the first day of the DBPCFC ) 
Visit S4 will be performed only for subjects who perform ed the first day of the Month 12  
DBPCFC. This visit corresponds to the second day of the Month 12 DBPCFC. No 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397760] within 7 days after Visit S3 . However, Visit S4 may be 
scheduled up to a maximum of 14  days  after Visit  S3 and documented in the eCRF, if 
either of the following occ ur: (1) the subject experiences reactions after the DBPCFC at 
Visit S3 that require more than 7  days to elapse before the next food challenge, or (2) 
any intercurrent  disease preventing the second day of the challenge to be conducted 
safely as planned; in this specific condition, the timeframe between the [ADDRESS_397761] be appropriately documented, or (3) the 
subjectâ€™s schedule or site logistics prevent the second day of food challenge to be 
performed within [ADDRESS_397762] day.  
A physical examination, including a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pr essure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measured  before the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
PEF measurements (depending on the subjectâ€™s age and ability to perf orm these tests) 
will be obtained.  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheets  (see Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaski n patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397763] dose of the 
challenge has been administered or the challenge stopped because of (a) clear 
objective reaction(s) has (have) occurred, the order of the challenge formulas can be 
unblinded and the results  of the challenge will be established  as described in 
Section  [IP_ADDRESS].2  and recorded in the eCRF.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 73 of 170 
[IP_ADDRESS]  Visit S5 (Month 18 Â±14 days ) 
Visit S5 (Month 18) will take place 18 months  Â±14 days after  Visit S1.  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1560] (when applicable) and parent(s)/guardian(s) before any procedures at this visit 
are performed. The appropriate  QoL questionnaire forms to complete depend on the 
age of the subject  at the time of Visit 1 . 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_696] r ate) for 
subjects in a sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemist ry laboratory tests, as well as 
immunological markers (IgE, IgG4) will be collected.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the sk in used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit S [ADDRESS_397764] and drug 
accountability/compl iance will be assessed.  
Site staff will login into IWRS to be allocated open -label [ADDRESS_397765].  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaph ylaxis 
Emergency Action Plan (Appendix  14.5) as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A urine pregnancy test will be performed for fema le subjects with childbearing potential.  
[IP_ADDRESS]  Visit S6 (Month 24 Â±14 days ; First Day of the optional Month 
24 DBPCFC)  
Visit S6 (Month 24) will take place 24 months  Â±[ADDRESS_397766] experienced a severe anaphylaxis to cowâ€™s milk during 
the MILES study, whether or not occurring during the DBPCFC, no further DBPCFC 
should be conducted for this subject.  
 If the subject decides to per form the DBPCFC,  no patch should be applied on that day 
until all DBPCFC procedures have been completed.  
QoL questionnaire FAQLQ/FAIM forms (Appendix 14.3) will be completed by [CONTACT_1766] 
(when applicable) and parent(s)/guardian(s) before any procedures at this visit are 
performed. The appropriate  QoL questionnaire forms to complete depend upon the age 
of the subject  at the time of Visit 1 . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 74 of 170 
Weight (kg) and height (cm) will be measured.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a  sitting position will be measured.  
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age and ability to 
perform these tests) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, a nd immunological 
markers (IgE, IgG4) will be collected.  
Only for subjects who signed the genetic ICF/IAF: a blood sample for epi[INVESTIGATOR_322195].  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will b e checked and given back to the subject and instructions 
repeated/reminded, if required.  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
There will be no dispensa tion of the Investiga tional product at this visit.  
Only for subjects performing the DBPCFC : the grading of each symptom will be 
made using the grading definitions in the OFC symptom score sheets 
(see Appendix  14.2). Physical examination and vital signs measurements can be 
repeated anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
AEs occurring during the DBPCFC should be collected.  
A minimum duration of [ADDRESS_397767] 
is discharged from the site. The observation period can be extended beyond 
3 hours if deemed necessa ry by [CONTACT_737].   
Only for subjects not performing the DBPCFC : The Visit S5 treatment box es will be 
collected from the subject and drug accountability/compliance will be assessed.  
[IP_ADDRESS]  Visit S7 (Second day of the  optional  Month 24 DBPCFC ; only 
for subjec ts who performed the first day of the DBPCFC ) 
Visit S7 corresponds to the second day of the Month [ADDRESS_397768] within 7 days after Visit S6 . However, Visit S7 may be 
scheduled up to a maximum of 14  days  after Visit  S6 and documented in the eCRF, if 
either of the following occur: (1) the subject experiences reactio ns after the DBPCFC at 
Visit S6 that require more than 7  days to elapse before the next food challenge, or (2) 
any intercurrent  disease preventing the second day of the challenge to be conducted 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 75 of 170 
safely as planned; in this specific condition, the timeframe between the [ADDRESS_397769] be appropriately documented, or (3) the 
subjectâ€™s schedule or site logistics prevent the second day of food challenge to be 
performed within [ADDRESS_397770] day.  
A physical examination, in cluding a complete skin examination, will be performed 
before the DBPCFC and can be repeated anytime during the DBPCFC, as judged 
necessary by [CONTACT_737].  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subje cts in a sitting position will be measured  before the DBPCFC and can be repeated 
anytime during the DBPCFC, as judged necessary by [CONTACT_737].  
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
DBPCFC will be performed and the grading of each symptom will be made using the 
grading definitions in the OFC symptom score sheets (see  Appendix  14.2). 
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be checked and given back to the subject and instructions 
repeated/reminded, if required.  
The Visit S5 treatment box es will be collected from the subject and drug 
accountability/complian ce will be assessed.  
Review/reminder of the utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis 
Emergency Action Plan  (Appendix  14.5), as necessary. The expi[INVESTIGATOR_322196] -
injector will be checked and a new auto -injector should be dispensed to the subject, as 
necessary.  
A minimum duration of [ADDRESS_397771] dose of the 
challenge has been administered or the challenge stopped because of (a) clear 
objective reaction(s) has (have) occurred, the order of the challe nge formulas can be 
unblinded and the results  of the challenge will be established  as described in 
Section  [IP_ADDRESS].[ADDRESS_397772] ace 14 days after 
Visit S7.  
[IP_ADDRESS]  Additional Phone Contacts  
In addition to the regular study visits at site, the study personnel will contact [CONTACT_12912]/subjectsâ€™ guardians or parents by [CONTACT_322253], especially 
skin-related symptoms, and con comitant treatments if any.  
During the first year of treatment with Viaskin Milk 300  Âµg, 3 PCs are scheduled at 
Month 1, Month 4 and Month 9, with a permitted window of ï‚± 14 days.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 76 of 170 
During the second year of treatment with Viaskin Milk 300  Âµg, 2 PCs are sche duled at 
Month 15 and Month 21, with a permitted window of ï‚± [ADDRESS_397773] 14  days Â±[ADDRESS_397774] : 
â€¢ If the subject did not perform the DBPCFC at Visit S6: 14 days Â±3 days  after 
Visit S 6; 
â€¢ If the subject performed the DBPCFC at Visit S6: 14  days Â±[ADDRESS_397775] for completion.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi[INVESTIGATOR_697]) for 
subjects in a sitting position will be measur ed. 
PEF measurements (depending on the subjectâ€™s age and ability to perform these tests) 
will be obtained.  
Any AEs that have occurred since the previous visit will be documented and any 
changes in medications reported.  
Examination, grading, and photography  of the area of the skin used for Viaskin patch 
application will be performed.  
Diary card will be collected.  
An EOS survey will be completed by [CONTACT_737].  
7.2.[ADDRESS_397776] for early 
withdrawal.  
The following data will be collected from subjects who are withdrawn before completing 
the study:  
QoL questionnaire FAQLQ /FAIM forms (Appendix 14.3) will be completed by [CONTACT_1560] (when applicable) and parent(s)/guardian(s) before any procedures at this visit 
are performed.  The appr opriate QoL questionnaire forms to complete depend on the 
age of the subject at the time of Visit 1.  
A physical examination, including a complete skin examination, will be performed.  
Vital signs (heart rate, systolic and diastolic blood pressure, and respi [INVESTIGATOR_697]) for 
subjects in a sitting position will be measured.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 77 of 170 
Spi[INVESTIGATOR_322194] (depending on the subjectâ€™s age  and ability to 
perform these tests ) will be obtained.  
SPT to cowâ€™s milk will be performed.  
Blood samples for hematology and  biochemistry laboratory tests, as well as 
immunological markers (IgE, IgG4) will be collected.  
A urine pregnancy test will be performed for female subjects with childbearing potential.  
Any AEs that have occurred since the previous visit will be documented an d any 
changes in medication s reported.  
Examination, grading, and photography of the area of the skin used for Viaskin patch  
application will be performed.  
Diary card will be collected.  
The treatment box from the previous visit is collected from the subject (when 
applicable) and drug accountability/compliance will be assessed.  
An EOS survey will be  completed by  [CONTACT_737].  
 
7.3 Efficacy  and Safety Variables   
The timepoints of the planned study assessments are summarized in  the Schedule of 
Assessmen ts (Table  2 to Table 7). 
7.3.1  Efficacy  Assessments  
Efficacy assessments will include the following  variables : 
â€¢ Cumulative Reactive Dose (CRD ) of cowâ€™s milk proteins during the DBPCFC  
â€¢ Serum immunology: Levels of sIgE and allergen -specific IgE to cowâ€™s milk, 
caseins, ï¡-lactalbumin, and ï¢-lactoglobulin , levels of specific IgG4 to total cowâ€™s  
milk (not applicable after the switch to Viaskin Milk 30 0 Âµg), to caseins, ï¡-
lactalbumin, and ï¢-lactoglobulin.  
â€¢ Severity of symptoms elicited during the milk DBPCFC  
â€¢ SPT to cowâ€™s milk  
â€¢ QoL assessments  
[IP_ADDRESS]  Double -Blind Placebo -Controlled Food Challenge to Cowâ€™s 
Milk (DBPCFC)  
A detailed Manual of Procedures for the pre paration of the challenge formulas and for 
the conduct of the DBPCFC will be provided to the Investigator s and their medical 
teams as well as to the site personnel that will be dedicated for the preparation of the 
challenge formulas. This could be dieticia ns, study nurses , pharmacists , pharmacy 
technicians, license d medical assistants , or any other qualified site personnel , as 
delegated by [CONTACT_737] ; only the site personnel dedicated to the preparation of 
the challenge formulas will be unblinded to the order of the formulas administered on 
the 2 days of the DBPCFCs . An outline of the procedures is specified in this section 
and the grading of each symptom will b e made using the grading definition of the OFC 
symptom score  sheet s provided in Appendix  14.2. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397777] 
will be gradually fed with increasing amounts of cowâ€™s milk proteins under medical 
observation. The challenge occurs over two days and must take place under direct 
medical supervision in a hospi[INVESTIGATOR_307]/clinic setting with resuscitation equipment a nd 
emergency medications and staff immediately available. It is recommended to have  an 
intravenous (i.v.) line  in place prior to challenging the subjects; however , the final 
decision not to place this i.v. line can be made on a case -by-case basis at the 
discretion of the Investigator . A local anesthetic  cream can be used for establishing this 
i.v. lin e, especially for children. If a site prefers to have the subjects come to the 
hospi[INVESTIGATOR_322201], to prepar e them for the following 
day, this is allowed and will not be considered an SAE.  
Subjects must be off antihistamines 1 to 7 days (depending of the half -life, see 
Appendix  14.7) prior to any DBPCFC. Subjects will not be allowed to use long-acting ï¢2 
agonists (e g, formoterol) within [ADDRESS_397778] day of the DBPCFC, the second day of the 
DBPCFC can be co nducted only from the fourth day onwards.  
A DBPCFC will be performed at screening (Visits 2 and 3), at Month  12 (Visits  12 
and 13); a DBPCFC was planned  at Month  24 (Visits 16 and 17)  and for subjects who 
entered the study extension , at Month  36 (Visits  19 and 20) and Month  48 (Visits  22 
and 23) , but these food challenges should no longer be performed while the subjects 
are still receiving Viaskin Milk 500  Âµg. A DBPCFC can be performed after 12 months 
(Visits S3 and S4) and /or 24 months (Visits S6  and S7) of treatment with Viaskin Milk 
[ADDRESS_397779] .  
No DBPCFC will be performed while the subjects are still receiving Viaskin Milk 
500 Âµg and  until they reach 12 months of treatment with Viaskin Milk 300  Âµg.  
Each DBPCFC will comprise 2 visits: [ADDRESS_397780] within 7 days (one week) after the first day of the food challenge.  
However, the second day may be scheduled up to a maximum of [ADDRESS_397781] 
food challenge and documented in the eCRF, if any of the following occur s: (1) the 
subject experiences reactions after the DBPCFC on the first day that require more than 
7 days to elapse before the next food challenge, or (2) any intercurr ent disease 
preventing the second day of the challenge to be conducted safely as planned , such as 
a rhinitis, bronchitis or gastrointestinal infection ; in this specific condition and for safety 
reasons, the timeframe between the [ADDRESS_397782] be appropriately documented , or (3) the subjectâ€™s schedule or site logistics 
prevent the second day of food challenge to be performed within [ADDRESS_397783] day.  
The order of the food challenge (milk or placebo) will be blinded;  it will be determined 
using a randomization table that will be distributed to site personnel dedicated to the 
preparation of the challenge formulas (see Section  8.4). After both days of a DBPCFC 
have been completed, the order of the food challenge (ie, actual visits that the milk and 
placebo challenges were administered) can be revealed for completion of the eCRF.  
The subject should have a light breakfast and may d rink water at home at least [ADDRESS_397784] of the challenge  no other 
food (except for the food challenge  formula ) should be consumed by [CONTACT_423]. Water 
should also ideally not be consumed , but limited amount of water will be tolerated 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397785] 1 hour before ingesting any other food and/or  drinking large volumes of  water. 
The contents of the first meal after the food challenge should be light.  
All DBPCFC s will consist of administering  cowâ€™s milk proteins (or placebo) in gradually 
increasing doses at 20 -minute intervals. The Investigator  may use clinical judgment to 
increase the intervals between doses in case  there is a suspi[INVESTIGATOR_322202] (see  Section  [IP_ADDRESS].3 ). 
Before implementation of Protocol Amendment 5, DBPCFCs to milk and to other 
allergens were strictly forbidden. After implementation of Protocol Amendment 5, 
DBPCFCs to milk ( including baked milk, and outside of the one described in this 
protocol ) will stil l be strictly forbidden as long as the subject is part of the study  but 
performing DBPCFCs  to any other food for the subjectâ€™s medical management will be 
permitted. Whether  the subjectâ€™s medical condition is still  compatible with the ir 
participation in the  study should be assessed by [CONTACT_2725]â€™s 
medical monitor  before the food challenge is performed . If not compatible , the Sponsor 
may decide to discontinue the subject from the study.  Note that the initiation of other 
immunotherapy tre atment remains prohibited during the participation of the subject in 
the MILES study (refer to Section 6.5.2 ). Viaskin Milk patches should not be applied 
on the day  of a food challenge  and until all procedures  are completed . Information 
on food challenges to other allergens than cowâ€™s milk will also be recorded in the 
eCRF.  
[IP_ADDRESS].1  DBPCFC at Screening (Visits 2 and 3)  
During the screening DBPCFC, the doses of cowâ€™s milk protein s to be ingested will be 
1 mg, 3 mg, 10 mg, 30 mg, 100  mg, and 300  mg administered at 20 -minute intervals. 
The Investigator  may use clinical judgment to increase the intervals between doses in 
case  there is a suspi[INVESTIGATOR_322203] (see 
Section  [IP_ADDRESS].3 ). Very occasionally , the Investigator  may use clinical judgment to 
repeat the same dose  (but only once ) before administration of the next higher dose  and 
only if there is a suspi[INVESTIGATOR_322204] (see 
Section  [IP_ADDRESS].3 ). The dose and the  time of administration of each dose (an d of a 
repeat ed dose when applicable)  will be recorded in the eCRF.  The subjects will be kept 
under observation for an additional [ADDRESS_397786] objectively  (see Section  [IP_ADDRESS].3 ) at or below the eliciting 
dose of 300 mg of cowâ€™s milk protein s to be eligible for randomization to treatment . 
Hence, this screening DBPCFC will be stopped at or below the dose of 300  mg on 
either day of the challenge  (milk or placebo) , whether reactions have occurred or not.  
Subjects who have not reacted objectively at or below the eliciting dose of 300 mg of 
cowâ€™s milk proteins will be considered ineligible for this study.   
All subjects sho uld undergo procedures of the DBPCFC on both days. However , in 
exceptional cases, the DBPCFC on the second day of the challenge might not be 
performed if the subject had a  severe  anaphylactic reaction  during the first day of the 
challenge, leaving no doubt  about the nature of the formula administered, ie, cowâ€™s 
milk. In this rare case and in this case only, the food challenge formula will be 
unblinded to confirm that the subject effectively received the milk formula.  A severe 
anaphylactic reaction would inv olve a >20% drop of blood pressure, cyanosis or 
Sp02<92%, confusion, collapse, loss of consciousness, 3 doses of epi[INVESTIGATOR_322205]  
(see Appendix  14.4).  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 80 of 170 
At the end of the second day of the food challenge (Visit  3), the sequence of the 
2 formulas (milk or placebo) administered  to the subject will be unblinded by [CONTACT_322254] (eg, dietician s, study nurse s, pharmacist s, pharmacy 
technicians, licensed medical assistants, or any other qualified site personnel, as 
delegated by [CONTACT_737] ) and revealed to the medical staff . The results of the 
challenge will then be establi shed  and recorded in the eCRF  as follows : 
1. The subject had objective symptoms to the placebo formula at any dose leading 
to stoppi[INVESTIGATOR_322206]. S/He cannot be randomized in the study.  
2. The subject had no objective symptoms during the [ADDRESS_397787] dose of 
300 mg of cowâ€™s milk protein s. S/He is considered not allergic enough to cowâ€™s 
milk to participate in this study and cannot be randomized in the study.  
3. The subject had no objective symptom when receiving placebo but had an 
objective reaction (as defined in Section [IP_ADDRESS].3 ) at 1 of the doses of the milk 
formula consumed between 1  mg and 300  mg inclusive. S/He will be 
randomized in the study as s/he reacted to a dose of milk proteins lower than or 
equal to 300  mg (eliciting dose).  
[IP_ADDRESS].2  DBPCFC at Month 12 (Visits 12 and 13) , Month  24 (Visits  16 and 17) , 
Month 36 (Visits 19 and 20) , and Month 48 (Visits  22 and 23) , and optional 
DBPCFC after 12 months (Visits S3 and S4) and 24 months (Visits S6 and 
S7) of treatment with Viaskin Milk [ADDRESS_397788] been completed . 
Following results of the 12 -month blinded period, the DBPCFCs that were to be 
performed at Month 24, Month 36 and Month 48 should not be conducted while the 
subjects are still receiving Viaskin Milk 500  Âµg.  
After subjects switch to Viaskin Milk 300  Âµg, the DBPCFCs at 12 months and 24 
months will be optional  and left at the Investigatorâ€™s  and the subjectâ€™s  decision.  
However, if a subject experienced a severe anaphylaxis to cowâ€™s milk during the 
MILES study, whether or not occurring during the DBPCFC, no further DBPCFC 
should be conducted for this subject . 
All DBPCFC s at Month [ADDRESS_397789] will be conducted using the same procedur es 
that are described for the screening DBPCFC, with the exception that the dos ing will 
continue beyond the 300  mg dose of cowâ€™s milk protein s if there are no objective 
symptoms (see Section  [IP_ADDRESS].3 ) at the [ADDRESS_397790] dose of 3000 mg of cowâ€™s milk proteins or until an objective 
reaction occurs  (as defined i n Section [IP_ADDRESS].3 ). 
For all DBPCFC s at Month [ADDRESS_397791] , the doses of cowâ€™s milk proteins will be 
1 mg, 3 mg, 10 mg, 30 mg, 100  mg, 300  mg, 1000  mg, 2000  mg, and 3000  mg 
administered at 20 -minute inter vals. The Investigator  may use clinical judgment to 
increase the intervals between doses in case  there is a suspi[INVESTIGATOR_322202] (see  Section  [IP_ADDRESS].3 ). Very occasionally, the Investigator  
may use clinical judgment to repeat the same dose (only once)  before administration of 
the next higher dose  and only if there is a suspi[INVESTIGATOR_322207] (see Section  [IP_ADDRESS].3 ). The dose  and time of administration of each dose 
(and of a repeat ed dose when applicable)  will be recorded in the eCRF.  The subjects 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397792] 
dose of the challenge formula.  
Subjects should undergo both days of the DBPCFC  (milk and placebo) . However , in 
exceptional cases, the DBPCFC on the  second day of the challenge might not be 
performed if the subject had a  severe  anaphylactic reaction  during the first day of the 
challenge, leaving no doubt  about the nature of the formula administered, ie , cowâ€™s 
milk. In this rare case and in this case only, the formula will be unblinded to confirm that 
the subject effectively received the milk formula.  A severe anaphyla ctic reaction would 
involve a > 20% drop of blood pressure, cyanosis or Sp02<92%, confusion, collap se, 
loss of consciousness, 3 doses of epi[INVESTIGATOR_322205]  (see Appendix  14.4). 
At the end of the second day of the food challenge, the sequence of the 2 formulas 
(milk or placebo) administered  will be unblinded  by [CONTACT_322255] (eg, 
dietician s, study nurse s, pharmacist s, pharmacy technicians, licensed medical 
assistants,  or any other qualified site personnel , as delegated by [CONTACT_737] ) and 
revealed to the medical staff. T he results of the challenge will then be established  and 
recorded in the eCRF . 
[IP_ADDRESS].3  Criteria for Stoppi[INVESTIGATOR_322208] -blind period (Screening, 
Month 12),  the Viaskin Milk 500 Âµg open -label period (Month 24, Month 36 and Month 
48) and the Viaskin Milk 300 Âµg open -label period (12 and 24 months after the switch) 
are provided below . Further details are provided in the Manual of Procedures for the 
DBPCFC.   
Only clear -cut OBJECTIVE  immediate -type symptom(s) requiring treatment  will be 
considered a permissible reason to stop the DBPCFC and to determine the eliciting 
dose (highest dose given during the challenge)  and the CRD of cowâ€™s milk . For the 
open -label treat ment period with Viaskin Milk 300  Âµg, abdominal complaints will also be 
considered as a criterion for stoppi[INVESTIGATOR_322206] (see below) . The main objective 
symptoms to expect are as follows ( this list is not exhaustive; also refer to  
Appendix  14.2, OFC Symptom Score Sheet s21, 22): local or generalized pruritus, 
flushing, local or generalized urticaria, hives, swollen lips, swollen tongue, throat 
tightness, vomiting, diarrhea, dyspnea, rh inorrhea, sneezing, wheezing, conjunctivitis, 
asthma, drop of the PEF, hypoxia, hypotension, hypotonia, decreased level of 
consciousness associated with collapse and/or incontinence or other life threatening 
symptoms.  
The stoppi[INVESTIGATOR_322209] s performed during the double -blind placebo -
controlled period and the open -label treatment period with Viaskin Milk 500  Âµg were the 
following:  
â€¢ There is a >1 -point rise in an objective symptom from any category in the OFC 
Symptom Score Sheets, except only f or pruritus, which requires >2 -point rise  
â€¢ There is â‰¥1-point rise in an objective symptom from â‰¥2 categories in the OFC 
Symptom Score Sheets  
â€¢ There is a 1 -point rise in an objective symptom from 1 category in the OFC 
Symptom Score Sheets, with the following exceptions:  
o Pruritus : 0 to 1 or 0 to 2  
o Urticaria: 0 to 1  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 82 of 170 
o Rash: 0 to 1  
o Sneezing/Itching: 0 to 1  
o Nasal Congestion: 0 to 1  
o Rhinorrhea: 0 to 1  
o Laryngeal: 0 to 1 (if explained and not persistent)  
The stoppi[INVESTIGATOR_322210] -label treatment 
period with Viaskin Milk 300  Âµg are the following:  
Only 1 out of 5 categories has increased its grading symptom score  
 
â‰¥ 1-point rise  
(i.e. mild, moderate or severe)  
OR â‰¥ 2-point rise  
(i.e. moderate or severe)  
OR 3-point rise  
(i.e. severe)  
o Wheezing  
o Objective Gastrointestinal ** 
o Cardiovascular/neurological *** o Urticaria  
o Angioedema  
o Rash  
 o Pruritus  
o Sneezing 
/Itching  
o Nasal 
Congestion  
o Rhinorrhea  
o Conjunctivitis  
o Abdominal 
complaints  
 
2 categories (or more) have increased their grading symptom scores  
 
â‰¥ 1-point rise  
(i.e. mild, moderate or severe)  
AND  â‰¥ 2-point rise  
(i.e. moderate or severe)  
o Urticaria  
o Angioedema  
o Rash  
o Laryngeal * 
o Wheezing  
o Objective Gastrointestinal ** 
o Cardiovascular/neurological *** o Pruritus  
o Sneezing/Itching  
o Nasal Congestion  
o Rhinorrhea  
o Conjunctivitis  
o Abdominal complaints  
 
* â€œLaryngeal â€ means symptoms due to laryngeal oedema and must be differentiated 
from another cause of cough like pharyngeal transient irritation or lower respi[INVESTIGATOR_56790] s. Transient laryngeal irritation will not be considered as an objective OFC 
symptom and will no t be considered in the stoppi[INVESTIGATOR_004].  
**For emesis/vomiting, the symptoms may result from two different situations: 
vomiting/spi[INVESTIGATOR_22940] -up during the feeding, resulting from subjective intolerance to the food 
formula or vomiting/emesis resulting from a gast rointestinal allergic reaction to the milk 
allergen, usually delayed from the feeding. Only the second situation will be considered  
as an objective OFC symptom and will be considered for the stoppi[INVESTIGATOR_004] . 
***Cardiovascula r symptoms: hypotension or cardio vascular failure directly related to 
the systemic allergic reaction. They have to be differentiated from similar symptoms 
related to another cause, such as a dizziness induced by [CONTACT_492] . 
In case of subjective symptoms, eg, mouth pruritus, throat pruritus , nausea, abdominal 
pain or any other subjective symptoms at a specific dose, deemed significant enough 
to question whether an objective symptom could occur, the Investigator  can, under 
these conditions,  extend the time between the previous dose and the next dose to see 
how the subjectâ€™s symptom(s) evolve(s). The same dose can be repeated only once, to 
check whether the subjective symptom(s) reappear(s) or not and with what intensity, 
and whether (an) objective symptom(s) now clearly appear(s ). If (an) objective 
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
V\PSWRPDSSHDUVWKDWZRXOGEHWKHHQGRIWKHIRRGFKDOOHQJH ,IRQO\DVXEMHFWLYH
V\PSWRPVVWLOOSHUVLVWVZLWKQRDSSHDUDQFHRIDQREMHFWLYH V\PSWRPWKHQH[W
KLJKHVWGRVHLVWKHQJLYHQWRWKHVXEMHFWDQGWKHFKDOOHQJHVK RXOGFRQWLQXHXQWLOWKH
DSSHDUDQFHRIDFOHDUREMHFWLYHV\PSWRPDWZKLFKWLPHWKHFKDO OHQJHZLOOEHVWRSSHG
&RPSOHWHLQIRUPDWLRQRIDOOUHDFWL RQVREMHFWLYHDQGVXEMHFWLYH V\PSWRPVWKDW
RFFXUUHGGXULQJWKH'%3&)&ZLOOEH UHSRUWHGLQWKHH&5)DORQJ ZLWKLQIRUPDWLRQ
DERXWWKHGRVHVRIFRZÂ¶VPLON SURWHLQVRUSODFHERDGPLQLVWHUHG WLPHRIGRVH
DGPLQLVWUDWLRQ ILUVWWLPHR IDSSHDUDQFHRIHDFKV\PSWRPVHYHU LW\JUDGHVRIHDFK
V\PSWRPWLPHRIDSSHDUDQFHRIH DFKVHYHULW\JUDGHDQGPHGLFDW LRQVWUHDWPHQWV
JLYHQWRWKHVXEMHFWWRWUHDWWKHVHV\PSWRPV
 6DIHW\5HFRPPHQGDWL RQV'XULQJWKH'%3&)&
$VDVDIHW\SUHFDXWLRQWKHREMHFWLYHV\PSWRPVVLJQDOOLQJWKH HQGRIWKH'%3&)&ZLOO
EHWUHDWHGE\DGPLQLVWUDWLRQRI WKHEHVWPHGLFDWLRQVWRWKHV XEMHFWDVSHUWKH
,QYHVWLJDWRUÂ¶VMXGJPHQW7KH,QYHVWLJDWRUDQGPHGLFDOVWDIIZLO OXVHWKHLURZQFOLQLFDO
MXGJPHQWIRUWKHPRVWHIIHFWLYHWUHDWPHQWWRJLYHWRWKHVXEMHF WFRQVLGHULQJKLVKHUDJH
WKHW\SHRIWKHDOOHUJLFUHDFWLRQVDQGWKHVHYHULW\RIWKHDOOH UJLFUHDFWLRQ$OVRUHIHUWR
UHFRPPHQGDWLRQVPDGHE\6DPSVRQHWD OIRUWUHDWLQJDQDSK\OD[LV
6XJJHVWHGWUHDWPHQWVIRUWKHGLIIHUHQWREMHFWLYHV\PSWRPVZLOO EHGHWDLOHGLQWKH
0DQXDORI3URFHGXUHVIRUWKH'%3&)&WKDWZLOOEHSURYLGHGWRWK HVLWHV,IWKHUHLVD
QHHGWRDGPLQLVWHUHSLQHSKULQHWRDVXEMHFWLWVKRXOGEHLQMHF WHGLQWUDPXVFXODUO\LQWKH
DQWHURODWHUDOWKLJK(SLQHSKULQH VKRXOG127EHDGPLQLVWHUHGLY DWWKHLQYHVWLJDWLYH
VLWHVWRWUHDWWKHUHDFWLRQVX QOHVVDVXEMHFWL VDGPLWWHGLQWR WKH,QWHQVLYH&DUH8QLWLQD
KRVSLWDOVHWWLQJWRWUHDWWK HVHYHULW\RIWKHUHDFWLRQV
6XEMHFWVZLOOEHNHSWXQGHUREVHUYDWLRQIRUDQDGGLWLRQDOKRX UVDIWHUWKHLQJHVWLRQRI
WKHODVWGRVHRIWKHFKDOOHQJHIRUPXOD%DVHGRQWKH,QYHVWLJDW RUÂ¶VMXGJPHQWWKH
REVHUYDWLRQSHULRGFRXOGEHH[WHQGHGEH\RQGKRXUVWRHQVXUHW KDWDOOV\PSWRPV
KDYHVXEVLGHGEHIRUHWKHVXEMHFWLVGLVFKDUJHG)RULQVWDQFHD QRYHUQLJKWVWD\PD\EH
FRQVLGHUHGQHFHVVDU\E\WKH,QYHVWLJDWRULIWKHV\PSWRPVKDV KDYHQRWFRPSOHWHO\
UHVROYHGZLWKLQWKHKRXUVRULIWKHV\PSWRPVKDYHEHHQVHYHUH RUVHULRXVDQGUHTXLUH
ORQJHUREVHUYDWLRQSHULRGV
 6HUXP,PPXQRORJ\0DUNHUV
%ORRGVDPSOHVZLOOEHFRO OHFWHGIURPVXEMHFWVWRDVVHVVOHYHOV RIV,J(DQGV,J*WR
FRZÂ¶VPLONFDVHLQV DODFWDOEXPLQDQG EODFWRJOREXOLQDWWKHWLPHSRLQWVOLVWHGLQWKH
6FKHGXOHRI$VVHVVPHQW V7DEOHWR 7DEOH([SORUDWRU\VHUXPLPPXQRORJ\
PDUNHUVDUHGLVFXVVHGEHORZL Q6HFWLRQ 
%ORRGVDPSOHVIRUVHUXPLPPXQRORJ\PDUNHUVZLOOEHDQDO\]HGDW DFHQWUDOODERUDWRU\
GHVLJQDWHGE\WKHVSRQVRU,QVWUXFWLRQVIRUEORRGVDPSOHFROOHF WLRQVWRUDJHDQG
VKLSPHQWZLOOEHSURYLGHGLQWK HODERUDWRU\PDQXDO
 6NLQ3ULFN7HVW
637VZLOOEHSHUIRUPHGDWWKHYLVLWVOLVWHGLQWKH6FKHGXOHRI $VVHVVPHQWV 7DEOHWR 
7DEOH637VZLOOEHSHUIRUPHGDWDOOVLWHVXVLQJWKHPDWHULDO UHFRPPHQGHGE \WKH
VSRQVRU WRHQVXUHFRQVLVWHQF\ LQWKH
UHVXOWV&RZÂ¶VPLONH[WUDFWSOXVQH JDWLYHFRQWURODQGSRVLWLYHFRQWUR OZLOOEHXVHGIRU 
WKH637CCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397793] not take  antihistamines  for 1 to 7 days (depending o n the half -life; 
see Appendix 14.7) prior to the test. Briefly, a skin lancet is pressed through a small 
drop of the commercial extract of cowâ€™s milk and positive (histamine) and negative 
controls, into the epi[INVESTIGATOR_322211]. 
The area is mea sured for the average wheal diameter after [ADDRESS_397794]â€™s dossier.  
The SPT should be performed by [CONTACT_322256] , if possible, and the 
results will be recorded  on the appropriate page(s) of the eCRF. 
[IP_ADDRESS]  Quality of Life Questionnaire Forms  
The QoL questionnaire FAQLQ/FAIM forms23 was to  be completed by [CONTACT_748] 
(when applicable, depending on age) and parents/guardians at Screening Visit 1, at 
Month  12 and Month  24, and at Month 36 and Month 48 for subjects who entered the 
study extensi on (Table  2, Table  3, Table  4, and Table  5). The QoL questionnaire will be 
completed  at the time of the switch and  after 6, 12, 18 and 24 months of treatment with 
Viaskin Milk 300  Âµg (Table 6 and Table 7). At these visits, the QoL forms must be 
completed by [CONTACT_748] (depending on the subjectâ€™s age at the time of Visit 1 ) and 
parents/guardians before any other study procedures are performed on that day.  
The appropriate QoL questionnaire forms to complete depend on the age of the subject 
at Visit  1, as follows:   
â€¢ Subjects 8 to 12 years old at the time of Visit 1 will complete the form 
FAQLQ -CF (Child Form) at Screening ( Visit 1 ) and at Month 12 and Month 24, 
and at Month  36 and Month 48 for subjects who entered the study extension . 
Subjects who are  7 years old at the time of Visit  1 may also complete the form 
FAQLQ -CF at Screening (Visit 1) , if the ir parent(s)/guardians(s) consider they 
are able to complete these questionnaires, so that when they turn [ADDRESS_397795] a baseline questionnaire available. However,  this is not 
mandatory.  
â€¢ Subjects 13 to 17 years old at the time of V isit 1 will complete the form 
FAQLQ -TF (Teenager Form) at Visit 1 and at Month 12 and Month 24, and at 
Month 36 and Month 48 for subjects who entered the study  extension .  
â€¢ Parent s/guardians of subjects 0 to 12 years  old at the time of Visit 1 will 
complete  the form  FAQLQ -PF at Visit 1 and at Month 12 and Month 24, and at 
Month 36 and Month 48 for subjects who entered the study  extension . 
â€¢ Parent s/guardians  of subjects [ADDRESS_397796] be entered on the appropriate pages of the 
eCRF.  In order to maintain an unbiased assessment, the Investi gator  or study site 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397797] and/or parent(s)/guardian(s) whil e they are 
completing the forms.  
7.3.2  Safety Assessments  
Safety assessments will include the following:  
â€¢ AEs (including Viaskin Milk -induced local AEs  and SAEs)  
â€¢ Vital Signs  
â€¢ Physical examinations  (including complete skin examination)  
â€¢ Clinical l aboratory data  
â€¢ Spi[INVESTIGATOR_322212] 
[IP_ADDRESS]  Adverse Events  
[IP_ADDRESS].[ADDRESS_397798] a causal 
relationship with this treatment.  An AE can therefore be any unfavourable and 
unintended sign (including an abnormal laboratory finding  or vital sign measurement ), 
sympto m, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product.24 This 
includes an exacerbation of pre -existing conditions or events, intercurrent illnesses, 
drug interaction or the significant worsening of the indication under investigation that is 
not recorded elsewhere in the eCRF under specific efficacy assessments.  Note: A 
procedure is not an AE, but the reason for the procedure may be an AE . 
It is the responsibility of the Investigator s to document all AEs that occur during the 
study.  AEs will be elicited by [CONTACT_322257]/her parent(s)/guardian(s) a 
nonleading question, for example, â€œAre there any new or changed symptoms since we 
last asked or since your last visit?â€ AEs should be reported on t he appropriate page of 
the eCRF.   
All AEs occurring after the first Viaskin patch application  will be considered treatment -
emergent AEs (TEAEs).  TEAEs will be defined as any AEs, regardless of  relationship 
to Investigational product , which occur during or after the initial Viaskin patch  
application  or any event already present that worsens in either intensity or frequency 
following exposure to the Viaskin patch . If relationship information is m issing  for a 
TEAE , it will be considered drug-related. AEs with missing or incomplete onset date will 
be treated as TE AEs and missing onset date w ill be imputed as date of initial Viaskin 
patch  application  unless there is evidence that the event occurred before  the treatment 
period . 
Assessment of Severity  
Each AE will be assigned a category by [CONTACT_322258]:  
Mild An AE that is easily tolerated by [CONTACT_423], causes minimal discomfort 
and does not interfere with everyday activities.  
Moderate  An AE that is sufficiently discomforting to interfere with normal everyday 
activities; intervention may be needed.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 86 of 170 
Severe  An AE that prevents normal everyday activities; treatment or other 
intervention may be  needed.  
If there is a change in seve rity of an AE, it must be recorded as a separate event.  
The severity of anaphylactic reactions, including those reported as part of medical 
history, will be assessed using the Anaphylaxis Staging System ( Appendix 14.4). For 
anaphylactic reactions occurring during the DBPCFC, only those considered to be a 
SAE will be assessed for severity.  
Assessment of C ausality  
The relationship between an AE and the investigational  product will be determined by 
[CONTACT_737] s on the basis of his/her clinical judgment and the following definitions:  
Unrelated  Clinical event with an incompatible time relationship to the 
investigational product administration , and that could be explained by 
[CONTACT_322259] . 
Unlikely  Clinical event whose time relationship to the investigational product  
administration makes a causal connection improbable, but that could 
plausibly be explained by [CONTACT_148542].  
Possible  Clinical event with a reasonable t ime relationship to the 
investigational product  administration , but that could also be 
explained by [CONTACT_9153].  
Probable  Clinical event with a reasonable time relationship to the 
investigational product  administration, and is unlikely to be attributed 
to concurrent disease or other drugs or chemicals.  
Definite  Clinical event with plausible time relationship to the investigational 
product  administration, and that cannot be explained by [CONTACT_322260] o r chemicals.  
All SAEs assessed as â€œdefinitely relatedâ€, â€œprobably relatedâ€ and â€œpossibly relatedâ€ will 
be categorized as â€œrelatedâ€ for expedited reporting.  
Action Taken  
The Investigator s will describe the action taken with the drug product in the appropriate 
section of the eCRF, as follows:  
â€¢ None: No change in the dose of the study product . 
â€¢ Discontinued permanently: The study product was permanently stopped.  
â€¢ Temporarily interrupted: Dosing of the study product was interr upted.  
â€¢ Other: Specify.  
Outcomes of Adverse Events  
The Investigator s will describe the outcome of the AEs in the appropriate section of the 
eCRF, as follows:  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 87 of 170 
â€¢ Recovered/Resolved: The subject fully recovered from the AE with no 
residual effect observed.  
â€¢ Recov ered/Resolved with sequelae: The residual effects of the AE are still 
present and observable.  
â€¢ Ongoing : The AE itself is still present and observable.  
â€¢ Death.  
â€¢ Unknown/Lost to follow up.  
Treatment Required  
The Investigator s will describe if the subject was tr eated for an AE in the appropriate 
section of the eCRF, as follows:  
â€¢ None: No treatment was required.  
â€¢ Medication required: Prescription and/or over -the-counter medication were 
required to treat the AE.  
â€¢ Hospi[INVESTIGATOR_46823]: Hospi[INVESTIGATOR_322213], whether or not medication was 
required.  
â€¢ Other: Specify.  
More than one option  can be recorded to report all treatments given for each AE.  
[IP_ADDRESS].[ADDRESS_397799] information concerning all 
AEs is included  on the appropriate pages of the eCRF . 
The following data should be documented for each AE:  
Diagnosis of the event if available and  description of the symptom event.  
Classification of â€˜seriousâ€™ or â€˜not serious.â€™  
Severity.  
Date of first occurrence and date of resolution (if applicable).  
Action taken.  
Treatment required.  
Causal relationship.  
Outcome of event (recovered, recovered with sequelae, ongoing , death [with date and 
cause reported] , unknown ). 
All Investigator s should follow up subjects with AEs until the event is resolved or until, 
in the opi[INVESTIGATOR_689] , the event is stabiliz ed or determined to be chronic.  
Details of AE resolution  must be documented in the eCRF.  
Based on the medical judgment of the Investigator , all non -serious AEs (including the 
abnormal laboratory values identified as AEs by [CONTACT_737] ) will be followed until 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397800] Viaskin patc h. All unresolved, nonserious  AEs 
beyond such date will be recorded as â€œongoingâ€ without further follow -up. 
[IP_ADDRESS]  Serious Adverse Events  
[IP_ADDRESS].[ADDRESS_397801] that, at any dose:  
â€¢ Results in death.  
â€¢ Is life -threatening . This means that the subject is at risk of death at the time of the 
event; it does not mean that the event might hypothetically have caused death if 
it was more severe .  
Note: Whereas  an anaphylactic reaction is generally considered to be 
potentially  life-threatening , not all anaphylax es put the subject s at immediate 
risk of death , if for ex ample  appropriate treatment s lead to symptoms reduction 
or disappearance . As per the  Anaphylaxis Staging System classification 
(Appendix 14.4), an anaphylaxis assessed as mild or moderate should not be 
classified as life -threatening.  
â€¢ Requires  hospi[INVESTIGATOR_059] (at least overnight stay or inpatient hospi[INVESTIGATOR_063])  
or prolongation of existing  hospi[INVESTIGATOR_322214] a SAE:  
1. Evaluation or treatment of a pre -existing (before informed consent 
signature) and non -exacerbating condition : 
a. The condition e xisted prior to the subjectâ€™s entry into the study and has 
been recorde d in the subjectâ€™s disease/medical history and the e -CRF 
AND  
b. The condition h as not worsened in severity or frequency during the 
subjectâ€™s exposure to the investigational product  AND   
c. It has not required a change in treatment management during the 
subjectâ€™ s exposure to the investigational product ; 
2. Hospi[INVESTIGATOR_272] a planned treatment of a pre -existing (before informed 
consent signature) and non-exacerbating  condition ; 
3. Hospi[INVESTIGATOR_322215] . 
â€¢ Results in persistent or significant disability/incapacity (an AE is incapacitating or 
disabling if it results in a substantial and/or permanent disruption of the 
subjectâ€™s ability to c arry out normal life functions).  
â€¢ Is a congenital anomaly/birth defect.  
â€¢ Is an â€œimportant medical eventâ€  that may not be immediately life -threatening or 
result in death or hospi[INVESTIGATOR_322216]. Examples of such events are 
intensive treatment in an emergency room or at home for a llergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development 
of drug dependency or drug abuse.   
o An anaphylactic reaction classified as severe using the Anaphylaxis Staging 
System in Appendix 14.4 (i.e., anaphylactic reaction with cyanosis or SpO2 
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
Â”K\SRWHQVLRQZLWK! GURSLQEORRGSUHVVXUHFRQIXVLRQ FROODSVH
ORVVRIFRQVFLRXVQHVVR ULQFRQWLQHQFHRUUHTXLULQJRUPRUHH SLQHSKULQH
XVHVVKRXOGEHUHSRUWHGDVDQÂ³L PSRUWDQWPHGLFDOHYHQWÂ´
o ,QWKHFRQWH[WRI'%3&)&LQDGGL WLRQWRVHYHUHDQDSK\OD[LVW KHRFFXUUHQFH
RI
Âƒ %URQFKRVSDVPDXGLEOHZKHH]LQJZLWKXVHRIDFFHVVRU\PXVFOHV
Âƒ 6HYHUHDQJLRHGHPD
Âƒ $GPLVVLRQLQLQWHQVLYHFDUHXQLWDQGRUUHTXLUHPHQWRIR[\JHQ
WKHUDS\
Âƒ ,QWDNHRIRUPRUHGRVH VRIHSLQHSKULQH
VKRXOGEHFRQVLGHUHGDVPHHWLQJW KHVHULRXVQHVVFULWHULRQRIÂ³L PSRUWDQW
PHGLFDOHYHQWÂ´
$OO6$(VRFFXUULQJDIWHUWKHVWDU WRI9LDVNLQSDWFKDSSOLFDWLRQ ZLOODOVREHGHILQHGDV
WUHDWPHQWHPHUJHQW6$(V7(6$(V
 5HSRUWLQJDQG)ROORZ8SRI6HULRXV$GYHUVH(YHQWV
$Q\6$(PXVWEHUHSRUWHGE\WKH,QYHVWLJDWRULILWRFFXUVGXULQ JWKHFOLQLFDOVWXG\IURP
WKHWLPHRILQIRUPHGFRQVHQWWKURX JKWRWKH(26YLVLWRULILW RFFXUVZLWKLQGD\VRI
UHFHLYLQJWKHODVWGRVHRIWKH LQYHVWLJDWLRQDOSURGXFWZKHWKHU RUQRWWKH6$(LV
FRQVLGHUHGWREHUHODWHGWRWKHLQYHVWLJDWLRQDOSURGXFWRUWRD Q\VWXG\SURFHGXUH$Q
6$(UHSRUWFRQVLVWVRIWKH6$(IRUPWKH$(IRUPDQGWKHFRQFR PLWDQWPHGLFDWLRQ
IRUP7KH'%9*OREDO6DIHW\DQG3KDUPDFRYLJLODQFH*63GHSDUWP HQWZLOOUHYLHZDOO
LQFRPLQJ6$(UHSRUWVIRUDFFXUD F\DQGFRPSOHWHQHVV7KH'%9*63 GHSDUWPHQWZLOO
SURYLGHWKHIRUPVWRWKHFOLQLFDOUHVHDUFKDVVRFLDWHDQGRU&52 IRUGLVWULEXWLRQWRWKH
VLWHV$FRS\RIWKHVHIRUPVPXVWEHVHQWE\HPDLO LPPHGLDWHO\DQGQRODWHUWKDQ
KRXUV WRWKHDWWHQWLRQRIWKH'%9*63GHSDUWPHQW
'%9*OREDO6DIHW\DQ G3KDUPDFRYLJLODQFH

)RUDQ\VXEMHFWVDIHW\FRQFHUQVSOHDVHFRQWDFW
6\QHRV+HDOWK0HGLFDO0RQLWRU





2U

'%97HFKQRORJLHV0HGLFDO0RQLWRU



$OORIWKHVHHYHQWVPXVWDOVREHUHFRUGHGLQWKHDSSU RSULDWHSDJHVRIWKHH&5)7KH
,QYHVWLJDWRUVKRXOGQRWZDLWWRUHFHLYHDGGLWLRQDOLQIRUPDWLRQ WRGRFXPHQWIXOO\WKH
HYHQWEHIRUHQRWLILFDWLRQRID6$(WKRXJKDGGLWLRQDOLQIRUPDWL RQPD\EHUHTXHVWHG
7KHPLQLPXPLQIRUPDWLRQWKDWLVUHTXLUHGIRUDQLQLWLDO6$(UHS RUWLVDVIROORZV
x 6XEMHFWQXPEHU[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 90 of 170 
â€¢ Investigator name [CONTACT_187419]  
â€¢ Event term  
â€¢ Event onset date  
â€¢ Serious criteria  
â€¢ Relationship to study drug  
Where applicable, information from relevant laboratory re sults, hospi[INVESTIGATOR_322217].  
Instances of death, congenital abnormality or an event that is of such clinical concern 
as to influence the overall assessment of safety, if brought to the attention of the 
Investigator  at any time after cessation of the investigational product  administration and 
linked by [CONTACT_322261].  
The sponsor and/or the CRO  will promptly notify all relevant Investigator s of findings 
that could  adversely affect the safety of subjects, impact on the conduct of the study , or 
alter the IRB approval/favourable opi[INVESTIGATOR_23748]. In addition, the CRO , on behalf 
of the sponsor, will expedite the reporting to all concerned Investigator s, to the DSMB  
and I RBs, where required, of all adverse reactions that a re both serious and 
unexpected.  The sponsor or designee will be responsible to notify the regulatory 
authorities  of any adverse reactions as described above.  
Follow -up of all SAEs will be done until  the outcome is resolved, has reached a stable  
condition in the Investigator â€™s opi[INVESTIGATOR_1649], or until the subject is lost to follow -up. 
[IP_ADDRESS]  Unexpected Adverse Reactions  
[IP_ADDRESS].[ADDRESS_397802] information ( eg, Investigator â€™s Brochure for an 
unauthori zed investigational product ). 
Serious adverse events that are both related (according to the Sponsor and/or the 
Investigator) to investigational medicinal product(s) and unexpected (according to the 
Sponsor based on the Reference Safety Information in use) will usually be assessed as 
reportable by [CONTACT_322262].  
Sponsor will directly or through contracted service providers submit expedited and 
periodic reports to Competent Authorities , Ethics Committees  and Investigators  per 
regulations  and procedures in use, taking into account local specific requirements.  
All suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be subject to 
expedited reporting.  The CRO  and/or t he sponsor shall ensure that all relevant 
information about a S[LOCATION_003]R that is fatal or life -threatening is reported to the relevant 
competent authorities , Ethics Committees and Investigators  within 7 calendar days 
after knowledge by [CONTACT_322263] a case and that relevant follow -up information 
is comm unicated within an additional 8  calendar days. All other S[LOCATION_003]Rs will be 
reported to the relevant competent authorities , Ethics Committees and Investigators  
within 15 calendar days after knowledge by [CONTACT_322263] a case.  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
:DLYHUWRH[SHGLWHGUHSRUWLQJ ,QFDVHDQDQDSK\ODFWLFUHDFWLRQLVH[SHULHQFHG
GXULQJWKH'%3&)&DQGDVVHVVHGDV VHULRXVE\WKH,QYHVWLJDWRU WKLVHYHQWVKRXOGEH
UHSRUWHGZLWKLQKRXUVRIDZDUHQHVVE\WKHLQYHVWLJDWLRQDOVL WHDVIRURWKHU6$(V 
$OOHUJLFUHDFWLRQVDUHYROXQWDULO \WULJJHUHGE\DIRRGPDWUL[ SODFHERPDWUL[RUDOOHUJHQ
SURWHLQPDWUL[GXULQJWKH' %3&)&SURFHGXUHVDQGDQDSK\OD[LVLV DQH[SHFWHG
RXWFRPH7KHVHDQDSK\ODFWLFUHDFWLRQ VZLOOEHFRQVLGHUHGDVH[S HFWHGH[FHSWLI
OHDGLQJWRGHDWKV HH$SSHQGL[ 6HULRXVDQDSK\ODFWLFUHDFWLRQVDVVHVVHGDV
UHODWHGWRWKH'%3&)&QRWUHO DWHGWRWKH,3ZLOOQRWEHVXEMH FWWRH[SHGLWHGUHSRUWLQJ
WRUHOHYDQW&RPSHWHQWDXWKRULWLHV RU(WKLFDO&RP PLWWHHVXQOHVV WKH\KDYHOHGWRGHDWK
$OO,QYHVWLJDWRUVVKRXOGIROORZX S686$5VXQWLOWKHHYHQWLVUH VROYHGRUXQWLOLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUWKHHYHQWLVVWDELOL]HGRUGHWHUPL QHGWREHFKURQLF,I
,QYHVWLJDWRUVEHFRPHDZDUHRISRVWVWXG\686$5VWKDWRFFXUDIWH UWKHVXEMHFWKDV
FRPSOHWHGWKHFOLQLFDOVWXG\WKHVHHYHQWVPXVWEHUHSRUWHGE\ WKH,QYHVWLJDWRUWRWKH
VSRQVRU
 :DUQLQJVDQG3UHFDXWLRQV
$QDSK\ODFWLFVKRFNLVDFOLQLFDOV\PSWRPRIIRRGDOOHUJLHVDQG FDQEHSRWHQWLDOO\
OLIHWKUHDWHQLQJ$QDQDSK\OD[LVHPHUJHQF\DFWLRQSODQ VLPLODUWRWKHRQHSURYLGHGLQ
$SSHQGL[ ZLOOEHGHVLJQHGIRUWKLVVWXG\DQGSURYLGHGWRWKHVLWHV EHIRUHLQLWLDWLRQ
$QHSLQHSKULQHDXWR LQMHFWRU ZLOOEHJLYHQ
WRHDFKVXEMHFW RUSDUHQWVJXDUGLDQVDW9LVLW DQGDVQHHGHGGXULQJWKH VWXG\WREH
XVHGDFFRUGLQJ WRWKHDQDSK\OD[LVHPHUJHQF\ DFWLRQSODQ7KHH[SLU\GDWHRIWKHDXWR 
LQMHFWRUZLOOEHFKHFNHGDQGDQHZDXWR LQMHFWRUVKRXOGEHGLVSHQVHGWRWKHVXEMHFWDV
QHFHVVDU\ 
6DIHW\SUHFDXWLRQVWREHIROORZH GGXULQJWKH'%3&)&DUHSUHVHQW HGLQ
6HFWLRQ 
 5HVFXH0HGLFDWLRQ
7RSLFDOFRUWLFRVWHURLGVDQWLKLVW DPLQHPHGLFDWLRQVDQGRUDORU LQKDOHGFRUWLFRVWHURLGV
PD\EHXVHGDVUHVFXHPHGLFDWLRQV GXULQJWKHVWXG\,QWKHHYHQ WWKDWDQWLKLVWDPLQH
PHGLFDWLRQLVQHHGHGRUDOWKHUDS\LVUHFRPPHQGHG7KH,QYHVWLJ DWRUVZLOOGHWHUPLQH
WKHEHVWFKRLFHRIDQWLKLVWDPLQH DQGFRUWLFRVWHURLGWUHDWPHQW $QLQKDODWLRQ
FRUWLFRVWHURLGFRQYHUVLRQW DEOHLVLQFOXGHGLQ $SSHQGL[
 3UHJQDQF\
7KH'%9*63GHSDUWPHQWDQGPHGL FDOPRQLWRUPXVWEHQRWLILHGRI DQ\VXEMHFWWKDW
EHFRPHVSUHJQDQWZKLOHSDU WLFLSDWLQJL QWKLVVWXG\$Q\VXEMHFW ZKREHFRPHVSUHJQDQW
ZLOOEHZLWKGUDZQIURPWKHVWXG\DQGPXVWSHUIRUPDQHDUO\WHUP LQDWLRQ(26YLVLW
$OWKRXJKSUHJQDQF\LVQRWWHFK QLFDOO\DQ$(DOOSUHJQDQFLHVPX VWEHIROORZHGWR
FRQFOXVLRQWRGHWHUPLQHWKHLURX WFRPH7KLVLQIRUPDWLRQLVLPSR UWDQWIRUERWKGUXJ
VDIHW\DQGSXEOLFKHDOWKFRQFHUQV,WLVWKHUHVSRQVLELOLW\RI WKH,QYHVWLJDWRURU
GHVLJQHHWRUHSRUWDQ\SUHJQ DQF\LQDVXEMHFWZKLFKRFFXUVGXU LQJWKHVWXG\E\XVLQJ
WKH3UHJQDQF\5HSRUWLQJ)RUP
,IDQ\VWXG\VXEMHFWEHFRPHVSUHJQDQWRUKDVDSRVLWLYHSUHJQDQ F\WHVWUHVXOWZKLOH
UHFHLYLQJWKHLQYHVWLJDWLRQDOSURGXFWRUZLWKLQGD\VRIGLV FRQWLQXLQJWKH
LQYHVWLJDWLRQDOSURGXFWWKH,QYHVWLJDWRUVKRXOGFRQWDFW'%9PH GLFDOPRQLWRURU
GHVLJQHHWRGLVFXVVVXEMHFWPDQDJHPHQW1RWLILFDWLRQRIWKHSUH JQDQF\LQFOXGLQJWKH
DQWLFLSDWHGGDWHRIELUWKVKR XOGEHVXEPLWWHGRQD3UHJQDQF\5 HSRUWLQJ)RUPCCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 92 of 170 
immediately and no l ater than 24 hours and reported to DBV GSP department using 
the same procedure as described for reporting SAEs  (Section  [IP_ADDRESS] ). If the pregnancy 
is to be termi nated, the anticipated date of termination should be provided.  
Follow -up in the Event of a Pregnancy  
The s ponsor will be informed of all pregnancies in study  subjects.  
The subject will be asked to provide information on the outcome of the pregnancy, 
including premature termination should the case arise. Spontaneous miscarriages , 
ectopic pregnancies  and congenital abnormalities will be reported as SAEs. Informa tion 
on the status of the mother and child will be forwarded to DBV  medical monitor and 
GSP . Generally, follow -up will be in accordance with regulatory guidance and at least 6 
to 8 weeks after the estimated delivery date. Any premature termination of the 
pregnancy will be reported.  
[IP_ADDRESS]  Adverse Events of Special Interest  to the Sponsor  
AEs of special interest (AESI) to the sponsor in this study will include : 
Local AESI :  
Any reaction at patch application site which could potentially lead to skin barrier 
disruption, such as but not limited to: blister, vesicle, ulcerative skin lesion, bleeding or 
any Grade 4 patch site reaction .  
 
Systemic AESI :  
Any acute systemic immediate allergic reactions (rapid onset) after exposure to known 
or suspected allergen, regardless of the causal relationship to the investigational 
product  and occurring outside the DBPCFCs : 
1. Anaphylacti c reaction:  
a. Any adverse event diagn osed by a physician as anaphylactic reaction, 
regardless of the severity and causal relationship  to the investigational 
product.  
b. Anaphylactic reaction defined as the occurrence of the following allergic 
symptoms:  
i. Major acute allergic reaction (associated o r not with other symptoms) : acute 
hypotension (>20% drop in blood pressure) or associated cardiovascular 
symptoms (hypotonia, confusion, loss of consciousness, collapse, syncope, 
incontinence) , 
ii. [ADDRESS_397803] 2 different 
organ systems such as, but not limited to:  
â€¢ Upper airway or respi[INVESTIGATOR_1856] (dyspnea, wheeze -
bronchospasm, stridor, hypoxemia, decreased SaO2)  
â€¢ Acute and persistent gastro -intestinal symptoms (abdominal pain, 
cramps, vomiting)  
â€¢ Acute sk in or mucosal tissue symptoms (angioedema, urticaria, 
pruritus, flush , swollen -lips-tongue, uvula)  
â€¢ Acute cardiovascular symptoms (hypotonia, reduced blood pressure)  
2. Any systemic hypersensitivity reaction leading to epi[INVESTIGATOR_107563].  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 93 of 170 
[IP_ADDRESS]  Accidental Consumption o f Cowâ€™s Milk 
Any reaction triggered by [CONTACT_322243]â€™s milk (in any form) during the 
conduct of the study. This event will be reported in a specific section of the eCRF.  
 
[IP_ADDRESS]  Vital Signs  
Vital sign measurements will include  heart rate, systolic and diastolic blood pressure, 
and respi[INVESTIGATOR_697] . Measurements  will be collected at  each visit ( see Table  2 to Table 
7), before the DBPCFC , and during the DBPCFC  at the Investigatorâ€™s discretion , when 
applicable.   
Vital signs will be measured  in a standardiz ed manner, ie, after the subject has rested 
in the sitting position for 5  minutes and recorded in the eCRF.  The criteria to determine  
clinically significant ab normalities in vital sign measurements are presented in  
Section  [IP_ADDRESS] . 
Weight and height measurements will also be collected for each subject at screening 
and at  6-month intervals during the study (Visits 10, 12, 15, and 16 , and for the 
subjects who entered the study extension  at Visits 18, 19, 21 , and 22 , and for the 
subjects who will switch to Viaskin Milk 300  Âµg, at Visits S1 to S7 ). 
[IP_ADDRESS]  Physical Examination  and Skin Reaction G rading  
Physical examination will include , but is not limited to,  head, eyes, ears, nose, and 
throat (HEENT ), as well as a complete examination of the skin , and will be performed  
at each visit  (see Table  2 to Table 7), before the DBPCFC , and during the DBPCFC at 
the Investigatorâ€™s discretion , when applicable.  
Local skin reactions of the area of the skin used for application of  the Viaskin patch on 
the arms (adolescents  and f ormer adolescents who become adults ) or back (children)  
will be grad ed (Table 1) by [CONTACT_322264], according to 
the slightly modified recommendations of the EAACI/GA2LEN position paper.25 
Table 1: Skin Reaction Grading System  
Grade  Skin Reaction  
Grade 0  Negative  
Grade 1  Only erythema, or erythema + infiltration  
Grade [ADDRESS_397804] should visit the site for the next application (see 
Section  6.3.2 ). 
Photographic records will be taken of the site(s) of application of the Viaskin patch and 
filed in the subjectâ€™s medical records or source documents  and provided to the CRO  or 
sponsor as necessary upon request . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 94 of 170 
[IP_ADDRESS]  Clinical Laboratory Evaluation  
Hematology , biochemistry , and any other laboratory tests will be analyzed  at a central 
laboratory (ies) designated by [CONTACT_456]. Reference ranges will be supplied and used 
by [CONTACT_322265].  
Blood samples will be collected from subjects at the timepoints listed in  the Schedule of 
Assessmen ts (Table  2 to Table 7). Instructions for blood sample collection , storage,  
and shipment will be provided in the laboratory manual.  
The following laboratory tests will be performed  using collected samples : 
Hematology  
Hemoglobin, hematocrit, platelets, red blood cells  (RBC) , white blood cells  (WBC) , and 
differentials . 
Bioc hemistry  
Aspartate aminotransferase  (AST) , alanine aminotransferase  (ALT) , total bilirubin, total 
protein, blo od urea nitrogen (BUN), and creatinine . 
Total Blood Volume Requirements  
The estimated maximum blood volume that will be collected from each subject during a 
visit will be approximately 15 mL for hematology and biochemistry laboratory tests and 
efficacy or exp loratory assessments (serum immunology markers [Section  [IP_ADDRESS] ], 
filaggrin mutations , and epi[INVESTIGATOR_81078]  [Section 7.3.3 ]), up to Month 48, and 
approximately 12.[ADDRESS_397805] up 
to Month  24 will be approximately 80 mL.  For subjects who enter the study extension 
(Month 24 to 48), approximately [ADDRESS_397806] during the whole study (up to Month 48 ) was to be approximately 130  mL. For 
subjects who switch to Viaskin Milk 300  Âµg, up to  57.5 mL of additional blood will be 
collected within 24 months. The total blood volume requirement does not exceed the 
recommended sample blood volume of 3 mL/kg and up to  50 mL total within 8 weeks .26 
[IP_ADDRESS]  Other L aboratory Variables  
For female subjects of childb earing potential, a urine sample will be collected to screen 
for pregnancy (urine Î²-HCG)  at the visits  listed in  Table  2 to Table 7. 
[IP_ADDRESS]  Spi[INVESTIGATOR_322218] , measured as FEV 1, will be performed for  subjects â‰¥6 years old ( unless 
they have documented inability to adequately perform spi[INVESTIGATOR_038] ) and the PEF will be 
assessed  for subjects â‰¥[ADDRESS_397807] < 5 years. Spi[INVESTIGATOR_10230]/or PEF data (depending on 
the subjectâ€™s age and ability to perform these tests)  will be documented on the 
appropriate page s of the eCRF.  
FEV 1 will be measured on a standardized calibrated spi[INVESTIGATOR_322219] (ATS) guidelines. At least 3 acceptable maneuvers  will be obtained 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397808] value will be recorded in the eCRF . 
[IP_ADDRESS]  Subject Diary Cards  
Diary cards will be dispensed to the subjects at Visit  [ADDRESS_397809] will be col lected for entry into the eCRF or  
into the clinical database.  
Subjects or their parent(s)/guardian(s) will be instructed how to use the diary card from 
Visit 4 (Day  1) and to bring the card to the site at each subsequent visit. Subjects or 
their parent(s)/guardian(s) will be instructed to record on their diary cards any 
AEs/medical events  and associated medications, the duration of application and 
reason for removal of the Viaskin patch, if the patch is removed before the 
recommended duration in addition to  any information regarding cowâ€™s milk consumption 
(including dairy products or any baked milk product) during the ir participation in the  
study.  
At the clinical site, upon review of the diary cards, the investigative staff will interview 
the subject to know whether the milk consumption was either accidental or voluntary. 
This will be useful for the Investigators to assess whether there has been any 
risk-taking behavior and collect as much information as possible about  those cases.  
7.3.[ADDRESS_397810] mite and grass pollen at the timepoints listed in the Schedule of 
Assessmen ts (Table  2 to Table 7).  Blood samples for serum immunology markers will 
be analyzed at a central laboratory designated by [CONTACT_456]. Instructions for blood 
sample  collection, storage, and shipment will be provided in the laboratory manual . 
For the analysis of the mutations in the filaggrin gene , blood samples will be collected 
from subjects only after the genetic ICF/IAF are signed. Blood samples will be collected 
at the time of Visit  1. If not collected at Visit 1, blo od samples for filaggrin analysis can 
be collected at any subsequent visit where blood is drawn  (see Table  2, Table  3, 
Table  4, and Table  5), but only 1 sample collection for filaggrin is required during the 
study . No blood sample will be drawn for filaggrin analysis during the 24 -month 
treatment  period  with Viaskin Milk 300  Âµg. The genetic screening of the mutations of 
the filaggrin gene will be performed  at a central laboratory designated by [CONTACT_456].  
For epi[INVESTIGATOR_81078], blood samples will be collected from subjects  only after the 
genetic ICF/IAF are signed. Blood samples will be collected at the visits specified in the 
Schedule s of Assessments  (Table  2 to Table 7). The sample will  be stored and may be 
used to asses s any epi[INVESTIGATOR_322220] -
related genes that could play a role in the development of immune tolerance. These 
tests will be done at a central laboratory designated by [CONTACT_456].  
Instructions for the collection , storage,  and shipment of samples collected for the 
filaggrin and/or epi[INVESTIGATOR_322221].  
An EOS  survey  will be completed  by [CONTACT_322266]  (see Table  2 to Table 7). This survey  will 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397811] after terminat ion of the 
study.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 103 of 170 
Table  2/Table  3/ Table 4/ Table 5 : (Continued) Schedule of Assessments  Legend  
1. Screening period, between V1 and V4 should be within 60 days. V2 (first day of food challenge) can be scheduled as soon as th e laboratory results from V1 are available.  
2. End-of-Study Early Termination Visit is appl icable only for subjects withdrawing from the study prematurely.  
3. Visit may be scheduled up to a maximum of [ADDRESS_397812] dosing visit. For subjects in Part A, procedures marked (4) should be perfor med at the site at the following timepoints: before the first Viaskin patch 
application, then 30 min, 1h, 2h; 3h and 6h after the first patch is applied. For subjects randomized in the Part B, the proc edures should be performed at the same 
timepoints, exce pt the 6h timepoint.  
5. V5 is applicable only for subjects randomized in Part A.  
6. Six (6) hours of observation for Part A subjects after the patch is applied at V4 ; 3h of observation for Part B subjects after the patch is applied at V4.  At visits when a 
DBPCF C is performed, a minimum of 3h of observation after the last dose of the food challenge formula has been ingested.  
7. Genetic Informed Consent for filaggrin and epi[INVESTIGATOR_322222].  
8. Including history of cowâ€™s milk allergy and any other types of allergy if applicable.  
9. Including date of birth, sex, ethnic origin, weight (kg) and height (cm). At V10, V12, V15 , V16, and at V18, V19, V21, and V22 for subjects who entered in the study 
extension, only the subjectâ€™s weight and height will be collected.  
10. Eligibility criteria must be checked and confirmed at V4 (Day 1).  
11. Including, but not limited to, head, eyes, ears, nose, and throat (HEENT), and a complete examination of the skin.  
12. Physical examination and vital sign measurements must be performed before the DBPCFC and can be repeated anytime during the D BPCFC, as judged necessary by 
[CONTACT_737].  
13. Vital signs  measured in a sitting position include heart rate, systolic and diastolic blood pressure and respi[INVESTIGATOR_697].  
14. FAQLQ/FAIM: Quality of Life questionnaire forms to be completed must correspond to each subjectâ€™s age at V1. The questionnair es must be complete d before any 
procedures at all visits when QoL forms are completed.  
15. Spi[INVESTIGATOR_10230]/or peak expi[INVESTIGATOR_118756], depending upon the subjectâ€™s age and ability to perform these tests.  
16. Laboratory tests include Hematology:  hemoglobin, hematocrit, plat elets, red blood cells, white blood cells and differentials; Biochemistry:  aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), total bilirubin, total protein, blood urea nitrogen (BUN) and creatinine.   
17. Immunological markers include: sIgE and sIgG4 to whole cowâ€™s milk proteins, caseins, Î± -lactalbumin, and Î² -lactoglobulin; and sIgE to peanut, egg, house dust mite, and 
grass pollen.  
18. Sample for the analysis of filaggrin mutations will be collected only once : this could be at V1 or at any of the v isits mentioned. This is optional. Samples will be collected 
only after the genetic ICF/IAF is signed.  
19. This is optional. Samples will be collected only after the genetic ICF/IAF is signed.  
20. Only for female subjects of child -bearing potential. Additional pr egnancy testing may be repeated during the study at the discretion of the Investigator.  
21. AEs are collected from the day of signing the ICF/IAF.  
22. The epi[INVESTIGATOR_107528] -injector and the Anaphylaxis Emergency Action Plan are dispensed and their utilization expla ined at V4; epi[INVESTIGATOR_107528] -injector training must be 
appropriately documented in the source documents. At subsequent study visits, utilization will be reviewed whenever necessary . Expi[INVESTIGATOR_322223] a new 
auto-injector provided as necessary.  
23. IP Dispensation at V17 and beyond is applicable only to subjects who enter the study extension.  
24. Subjects will perform only one FU visit , [ADDRESS_397813] within 14 days 
of V16.  
25. Signed Informed Consent/Assent to enter study extension will be obtained no la ter than at V17.  
26. Eligibili ty criteria will be assessed at V17 before subjects enter the study extension.  
27. Following results of the 12-month blinded period, the DBPCFCs that were to be performed at Month 24, Month [ADDRESS_397814] and fourth years are applicable only to subjects who entered the study extension a fter V17.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 104 of 170 
Abbrev iations : D=Day; DBPCFC=Double -Blind Placebo -Controlled Food Challenge; EOS=End -of-Study; ET=Early Termination; FAIM=Food Allergy Independent Measure; 
FAQLQ=Food Allergy Quality of Life Questionnaire ; FEV 1=Forced Expi[INVESTIGATOR_1814] 1 second; FU=Foll ow-up; Ig=Immunoglobulin; IP=Investigational Product; M=Month; 
Min=Minimum; NA=Not Applicable; PC=Phone Contact; V=Visit ; W=Week.  
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 107 of 170 
Legend for Table 6 and Table 7: 
1. End-of-Study Early Termination Visit is applicable only for subjects withdrawing from the study prematurely.  
2. Visit may be scheduled up to a maximum of [ADDRESS_397815] dose of the food cha llenge formula has been ingested.  
4. Including, but not limited to, head, eyes, ears, nose, and throat (HEENT), and a complete examination of the skin.  
5. Physical examination and vital sign measurements must be performed before the DBPCFC and can be repeated an ytime during the DBPCFC, as judged necessary by 
[CONTACT_737].  
6. Vital signs measured in a sitting position include heart rate, systolic and diastolic blood pressure and respi[INVESTIGATOR_697].  
7. FAQLQ/FAIM: Quality of Life questionnaire forms to be completed mus t correspond to each subjectâ€™s age at V1. The questionnaires must be completed before any 
procedures at all visits when QoL forms are completed.  
8. Spi[INVESTIGATOR_10230]/or peak expi[INVESTIGATOR_118756], depending upon the subjectâ€™s age and ability to perform th ese tests.  
9. Laboratory tests include Hematology:  hemoglobin, hematocrit, platelets, red blood cells, white blood cells and differentials; Biochemistry:  aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), total bilirubin, total protein, blood urea nitrogen (BUN) and creatinine.   
10. If performed within 1 month  of VS1 , the collection of blood for laboratory tests, immunological markers and epi[INVESTIGATOR_322224]1 . 
11. Immunological markers include: sIgE to whole cowâ€™s milk proteins, caseins, Î± -lactalbumin, and Î² -lactoglobulin; sIgG4 to caseins, Î± -lactalbumin, and Î² -lactoglobulin ; sIgE 
to peanut, egg, house dust mite, and grass pollen.  
12. For subjects who signed the  geneti c ICF/IAF.  
13. Only for female subjects of child -bearing potential. Additional pregnancy testing may be repeated during the study at the discretion of the Investigator.  
14. DBPCFC is optional and left at the Investigatorâ€™s and the subjectâ€™s decision  
15. Review of  utilization of the epi[INVESTIGATOR_107528] -injector and the Anaphylaxis Emergency Action Plan whenever necessary. Expi[INVESTIGATOR_322225], and a new auto -
injector provided as necessary.  
16. IP accountability will be performed at Visit S6 if the subject does not perfo rm the DBPCFC at Visit S6. IP accountability will be performed at Visit S7 if the subject performs 
the DBPCFC at Visit S6.  
Abbreviations:  D=Day; DBPCFC=Double -Blind Placebo -Controlled Food Challenge; EOS=End -of-Study; ET=Early Termination; FAIM=Food Allerg y Independent Measure; 
FAQLQ=Food Allergy Quality of Life Questionnaire; FEV 1=Forced Expi[INVESTIGATOR_1814] 1 second; FU=Follow -up; Ig=Immunoglobulin; IP=Investigational Product; M=Month; 
Min=Minimum; PC=Phone Contact; V=Visit; W=Week.  
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 108 of 170 
8 Statistical Methods  
8.1 Statistical and Analytical  Plans 
A statistical analysis plan (SAP) will be prepared and finalized prior to  database lock.  
The SAP will ensure that  the study data listings, summary tables , and figures that will 
be produced, and the statistical methodologies that will be used, are complete and 
appropriate to allow valid conclusions regarding the study objectives.  
8.1.1  Datasets or Populations Analyz ed 
The Safety Set (SS) will include all subjects who applied at least [ADDRESS_397816] , or as it will be determined at the Blind Data Review Meeting  (BDRM) , on a 
case -by-case basis . The SS will be used for all safety analys is tables and listings . 
The Intent -to-Treat  Set ( ITT) will include all randomized subjects. Subjects will be 
analyzed according to randomized treatment.  The ITT Set will be used for all analyses 
of efficacy endpoints.   
The Per Protocol Set (PPS) will include all subjects from the ITT population who do not 
have major protocol violations that may affect the primary endpoint.  Major protocol 
deviations will be defined in the SAP.   
Protocol deviations will be categorized as either major or minor and discussed during  
the blinded data review  meeting (BDRM). Decisions taken at the BDRM will be 
documented and approved by [CONTACT_322267].  
The Open -label Set s (OLS) will include  all subjects from the ITT who entered the 
open -label treatment period (ie , who appli ed at least one Viaskin Milk patch during the 
open -label treatment period)  and will be described in the SAP .  
The Open -label Set  300 Âµg  (OLS_300) will include  all subjects who switch ed to Viaskin 
Milk 300 Âµg and will be described in the SAP .  
8.1.2  General Considerations  
There will be 2 age groups considered for the statistical analyses:  
â€¢ Children: 2 to 11 years of age at the time of Visit 1  
â€¢ Adolescents: 12 to 17 years of age at the time of Visit 1  
Data will be summarized by [CONTACT_551], dose level, and  pooled placebo group for the 
randomized blinded treatment period  (Months 0  to 12) as follows:  
Part A  and Part B : Viaskin Milk  150 Âµg, 300  Âµg, 500  Âµg of cowâ€™s milk proteins , and 
placebo.  
Part A and Part  B subjects will be combined and pooled by [CONTACT_15994], as 
applicable, for the efficacy analyses at Month  12. 
In general, categorical data will be summarized using counts and percentages, and 
continuous variables will be summarized using the number of subjects with evaluable 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 109 of 170 
data (n), mean, standard devi ation, median, first and third quartiles (Q1, Q3), minimum 
and maximum.  
All hypothesis tests will be in scope of dose -response or longitudinal analyses.  
Listings of raw subject data will be sorted by [CONTACT_15994] , randomization number and  
visit, as applicable , for all randomized subjects. For subjects in Part A, data from 
Cohorts  1, 2, and [ADDRESS_397817] Disposition  
The number and percentage of subjects in each analysis population (ITT, PPS, SS, 
OLS and OLS_300 ) will be summarized overall and by [CONTACT_1570] (dose 
level/placebo).  
Subject disposition will be summarized for all subjects in the  ITT. The number and 
percentage of subject completed, discontinued, and the primary reason for early 
withdrawal fro m the study will be tabulated by [CONTACT_322268].  
8.1.4  Demographic and Other Baseline Characteristics  
For continuous demographic variables and baseline characteristics (including age, 
height, weight , body mass index  (BMI, kg/mÂ²), body surface (mÂ²),  weight/height (kg/m), 
SPT mean wheal diameter, FEV 1 percent predicted [spi[INVESTIGATOR_038]] , PEF percent 
predicted , CRD of cowâ€™s milk, and milk sIgE), descriptive will be generated for each 
dose level and  placebo  group at V isit 1 for all subjects in the  ITT. 
For categorical demographic variables and baseline characteristics (including sex, 
ethnic origin, and medical  history) , the number and percent of subjects in each 
category  will be tabulated for each dose level and  placebo  group at Visit [ADDRESS_397818] demographic and baseline characteristics data will be listed.  
8.1.5  Concomitant Medication s 
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHODrug). A summary of concomitant medications by [CONTACT_322269] (ATC) term and preferred term will be produced 
overall and by [CONTACT_322270] e group, for each dose level and placebo group on the ITT for the 
randomized blinded treatment period (Months 0 to 12).  
Concomitant medications during the open -label treatment periods after Month 12 will 
be described. Details will be provided in the SAP.  
 
8.1.6  Efficacy  
Missing data will not be imputed for the efficacy analyses  except for the classification of 
treatment responders / non responders for the primary efficacy analysis . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 110 of 170 
[IP_ADDRESS]  Primary Efficacy Endpoint  and Analysis  
The primary efficacy endpoint will be the percentage (%) of subjects who are treatment 
responders after [ADDRESS_397819] one of the following 
criteria:  
â€¢ A â‰¥10-fold increase in the CRD  of cowâ€™s milk proteins at the Month [ADDRESS_397820] 144 mg  of cowâ€™s milk 
proteins (approximately  4.5 mL of milk) . 
â€¢ A CRD  of cowâ€™s milk proteins â‰¥1444 mg ( approximately 45  mL of milk ) at the 
Month  [ADDRESS_397821] of cowâ€™s milk proteins is entered directly in CRF  by [CONTACT_322271] c owâ€™s milk proteins  given  during the challenge , including repeat 
doses if applicable, and exact quantity of the last dose given (if not given in totality).  
The percentage of subjects who are treatment responders after 12 months of EPIT 
treatment will be calculated on the ITT population using missing = failure imputation 
method (ie, subjects with missing observation at Month  12 will be considered as non -
responder s). 
The numb er and percentage of responders  will be summarized overall and by [CONTACT_135911], for each pooled dose level  (Part A and Part B) and placebo  group , for the 
blinded treatment period (Months 0 to 12) . 
Methods of exact logistic regression will be used to compare the proportion of 
treatment responders at Month  [ADDRESS_397822], for subjects in the ITT 
population. P -values, odds rat ios together with associated 95% Confidence Intervals 
(95% CI) will be presented.   
The primary efficacy endpoint of this study, together with additional exploratory 
analyses, will assess the dose -response relationship and aim to inform the dose 
selection f or phase 3.  Model -based analytical approaches of exploratory dose 
finding (e.g., MCP -Mod) will be used to evaluate the dose -response relationship 
and estimate target dose(s).  
Further details of the statistical methodology and considerations for the appro aches 
to be used in the analysis will be specified in the SAP.  
[IP_ADDRESS].[ADDRESS_397823] of the primary 
efficacy criteria to the results and interpretation of s tudy results. The analysis described 
above will be repeated for subjects in the ITT using observed data  and in the PPS . A 
similar analysis will be performed on ITT population  using multiple imputation instead of 
missing = failure imputation method. Multipl e imputation method will be further 
described in the SAP.   
Other covariates of interest including baseline IgE (by [INVESTIGATOR_67132]) and country will be 
explored.   
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 111 of 170 
Finally, the primary efficacy analysis will be repeated for each age group as well as for 
each filaggr in mutation group (With filaggrin mutation / Without filaggrin mutation). 
Within subgroup, the treatment group comparisons will be  conducted at a two -sided 
10% significance level.  
[IP_ADDRESS]  Secondary Efficacy Endpoints  and Analysis  
The secondary endpoints for the double -blind, placebo -controlled treatment period up 
to Month 12 are: 
â€¢ The mean and median CRD of cowâ€™s milk proteins at Month  12 and change 
from baseline.  
â€¢ The change from baseline value in levels of sIgE and allergen -specifi c 
immunoglobulin G4 (sIgG4) to cowâ€™s milk at all timepoints evaluated up to 
Month  12. 
â€¢ The change from baseline value in levels of sIgE and sIgG4 to caseins, Î± -
lactalbumin, and Î² -lactoglobulin at all timepoints evaluated up to Month  12.  
â€¢ The change from bas eline in SPT wheal at all timepoints evaluated up to 
Month  12. 
â€¢ The change in the severity of symptoms elicited during the milk DBPCFC from 
baseline to Month  12.  
â€¢ The change from baseline in Quality of Life (QoL) assessments at Month  12. 
The endpoints after Month 12 for the open -label treatment periods with Viaskin Milk 
500 Âµg up to 48 months and Viaskin Milk 300  Âµg for 24 months are: 
â€¢ The percentage of subjects who are treatment responders over the course of 
open -label treatment with Viaskin Milk 500  Âµg and 300 Âµg.  
â€¢ The CRD of cowâ€™s milk proteins over the course of open -label treatment with 
Viaskin Milk 500  Âµg and 300 Âµg.  
â€¢ The levels of sIgE to cowâ€™s milk over the course of open -label treatment with 
Viaskin Milk 500  Âµg and 300 Âµg.  
â€¢ The levels of sIgG4 to cowâ€™s milk proteins over the course of open -label 
treatment with Viaskin Milk 500 Âµg.  
â€¢ The levels of sIgE and sIgG4 to caseins, Î± -lactalbumin, and Î² -lactoglobulin over 
the course of open -label treatment with Viaskin Milk 500  Âµg and 300 Âµg.  
â€¢ The SPT wheal over the course of open -label treatment with Viaskin Milk 
500 Âµg and 300 Âµg.  
â€¢ The severity of symptoms elicited during the milk DBPCFC over the course of 
open -label treatment with Viaskin Milk 500  Âµg and 300 Âµg  
â€¢ The QoL assessments over the course of open -label treatment with Viaskin Milk 
500 Âµg and 300 Âµg.  
[IP_ADDRESS].1  Treatment Responders  
Treatment r esponders during the open -label treatment periods after Month 12 w ill be 
explored. Details will be provided in the SAP.  
[IP_ADDRESS].2  Cumulative Reactive Dose (CRD) of Cowâ€™s Milk Proteins  
The CRD and changes from baseline will be summarized overall and by [CONTACT_551], 
dose level group (Part A and Part B pooled), and timepoint  on the ITT  for the 
randomized blinded treatment period (Months 0 -12).  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397824] during the open -label treatment periods after Month 12 will be explored.  Details 
will be provided in the SAP.   
[IP_ADDRESS].3  Immunological Markers  
All analyses will be carried out on the ITT population.   
Absolute values and changes from baseline for the immunological markers were  to be 
summarized overall and by [CONTACT_551], dose level and placebo groups, and timepoint 
for the randomized blinded treatment period (Months 0  to 12). 
Longitudinal analyses will be explored for each of the following parameters:  
â€¢ cowâ€™s milk sIgE and sIgG4  (cowâ€™s milk sIgG4 will not be collected  after the 
switch to Viaskin Milk 300  Âµg) 
â€¢ sIgE and sIgG4 to  
o caseins,  
o Î±-lactalbumin , and  
o Î²-lactoglobulin . 
Detai ls will be provided in the SAP.  
Immunological markers during the open -label treatment periods after Month 12 will be 
explored. Details will be provided in the SAP.  
[IP_ADDRESS].[ADDRESS_397825] ics overall 
and by [CONTACT_551], dose level and placebo group  on the ITT for the randomized blinded 
treatment period (Months 0  to 12).  
The change from baseline (Visit 1) will be assessed using the ratio of the average 
wheal diameter at each time point versus  baseline, derived as improvement ( if the ratio 
of the average wheal diameter â‰¤  0.75) / no significant improvement ( if the ratio of the 
average wheal diameter >  0.75) and will be compared between each dose level group 
and placebo, at each respective visit up to Month  [ADDRESS_397826] 
logistic regression (same model as for the primary criteria) in case of low sample sizes 
(at least one theoretical frequency l ower than 5) .  
The number of subjects with a mean weal diameter equals to 0 will be presented . 
Longitudinal analyses will be explored for SPT average wheal diameter.  Details will be 
provided in the SAP.  
SPT during the open -label treatment periods after Mo nth 12 will be explored. Details 
will be provided in the SAP.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 113 of 170 
[IP_ADDRESS].5  Analysis of Severity D uring the Milk DBPCFC  
The change in the severity of symptoms elicited during the milk DBPCFC from baseline  
will be assessed  at Month 12 . Grading of symptoms will be done  using the grading 
definition in the OFC Symptom Score Sheet s., Each sy mptom (objective and subjective) 
will be graded 0, 1, 2 or 3 . A total symptom score  will be derived  for objective symptoms . 
The total summary score (absolute and change from baseline) will be summarized 
overall and by [CONTACT_551], dose level and placebo group  on the ITT for the randomized 
blinded treatment period (Months  0 to 12).  
A second severity score will be derived to asses s the change from Baseline in the 
severity of symptoms elicited during the milk DBPCFC  at comparable cowâ€™s milk 
proteins dose . The calculation of this severity score at comparable cowâ€™s milk proteins 
dose  will be further described in the SAP. This score wi ll be summarized overall and by 
[CONTACT_551], dose level and placebo group, and timepoint on the ITT for the randomized 
blinded treatment period (Months  0 to 12).  
Longitudinal analyses will be explored for severity score.  Details will be provided in the 
SAP. 
Time -to-first objective symptom  at Month 12  will be summarized and Kaplan -Meier 
curves will be provided. Patients without any objective symptom during the DBPCFC 
will be censored at the time of discharge.  
Analysis of severity of symptoms  during the open -label treatment periods after Month 12 
will be explored. Details will be provided in the SAP.  
[IP_ADDRESS].6  Quality of Life Assessments  
FAQLQ QoL questionnaires will be completed by [CONTACT_322272] 8 years old 
and older (CF for age range 8  to 12 years old, TF for age range 13  to 17 years old). 
Subjects who are 7 years old at the time of Visit  1 may also complete the form 
FAQLQ -CF at Screening (Visit 1), if their parent(s)/guardians(s) consider they are able 
to complete these questionnaires, so that when they tu rn [ADDRESS_397827] a baseline questionnaire available. However, this is not mandatory. Parents 
will also complete a FAQLQ for subjects 0  to 12 years old (PF) and for subjects 13  to 
17 years old (PFT). The same questionnaire will be completed throughout the study 
according to  the subjectâ€™s  age at Visit  1. 
Each questionnaire type will be summarized by [CONTACT_322273] d (Months 0  to 12). The summary scores presented will be those 
derived for the respective questionnaire. No attempt will be made to combine 
questionnaire types.  
Longitudinal analyses will be explored for QoL assessments.  Details will be provided in 
the SA P. 
QoL questionnaires during the open -label treatment periods after Month 12 will be 
explored. Details will be provided in the SAP.  
8.1.7  Safety Variables  
Safety endpoints will include the following:  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 114 of 170 
â€¢ AEs and TEAEs by [CONTACT_9313] , preferred term , maximum severity , and 
relatedness  to the i nvestigational product . 
â€¢ SAEs and TESAEs by [CONTACT_9313] , preferred term , severity , and 
relatedness  to the investigational product . 
â€¢ TEAEs leading to study discontinuation, and relatedness to t he investigational 
product.  
â€¢ Incidence, duration , and maximum severity  of local cutaneous reactions , as 
assessed by [CONTACT_423] . 
â€¢ Severity of local cutaneous  reactions , as assessed by [CONTACT_737].  
â€¢ AESI including systemic allergic symptoms  and local AESI  
â€¢ Frequency and severity of symptoms elicited during the DBPCFC.  
â€¢ Vital signs , physical examinations, and laboratory data.  
â€¢ Spi[INVESTIGATOR_322166].  
In all safety presentations, imputation of missing data will take the option of the most 
conservative outcome, so that, for example, missing relatedness  for a TEAE  will be 
assumed to be related and missing severity will be assumed to be severe  if the severity 
is missing for an AE starting on or after the date of initial Viaskin Milk patch appl ication  
and mild  if the severity is missing for an AE starting prior to the date of initial Viaskin 
Milk patch application . 
[IP_ADDRESS]  Adverse Events  
For adverse events analyses, serious adverse events elicited during DBPCFC will not 
be considered, they will be descr ibed separately.  
All AEs and TEAEs will be listed and tabulated separately by [CONTACT_16252]  (MedDRA ) System Organ Class (SOC) and Preferred Term. 
Incidence tables will be presented for all TEAEs and TESAEs for the reporting p eriod 
as defined in  Section [IP_ADDRESS] . The following tabulations will be produced overall and by 
[CONTACT_551], dose level and pooled placebo group  on the Safety Set (SS) for the 
randomized blinded treatment period (Months 0 to 12) : 
â€¢ AEs and TEAEs overall and by [CONTACT_6657]  
â€¢ AEs and TEAEs by [CONTACT_764], overall and by [CONTACT_39812]  
â€¢ TEAEs considered related to investigational product (IP) , overall and by [CONTACT_322274]  
â€¢ Number of TEAEs and number of TEAEs considered related to IP by [CONTACT_926]   
â€¢ SAEs and TESAEs overall and by [CONTACT_6657]  
â€¢ SAEs and TESAEs by [CONTACT_764], overall and by [CONTACT_196209]  
â€¢ TESAEs consid ered related to IP, overall and by [CONTACT_322275]: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 115 of 170 
â€¢ Viaskin Milk -induced local AEs overall and by [CONTACT_322276], a summary of AEs will be produced 
for a subse t of subjects who  received the highest safe dose determined during the 
study from Months [ADDRESS_397828] -years, the number of subjects with a TEAE ( and respectively , a TEAE 
considered related to IP) per subject -year, and the number of TEAEs ( and respectively , 
TEAEs considered related to IP) per s ubject -year, for each dose level.  
Separate listings and tabulations will summarize:  
â€¢ Systemic AESI whatever the causal relationship with IP .  
â€¢ Local AESI . 
â€¢ Severity of symptoms elicited during the DBPCFC.  
â€¢ Discontinuations due to AEs will also be summarized . 
Local and systemic AESI will be identified using systematic retrieval strategies that will 
be detailed in the SAP.  
Adverse events occurring during the open -label treatment periods after Month 12 will 
be described. Details will be provided in the SAP.  
[IP_ADDRESS]  Vital Signs  
Vital signs will include heart rate , systolic blood pressure , diastolic blood pressure , and 
respi[INVESTIGATOR_697] . Observed vital sign values and  changes from baseline will be 
summarized using descriptive statistics overall and by [CONTACT_551], visit, timepoint and 
dose level/placebo group  on the SS for the randomized blinded treatment period 
(Months  0 to 12). Listings of values that are potentially clinically significant will be 
presented by [CONTACT_322277] , where applicable . 
Vital signs of potential clinical significance for children and adolescents are defined as 
follows:  
Vital Sign  Criteria for Clinically Significant Abnormalities  
Heart rate  >120 beats per minute or an increase from pre -dosing of 
>20 beats per minute,  
or 
<50 beats per minute or a decrease from pre -dosing of 
>20 beats per minute  
Systolic blood 
pressure  > 140 mmHg or an increase from pre -dosing of  >40 m mHg, 
or 
< 90 mmHg or a decrease from pre -dosing of  >30 mmHg  
Diastolic blood 
pressure  > 90 mmHg or an increase from pre -dosing of > 30 mmHg,  
or 
< 50 mmHg or a decrease from pre -dosing of > 20 mmHg  
The Investigator s will assess whether any of the abnormal values are clinically 
significant . Clinically significant abnormal values will be recorded as an AE.  
Vital signs measured during the open -label treatment periods after Month 12 will be 
described. Details will be pr ovided in the SAP.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 116 of 170 
[IP_ADDRESS]  Physical Examination  and P atch Site Examination  
Physical examination results, including complete observation of the skin will be listed 
and summarized overall and by [CONTACT_551], visit, timepoint, and dose level/placebo 
group  on the SS for the randomized blinded treatment period (Months  0 to 12).  
Physical examination during the open -label treatment periods after Month 12 will be 
described. Details will be provided in the SAP.  
In addition, examination of the skin at the site of  Viaskin patch application will be  
graded from Grade  0 (negative) up to Grade  4 (erythema, vesicles). These results will 
be summarized using descriptive statistics and presented overall and by [CONTACT_551], 
visit, dose level and placebo group in the SS for th e randomized blinded treatment 
period (Months  0 to 12) . Worst grade reported  by [CONTACT_322278] -label treatment period will also be tabulated.  
Examination of skin at patch site during the open -label treatment periods after Mon th 
12 will be described. Details will be provided in the SAP.  
[IP_ADDRESS]  Clinical Laboratory Tests  
Clinical laboratory test results will be presented in Standard International (SI) units 
unless otherwise specified and will be summarized overall and by [CONTACT_551], dose  
level and placebo group, and timepoint for both absolute values and changes from 
baseline for the randomized blinded treatment period (Months  0 to 12).  
Shift tables will be generated to compare baseline values to the values collected at 
Month  12. Listed data values that are outside the reference range will be flagged.  
Clinical laboratory test results assessed during the open -label treatment periods after 
Month [ADDRESS_397829] results will be listed.  
[IP_ADDRESS]  Spi[INVESTIGATOR_322226] (FEV 1) and PEF results as % predicted values will be summarized overall 
and by [CONTACT_551], dose level and placebo  group,  and timepoint using descriptive 
statistics on the SS for the randomized blinded treatment period (Months  0 to 12). 
Spi[INVESTIGATOR_322227] -label treatment periods after 
Month 12 will be described. Details will be provided in the SAP.  
Spi[INVESTIGATOR_322228].  
[IP_ADDRESS]  Subject Diary Card  Data  
Diary card data will be listed. Data derived from the diaries (eg, number of days of 
itching, redness and swelling [ with associated g rades] , worst grades of itching, redness 
and swelling documented by [CONTACT_748] , compliance of treatment and  duratio n of 
patch application ) will be summarized.  
8.1.[ADDRESS_397830] mite, and grass pollen  at all timepoints.   
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
([SORUDWRU\HQGSRLQWVZLOODOVRLQFOXGHWKHFKDQJHIURPEDVHOLQ HLQHSLJHQHWLF
PRGLILFDWLRQVDW0RQWKDQGDIWHU0RQWKLIHYDOXDWHG
7KHDERYHDQDO\VHVZLOOEHGHILQHGLQWKH6$3
)LODJJULQJHQHPXWDWLRQVZLOO EHDVVHVVHGIURPDEORRGVDPSOHF ROOHFWHGDWYLVLWDQG
WKHUHVXOWVZLOOEHOLVWHG7 KHUHODWLRQVKLSEHWZHHQWKHSUHVHQ FHRIILODJJULQPXWDWLRQV
VDIHW\DQGUHVSRQVHWRWUHDWPHQWZLOODOVREHLQYHVWLJDWHG7KL VDQDO\VLVZLOOEHGHILQHG
LQWKH6$3
([SORUDWRU\HQGSRLQWVZLOODO VRLQFOXGHWKHHQXPHUDWLRQDQGFKD UDFWHUL]DWLRQRI
UHDFWLRQVWULJJHUHGE\DFFLGHQWDOFRQVXPSWLRQRIFRZÂ¶VPLONLQ DQ\IRUPDQGWKH
DQDO\VLVRIÂ³ULVNWDNLQJEHKDYLRUÂ´RIVXEMHFWVRUYROXQWDU\PL ONFRQVXPSWLRQDV
DVVHVVHGE\WKH,QYHVWLJDWRUVGXU LQJWKHVWXG\%RWKSLHFHVRI LQIRUPDWLRQDFFLGHQWDO
FRQVXPSWLRQDQGUHDFWLRQVWULJJHUHGE\FRQVXPSWLRQZLOOEHFRO OHFWHGIURPVXEMHFW
'LDU\&DUGVDQGYROXQWDU\RUDFFL GHQWDOFRQVXPSWLRQZLOOEHDVV HVVHGE\WKH
LQYHVWLJDWLYHVWDIIZKLOHLQW HUYLHZLQJWKHVXEMHFWV
)UHTXHQF\RIDFFLGHQWDOFRQVXPSWL RQRIFRZÂ¶VPLONLQDQ\IRUP FRQGLWLRQVDURXQGWKH
DFFLGHQWDOFRQVXPSWLRQHVWLPDWHGTX DQWLW\FRQVXPHGDWHDFKRFF XUUHQFHDQG
DVVRFLDWHGUHDFWLRQVDQGVHYHULW\RI UHDFWLRQVZLOOEHDQDO\]HG VHSDUDWHO\
5LVNWDNLQJEHKDYLRUVIUHTXHQF\RIGHOLEHUDWHFRQVXPSWLRQRIF RZÂ¶VPLONLQDQ\IRUP
FRQGLWLRQVDURXQGWKHFRQVXPSWLRQ HVWLPDWHGTXDQWLW\FRQVXPHG DWHDFKRFFXUUHQFH
DQGDVVRFLDWHGUHDFWLRQVZLWKWKH VHFRQVXPSWLRQVZLOOEHDQDO\] HGVHSDUDWHO\
5HODWHGQHVVWRWKHVXEMHFWÂ¶VDJHFDWHJRU\ZLOODOVREHDQDO\]HG 
(QGRIVWXG\VXUYH\VFRPSOHWHGE\WKHLQYHVWLJDWRUVZLOOEHDQD O\]HGWRDVVHVVWKH
SODQQHGPDQDJHPHQWRIHDFKVXEMHFW DIWHUWHUPLQDWLRQRIWKHVWX G\
 ,QWHULP$QDO\VHV
7KHUHDUHQRLQWHULPHIILFDF\DQDO\VHVSODQQHGIRUWKLVVWXG\ KRZHYHUDUHSRUWZLOOEH
SURYLGHGEDVHGRQWKHVDIHW\GDWD FROOHFWHGIURP3DUW$VXEMHFW VDQGDQDO\VLVRIWKH
VDIHW\GDWDE\WUHDWPHQWJURXSVDVGHVFULEHGLQWKH6$3
$IWHUDOOVXEMHFWVIURP3DUW$D QG3DUW%KDYHUHFHLYHGPRQW KVRIWUHDWPHQWZLWK
9LDVNLQSDWFKDQGFRPSOHWHGWKH0RQWK'%3&)&DGDWDWUDQVIH UZLOOEHSHUIRUPHG
DIWHUWKHGDWDDUHFOHDQHGFRG HGDQGUHFRQFLOHGZLWK6$(DQG ODERUDWRU\GDWD7KH
GDWDEDVHZLOOEHSXWRQKROGLHQRXSGDWHVZLOOEHSHUIRUPHG GXULQJWKHWLPHRIWKH
DQDO\VLV7KHVWXG\GDWDZLOOEHDQDO\]HGDVGHVFULEHGLQWKH6 $3DQGWKHUHVXOWVZLOO
EHUHSRUWHGLQWKHPRQWK&65
$IWHUWKH0RQWK'%3&)&VXEMH FWVZHUHWRFRQWLQXHWUHDWPHQW ZLWKDFWLYH9LDVNLQ
0LONSDWFKLQDQRSHQODEHOPDQQHUDWWKHKLJKHVWGRVHÂ—J DVVHVVHGWREHVDIH
EDVHGRIVDIHW\GDWDRI3DUW$VXE MHFWVXQWLO0R QWKEXWZL OOEHVZLWFKHGWR9LDVNLQ
0LONÂ—JIRUPRQWKVEHIRUH0RQWK7KHVWXG\GDWDZLOO EHDQDO\]HGDV
GHVFULEHGLQWKH6$3DQGWKHUHVXOWVZLOOEHUHSRUWHGLQWKHIL QDO&65
 'HWHUPLQDWLRQRI6DPSOH6L]H
CCI
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
 5DQGRPL]DWLRQ3URFHGXUHV
8SWRDSSUR[LPDWHO\VXEMHFWVZLOOEHUDQGRPL]HGLQWKHVWXG \VXEMHFWVLQ3DUW$
DQGVXEMHFWVLQ3DUW%
,Q3DUW$VXEMHFWVZLOOEHUDQ GRPL]HGLQVXFFHVVLYHFRKRUWV RIVXEMHFWVHDFKWR
UHFHLYH9LDVNLQ0LONRUSODFHERL QDUDWLR7KHVDIHW\RIW KHGRVHVRI9LDVNLQ0LON
ZLOOEHDVVHVVHGRYHUDZHHNWUHDWPHQWSHULRGIRUHDFKGRVHE HIRUHSURFHHGLQJWR
3DUW%ZLWKWKHVDIHGRVHV7KHDQDO\VLVRIWKHFXPXODWLYHVD IHW\GDWDSHUPLWWHGWKH
VHOHFWLRQRIWKH9LDVNLQ0LON GRVHVÂ—JÂ—JDQG Â—JRIFRZÂ¶VPLON
SURWHLQVIRUUDQGRPL]DWLRQLQWR3DUW%RIWKHVWXG\7KHVFUHH QLQJRIVXEMHFWVLQ3DUW%
RIWKHVWXG\PD\FRQWLQXHZKHQ WKHHQUROOPHQWLQ3DUW$LVFRPS OHWHKRZHYHUQR
VXEMHFWZLOOEHUDQGRPL]HGLQWRRUWUHDWHGLQ3DUW%EHIRUHW KHUHYLHZRIWKHVDIHW\
GDWDIURP3DUW$KDVEHHQFRPSOHW HGE\ERWKWKH'60%DQGWKH)' $$SDXVHLQWKH
UDQGRPL]DWLRQZLOODOORZIRUWK LVVDIHW\UHYLHZWRRFFXUDQGUH FRPPHQGDWLRQVWREH
UHOHDVHG
,Q3DUW%DSSUR[LPDWHO\DGGLWLRQDOVXEMHFWVZLOOEHUDQGRP L]HGUDWLRWR
UHFHLYH9LDVNLQ0LONÂ—JQ RU9LDVNLQ0LONÂ—JQ  RU9LDVNLQ0LON
Â—JQ RUSODFHERQ  XQWLO0RQWK5DQGRPL]DWLRQL Q3DUW%ZLOOEH
VWUDWLILHGE\VLWHDQGE\WKHIRO ORZLQJDJHFDWHJRULHVFKLOGUH QWR\HDUVROGDQG
DGROHVFHQWVWR\HDUVROGEDVHGRQWKHVXEMHFWÂ¶VDJHDW9 LVLW
6XEMHFWVZLOOEHUD QGRPL]HGWR WKHGRVHOHYHOJURXSRUSO DFHERLQDFFRUGDQFHZLWKWKH
UDQGRPL]DWLRQVFKHGXOHJHQHUDWHGE\ WKH&52XVLQJ $QH[WHUQDO
,:56ZLOOEHXVHGWRDOORFDWHVXEMH FWVWRWKHGRVHOHYHOJURXS RUSODFHER DV
DSSOLFDEOH 
5DQGRP6HTXHQFLQJRIWKH&KDOOHQ JH)RUPXODV'XULQJWKH'%3&)& 
7KHVHTXHQFHRIIRRGFKDOOHQJH IRUPXODVRQWKHILUVWGD\DQGWK HVHFRQGGD\RIWKH
'%3&)&VZLOODOVREHUDQGRPL]HG(DFKVLWHZLOOEHSURYLGHGZLW KDUDQGRPL]DWLRQ
WDEOHDW6FUHHQLQJ0RQWKV DQG7KHXQEOLQGHGVL WHSHUVRQQHOLQFKDUJH
RIWKHSUHSDUDWLRQRIWKHIRRGFKDOOHQJHIRUPXODZLOOEHJLYHQ DSDVVZRUGSURWHFWHG
WDEOH)RUHDFKVXEMHFWWREHFKD OOHQJHGWKHXQEOLQGHGVLWHSH UVRQQHOZLOOHQWHUWKHCCI
CCI
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
VXEMHFWLQIRUPDWLRQDQGWKHWD EOHZLOOSRSXODWHDXWRPDWLFDOO\W RGHWHUPLQHZKLFKIRUPXOD
0LONRUSODFHERLVJLYHQRQWKHILUVWGD\RIWKHIRRGFKDOOHQ JHDQGZKLFKIRUPXOD0LON
RUSODFHERZLOOEHJLYHQWKHVHFRQGGD\RIWKHFKDOOHQJH7KH VXEMHFWDQGWKH
DVVHVVRUVZLOOUHPDLQEOLQGWRWKHIRUPXODVÂ¶RUGHUGXULQJWKHF RQGXFWRIWKHFKDOOHQJH
RQERWKGD\VVHH 6HFWLRQ IRUHPHUJ HQF\XQEOLQGLQJSURFHGXUHV2QO\DWWKH
HQGRIWKHVHFRQGGD\RIFKDOOHQJHZLOOWKHRUGHURIWKHIRUPXO DVEHXQEOLQGHGWRWKH
VXEMHFWDQGWKHDVVHVVRUV
 4XDOLW\$VVXUDQFHDQG4XDOLW\&RQWURO
 $XGLWDQG,QVSHFWLRQ
6WXG\VLWHVDQGVWXG\GRFXPHQWDW LRQZLOOEHVXEMHFWWRTXDOLW\ DVVXUDQFH4$DXGLW
GXULQJWKHFRXUVHRIWKHVWXG\E\ WKHVSRQVRUDQGWKH&52UHSUH VHQWDWLYHV,Q
DGGLWLRQLQVSHFWLRQVPD\EHFRQG XFWHGE\UHJXODWRU\DXWKRULWLH VDWWKHLUGLVFUHWLRQ7KH
,QYHVWLJDWRUPXVWSHUPLWGLUHFWDFFHVVWRDOOVWXG\UHODWHGGRF XPHQWVGXULQJWKHDXGLWV
 0RQLWRULQJ
7KHVWXG\GDWDIRUHDFKVXEMHFWZLOOEHUHFRUGHGLQWKHH&5)' DWDFROOHFWLRQPXVWEH
FRPSOHWHGIRUHDFKVXEMHFWZKRLVDGPLQLVWHUHGWKHLQYHVWLJDWLR QDOSURGXFWDQGIRUWKHLU
SDUHQWVJXDUGLDQVDVDSSOL FDEOHZKRVLJQV DQ,&),$)
,QDFFRUGDQFHZLWKFXUUHQW*RRG&O LQLFDO3UDFWLFHF*&3DQG,& +JXLGHOLQHVWKH
FOLQLFDOPRQLWRURIWKH&52ZLOOSHUIRUPVRXUFHGRFXPHQWYHULIL FDWLRQDWUHJXODU
LQWHUYDOVWRHQVXUHWKDWWKHGD WDFROOHFWHGLQWKHH&5)DUHDFF XUDWHDQGUHOLDEOH7KH
IUHTXHQF\RIPRQLWRULQJYLVLWVZLOOEHGHWHUPLQHGE\WKHUDWHR IVXEMHFWUHFUXLWPHQW
7KHIROORZLQJZLOOEHUHYLHZHGDWWKHVHYLVLWV
x&RPSOLDQFHZLWKWKHSURWRFRO
x&RQVHQWSURFHGXUHV
x$(FROOHFWLRQSURFHGXUHV
x5HJXODWRU\(VVHQWLDO 'RFXPHQWPDLQWHQDQFH
x6WRUDJHDQGDFFRXQWDELOLW\RIPDWHULDOV
7KHPRQLWRULQJYLVLWVDOVRSURY LGHWKHVSRQVRUZLWKWKHRSSRUWX QLW\WRHQVXUHWKH
,QYHVWLJDWRUÂ¶VREOLJDWLRQVDQGDOO DSSOLFDEOH,&+RUKHDOWKDXW KRULW\UHJXODWLRQ
UHTXLUHPHQWVDUHEHLQJIXOILOOHG7KH,QYHVWLJDWRUPXVWSHUPLW WKHPRQLWRUWKH,5%WKH
VSRQVRUÂ¶VLQWHUQDODXGLWRUVDQGU HSUHVHQWDWLYHVIURPUHJXODWRU \DXWKRULWLHVGLUHFW
DFFHVVWRDOOVWXG\UHODWHGGRFXPHQWVDQGSHUWLQHQWKRVSLWDORU PHGLFDOUHFRUGVIRU
FRQILUPDWLRQRIGDWDFRQWDLQHGZ LWKLQWKHH&5)V6XEMHFWFRQILG HQWLDOLW\ZLOOEH
SURWHFWHGDWDOOWLPHV
 'DWD0DQDJHPHQWDQG&RGLQJ
7KH&52 ZLOOEHUHVSRQVLEOHIRUDFWLYLWLHVDVVRFLDWHGZLWKWKHGDWDPDQ DJHPHQWRIWKLV
VWXG\7KLVZLOOLQFOXGHVHWWLQJXSD UHOHYDQWGDWDEDVH DQGHOHFWURQLFGDWDFDSWXUH
('&V\VWHP DQGGDWDWUDQVI HUPHFKDQLVPVDORQJZLWKDSSURSULDWH
YDOLGDWLRQRIGDWDDQGUHVROXWLR QRITXHULHV'DWDJHQHUDWHGZL WKLQWKLVFOLQLFDOVWXG\ZLOO
EHKDQGOHGDFFRUGLQJWRWKHUHO HYDQW623VRIWKHGDWDPDQDJHPHQ WDQGELRVWDWLVWLFV
GHSDUWPHQWVRI WKH&52 C
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 120 of 170 
All data  that are not available in electronic format  (eg, diary cards ) will be 
double -entered into the data management system , if these data have to be entered by 
[CONTACT_322279] . Following data verification (completion of second data entry  and 
further verification of the  entries ), the audit trail will be switched on ( ie, a computeriz ed 
log of all subsequent changes to the data will be recorded). Automated checks will be 
made against the data to ensure completeness and consistency. The database and 
check programs will be v alidated before implementation.  
MedDRA will be used to code  concomitant diseases and AEs and the WHODrug will be 
used for concomitant medicati ons. 
Missing or inconsistent data will be queried in writing to the Investigator  for clarification. 
Subsequent modifications to t he database will be documented.  
The sites  will enter d ata directly into the EDC system by [CONTACT_120081] a 
secure internet connection.  The CRO  will provide training on how to use the system to 
the Investigator s at each site. Data entered into the eCRF must be verifiable against 
source documents at the site. Data to be recorded directly in the eCRF (without prior 
written or electronic record) will be identified and the eCRF will be considered the 
source document. Any changes to the data entered into the EDC system will be 
recorded in the audit trail and is FDA CFR  21 Part  11 compliant.  
Data entered into the eCRF will be validated as will be defined in the data validation 
specification . External data ch ecks will be programmed where appropriate ( eg for 
laboratory data) as well as for cross table checking between eCRFâ€™s ( eg AE and 
concomitant medication forms).  
[ADDRESS_397831]  (including placebo product , as applicable ), the 
Investigator  (or deputy) will conduct an inventory of the supplies and verify that the 
investigational product  supplies are received intact and in the correct amounts before  
completing  a supplies receipt.  The Investigator  will retain a copy of this receipt at the  
site and return the original receipt to the study monitor.  The investigational product will 
be shipped by [CONTACT_322280] a designated person at the study site and must be stored in 
a locked and secured storage facility, accessible only to those individuals authorized by 
[CONTACT_737] . The inven tory of supplies at each study site  may be checked at any 
time d uring the study by [CONTACT_2037].  
It is the responsibility of the study monito r to ensure that the Investigator  (or deputy) 
has correctly documented the amount received, dispens ed and return ed of the 
investigational product  on the dispensing log that will be provided.  A full product  
accountability log will be maintained at the  site at all times.  The study monitor will 
arrange regular collection of unused investigational product that was  returned by [CONTACT_1560].  The study monitor will also perform an inventory of investigational product  at 
the close -out visit to the study site . All di screpancies must b e accounted for and 
documented.  
At the end of the study, the sites will be responsible for destroying unused 
investigational product and providing a corresponding certificate of destruction . 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 121 of 170 
10.2 Financing and Insurance  
Financing and insurance of this study will be outlined in a se parate agreement between 
the CRO  and the sponsor.  
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397832] be obtained, in particular, for changes to the study 
such as modification of the protocol, the  ICFs, IAFs, the written information provided to 
subjects and/or parent(s)/guardian(s) , and/or other procedures.  
The Investigator  will report promptly to the IRB any new information that may adversely 
affect the safety of the subjects or the conduct of the study.  The Investigator  will submit 
written summaries of the stu dy status to the IRB annually, or more frequently if 
requested by [CONTACT_1201].  On completion of the study, the sponsor will notify the IRB that 
the study has ended.  
11.[ADDRESS_397833] of the Study  
This study will be conducted in accordance with applicable laws an d regulations 
including, but not limited to, the ICH guidelines for Good Clinical Practice (ICH E6)27, 
the ethical principles from the declaration of Helsinki28 (Appendix 14.7), and applicable 
local regulatory requirements. The IRB must review and approve the protocol and 
ICFs/IAFs before any subject s are enrolled in to the study. Each subject and/or 
parent(s)/guardian(s) must sign and date the IRB -approved ICFs/IAFs , before any 
protocol -required procedures are performed.  
11.[ADDRESS_397834] â€™s parent(s)/ guardian (s) has given 
written informed consent . Subjects â‰¥7 years old (or as per local or country  specific 
guidelines or regulations ) will be encouraged  to sign the IAF  to particip ate in the study.  
The written ICF/IAF must be given by [CONTACT_3184]/or his/her  parent(s)/ guardian (s), 
after detailed information about the study has been given by [CONTACT_322281].  The verbal explanation will cover all the elements specified in the 
written inform ation provided for the subject and/or parent(s)/guardian(s).  
The Investigator  or designated personnel will inform the subject and/or 
parent(s)/guardian(s) of the objectives, methods, anticipated benefits and potential 
risks and inconveniences of the study.  The subject and/or parent (s)/guardian (s) should  
be given every opportunity to ask for clarification of  any points he/she does not 
understand and, if necessary, for more information.  At the end of the interview, the 
subject and/or parent(s)/guardian(s) will be given time to consider the study , if needed , 
or if the subject and/or parent(s)/guardian(s) reques ts more time.  Parent(s)/guardian(s)  
will be required to sign and date the ICF(s). After signatures are obtained, the 
ICF(s)/IAF(s)  will be kept and archived by [CONTACT_322282] â€™s study file 
for possible inspection by [CONTACT_322283], the IRB, and the CRO  personnel.  
It should be emphasi zed to the subject and/or parent(s)/guardian(s) that he/she is at 
liberty to withdraw from the study at any time.  Subjects and/or parent(s)/guardian(s) 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397835] Confidentiality  
All personal data collected and processed for the purposes of this study should be 
managed by [CONTACT_63047]/her staff with adequate precautions t o ensure 
confidentiality of those data, and in accordance with the Health Insurance Portabilit y 
and Accountability Act29, applicable to national and/or local laws and regulations on 
personal data protection.  
Monitors, auditors, and other authorized a gents o f the sponsor and/or its designee, the 
ethics committees approving this research, and the FDA, as well as those  of any other 
applicable agenc y, will be granted direct access to the study subjectsâ€™ original medical 
records for verification of clinical study procedures and/or data, without violating the 
confidentiality of the subjects to the extent permitted by [CONTACT_45025]. In any 
presentations of the results of this study or in publications, the subjectsâ€™ identity will 
remain confidential.  
  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
 6WXG\$GPLQLVWUDWLRQ5HSRUWLQ JDQG3XEOLFDWLRQ,QFOXGLQJ$ UFKLYLQJ
 6WXG\$GPLQLVWUDWLRQ
,QWHUQDWLRQDO&RRUGLQDWLQJ,QYHVWLJDWRU







'%97HFKQRORJLHV3 HUVRQQHO
93+HDGRI%LRPHWULFV





693*OREDO5HJXODWRU\$IIDLUV




693&OLQLFDO2SHUDWLRQV




'LUHFWRU&OLQLFDO3URMHFWV




&OLQLFDO3URMHFW0DQDJHU 





0HGLFDO0RQLWRU




6DIHW\DQG3KDUPDFRYLJLODQFH2IILFHU'%9*OREDO6DIHW\DQG3K DUPDFRYLJLODQFH'HSDUWPHQW 

[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
6\QHRV+HDOWKIR UPHUO\,1&5HVHDUFK3HUVRQQHO
7KH&526\QHRV+HDOWKIRUPHUO\, 1&5HVHDUFKLVFRQGXFWLQJWK LVFOLQLFDOVWXG\RQ
EHKDOIRIWKHVSRQVRU'%97HFKQRORJLHV
0HGLFDO0RQLWRU




&OLQLFDO'UXJ6XSSO\DQG& HQWUDO/DERUDWRULHV
ZLOOPDQXIDFWXUHERWKWKHDFWLYH9LDVNLQ0LONDQG
SODFHERSDWFK HV
&HQWUDODQGRWKHUODERUDWRULHVZLOOEHGHVLJQDWHGE\WKHVSRQVR U'%97HFKQRORJLHV
DQGDSSURSULDWHFRQWDFWLQIRUPDWLRQDQ GODERUDWRU\PDQXDOVZLOO EHSURYLGHGWRWKH
VLWHV
 5HSRUWLQJDQG3XEOLFDW LRQ,QFOXGLQJ$UFKLYLQJ
(VVHQWLDOGRFXPHQWVDUHWKRVHGRFX PHQWVWKDWLQGLYLGXDOO\DQGF ROOHFWLYHO\SHUPLW
HYDOXDWLRQRIWKHVWXG\DQGTXD OLW\RIWKHGDWDSURGXFHG$IWHU FRPSOHWLRQRIWKHVWXG\
DOOGRFXPHQWVDQGGDWDUHODWLQJWRWKHVWXG\ZLOOEHNHSWLQDQ RUGHUO\PDQQHUE\WKH
,QYHVWLJDWRULQDVHFXUHVWXG\ILOH7KLVILOHZLOOEHDYDLODEO HIRULQVSHFWLRQE\WKH
VSRQVRURULWVUHSUHVHQWDWLYHV( VVHQWLDOGRFXPHQWVVKRXOGEHU HWDLQHGIRU\HDUV
DIWHUWKHILQDOPDUNHWLQJDSSURYDOLQDQ,&+UHJLRQRUIRUDWO HDVW\HDUVVLQFHWKH
GLVFRQWLQXDWLRQRIFOLQLFDOGHYHORSPHQWRIWKHLQYHVWLJDWLRQDO SURGXFW,WLVWKH
UHVSRQVLELOLW\RIWKHVSRQVRUWRLQ IRUPWKHVWXG\VLWHRIZKHQ WKHVHGRFXPHQWVQR
ORQJHUQHHGWREHUHWDLQHG7KH,QYHVWLJDWRUPXVWFRQWDFWWKHV SRQVRUEHIRUH
GHVWUR\LQJDQ\VWXG\UHODWHGGRF XPHQWDWLRQ,QDGGLWLRQDOOVX EMHFWPHGLFDOUHFRUGV
DQGRWKHUVRXUFHGRFXPHQWDWLRQZLOOEHNHSWIRUWKHPD[LPXPWLP HSHUPLWWHGE\WKH
KRVSLWDOLQVWLWXWLRQRUPHGLFDOSUDFWLFH
7KHVSRQVRUPXVWUHYLHZDQGDSSURYHDQ\UHVXOWVRIWKHVWXG\RU DEVWUDFWVIRU
SURIHVVLRQDOPHHWLQJVSUHSDUHGE\ WKH,QYHVWLJDWRUV3XEOLVKH GGDWDPXVWQRW
FRPSURPLVHWKHREMHFWLYHVRIWKHVWXG\'DWDIURPLQGLYLGXDOVW XG\VLWHVLQPXOWLFHQWHU
VWXGLHVPXVWQRWEHSXEOLVKHGVHSDUDWHO\
[COMPANY_003]
CCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.[ADDRESS_397836]. 2011; 121(3):827 -835. 
2 Nowak -WÄ™grzyn A and Sampson HA. Future Therapi[INVESTIGATOR_322229]. J Allergy 
Clin Immunol. 2011; 127(3):[ADDRESS_397837] A. Frequency of cowâ€™s milk allergy in childhood. Ann Allergy Asthma Immunol. 
2002; 89(6suppl1):33 -37 
4 Crisafulli G, Caminiti L and P ajno GB. Oral Desensitization for Immunoglobulin E -
Mediated Milk and Egg Allergies. Isr Med Assoc J. 2012; 14(1):[ADDRESS_397838] 3 years of life. Clinical course in re lation to clinical and immunological type of 
hypersensitivity reaction. Allergy. 1990; 45(8): 587 -596 
6 Elizur A, Rajuan N, Goldberg MR, Leshno M, Cohen A and Katz Y. Natural Course 
and Risk Factors for Persistence of IgE -Mediated Cowâ€™s Milk Allergy. J Ped iatr. 2012, 
161(3):482 -487 
7 Skripak JM, Matsui EC, Mudd K and Wood RA. The natural history of IgE -mediated 
cowâ€™s milk allergy. J Allergy Clin Immunol. 2007; 120(5):1172 -1177  
8 Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleisher DM, Henning AK, 
Mayer L, Burks W, Grishin A, Stablein D and Sampson HA. The natural history of 
milk allergy in an observational cohort. J Allergy Clin Immunol. 2013; 131(3):805 -812 
9 Spergel JM. Natural history of cowâ€™s milk allergy. Natural history of cowâ€™s milk allergy. 
J Allergy Clin Immunol. 2013; 131(3):813 -814. 
10 Savilahti EM and Savilahti E. Development of natural tolerance and induced 
desensitization in cowâ€™s milk allergy. Pediatr Allergy Immunol. 2013; 24(2):114 -121. 
11 Boyano -MartÃ­nez T, GarcÃ­a -Ara C, Pedrosa M, DÃ­az -Pena JM and Quirce S. 
Accidental allergic reactions in children allergic to cowâ€™s milk proteins. J Allergy Clin 
Immunol. 2009; 123(4):883 -888 
12 Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG,  Matsui EC, 
Burks AW and Wood RA. A randomized, double -blind, placebo -controlled study of 
milk oral immunotherapy for cowâ€™s milk allergy. J Allergy Clin Immunol. 2008; 
122(6):1154 -1160  
13 Keet CA, Frischmeyer -Guerrerio PA, Thyagarajan A, Schroeder JT, Hamil ton RG, 
Boden S, Steele P, Driggers S, Burks AW and Wood RA. The safety and efficacy of 
sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012; 
129(2):448 -455 
14 BroÅ¼ek JL, Terracciano L, Hsu J, Kreis J, Compalati E, Santesso N, Fi occhi A and 
SchÃ¼nemann HJ. Oral immunotherapy for IgE -mediated cowâ€™s milk allergy: a 
systematic review and meta -analysis. Clin Exp Allergy. 2012; 42(3):363 -374 
15 Viaskin Milk (DBV135) Investigat orâ€™s Brochure  (Edition 2, 2015 ). 
16 Dupont C, Kalach N, Soulain es P, Legoue -Morillon S, Pi[INVESTIGATOR_322230] H, Benhamou PH. 
Cow's milk epi[INVESTIGATOR_322231]: a pi[INVESTIGATOR_322232], 
acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 
2010;125(5):1165 -1167  
17 Sampson HA, MuÃ±oz -Furlong A, Camp bell RL, Adkinson NF Jr, Bock SA, Branum A, 
et al. Second symposium on the definition and management of anaphylaxis: 
                                                 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 127 of 170 
                                                                                                                                          
summary report â€“ second National Institute of Allergy and Infectious Disease/Food 
Allergy and Anaphylaxis Network symposium. J Allergy Clin  Immunol 2006; 117(2): 
391-397 
18 American Thoracic Society guidelines (2005); Available online at: 
http://www.thoracic.org/statements/resources/pft/PFT2.pdf . Accessed on 
13 Apr 2014.  
19 Expert Panel Report 3 (EPR -3): Guidelines for the Diagnosis and Management of 
Asthma - Summary Report 2007. Available online at: 
http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf . Accessed on [ADDRESS_397839] â€“retest reliability of the Food Allergy Quality of Life Questionnaires 
(FAQLQ)  for children, adolescents and adults. Qual Life Res 2009 ; 18:245 â€“251 
21 Nowak -Wegrzyn A, Assaâ€™ad AH, Bahna SL, Bock SA, Sicherer SH and Teuber SS. 
Work group report: oral food challenge testing. J Allergy Clin Immunol. 2009; 
123:S365 -S383  
22 Sampson HA, Ger th van Wijk R, Bindslev -Jensen C, Sicherer S, Teuber SS, Burks 
WA, et al. Standardizing double -blind, placebo -controlled oral food challenges: 
American Academy of Allergy, Asthma & Immunology â€“European Academy of Allergy 
and Clinical Immunology PRACTALL con sensus report. J Allergy Clin Immunol. 
2012; 130(6):1260 -1274  
23 Flokstra -de Blok BMJ, DunnGalvin A, Vlieg -Boerstra BJ, Oude Elberink JNG, 
Duiverman EJ, Hourihane JO, Dubois AEJ. Development and validation of the self -
administered Food Allergy Quality of Li fe Questionnaire for adolescents. J  Allergy 
Clin Immunol 2008 Jul;  122(1):139 -144. 
24 International Conference on Harmonisation, ICH E2A Guideline, Clinical Safety Data 
Management: Definitions and Standards or Expedited Reporting, October 1994  
25 Turjanmaa K , Darsow U, Niggemann B, et al. EAACI/GA2LEN position paper: 
present status of the atopy patch test. Allergy 2006; 61:1377 -1384.  
26 Howie  SRC. Blood sample volumes in child health research: review of safe limits . 
Bull World Health Organ 2011;  89:46 â€“53 
27 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. 
Good Clinical Practice. CPMP/ICH/135/35. [ADDRESS_397840] (HIPAA) of 1996 (P.L.104 -191) [HIPAA]. 
http://aspe.hhs.gov/admnsimp/pl104191.htm. Effective 21  Aug 1996  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 128 of 170 
14 Appendices  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 129 of 170 
14.1 Investigator Signature [CONTACT_68516]:  A Double -Blind, Placebo -Controlled Randomized Trial to Study 
the Viaskin MILk Efficacy and Safety for Treating IgE -Mediated 
Cowâ€™s Milk Allergy in Children (MILES Study)  
 
Protocol Number:  MILES  
Confidentiality and cGCP Compliance Statement  
I, the undersigned, have reviewed this protocol, including appendices , and I will 
conduct the study as described in compli ance with this protocol, GCP, and relevant 
ICH g uidelines.  
Once the protocol has been approved by [CONTACT_1201], I will not modify this protocol wi thout 
obtaining prior approval of DBV Technologies  and of the IRB. I will submit the protocol 
modifications and/or any ICF /IAF modifications to DBV Technologies  and the IRB, and 
approval will be obtained before any modifications are implemented.  
I understa nd that all information obtained during the conduct of the study related to the 
subjectsâ€™ state of health wi ll be regarded as confidential.  No subject sâ€™ names will be 
disclosed.  All subject s will be identified by [CONTACT_266148], laboratory 
samples or source documents forwarded to the sponsor.  Clinical information may be 
reviewed by [CONTACT_266149].  Agreement must be 
obtained from the subject before disclosure of subjec t information to a third party.  
Informatio n developed in this clinical study may be disclosed by [CONTACT_322284] , to 
other clinical Investigator s, regulatory agencies, or other health authority or g overnment 
agencies , as required.  
   
Investigator Signature   [CONTACT_322293]: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 130 of 170 
14.2 Oral Food Challenge Symptom Score Sheets 
I. SKIN  
 Stoppi[INVESTIGATOR_004]:  
# of grade increase  
 Alone  Associated  
A. Pruritus  +3 +2 
0 = Absent    
1 = Mild: occasional scratching    
2 = Moderate: scratching continuously for >2 minutes at a time   
3 = Severe: hard continuous scratching excoriations    
B. Urticaria  +2 +1 
0 = Absent    
1 = Mild: â‰¤3 hives    
2 = Moderate: <10 hives but >3    
3 = Severe: generalized involvement    
C. Angioedema  +2 +1 
0 = Absent    
1 = Mild: mild lip edema    
2 = Moderate: significant lip or face edema    
3 = Severe: generalized involvement    
D. Erythematous Rash  +2 +1 
0 = Absent    
1 = Mild: few areas of faint erythema    
2 = Moderate: areas of erythema (>20% and <50%), macular and raised rash    
3 = Severe: generalized marked erythema (>50%), extensive raised lesions 
(>25%)    
Erythematous Rash % area involved (see below):  /_____/____/%  
 
 1-4 years old  5-8 years old  9-12 years old  â‰¥13 years old  
Head  17% 16% 12% 4.5%  
Neck  2% 2% 2% 1% 
Anterior trunk  16% 14% 14% 18% 
Posterior trunk  16% 18% 18% 18% 
Leg (1)  15% 15% 17% 18% 
Arm (1)  9.5%  10% 10% 9% 
Adapted from Lund CC, Browder NC (1944) The estimation of areas of burns. Surg Gynecol 
Obstet 79: 352 â€“8 
 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 131 of 170 
II. UPPER RESPI[INVESTIGATOR_6709]/OCCULAR  
 Stoppi[INVESTIGATOR_004]:  
minimal # of grade 
increase  
 Alone  Associated  
A. Sneezing/Itching  +3 +2 
0 = Absent    
1 = Mild: rare bursts    
2 = Moderate: bursts <10, intermittent rubbing of nose / eyes / external ear 
canals    
3 = Severe: continuous rubbing of nose / eyes, periocular swelling and/or long    
bursts of sneezing    
B. Nasal Congestion  +3 +2 
0 = Absent    
1 = Mild: some hindrance to breathing    
2 = Moderate: nostrils feel blocked, breathing through mouth most of time    
3 = Severe: nostrils occluded    
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 132 of 170 
C. Rhinorrhea  +3 +2 
0 = Absent    
1 = Mild: occasional sniffling    
2 = Moderate: frequent sniffling, requires tissues    
3 = Severe: nose runs freely despi[INVESTIGATOR_318176]    
D. Laryngeal  (only symptoms due to  laryngeal edema)  +2 +1 
0 = Absent    
1 = Mild: throat clearing, occasional cough    
2 = Moderate: hoarseness, frequent dry cough    
3 = Severe: inspi[INVESTIGATOR_322233]    
E. Conjunctivitis (see example below)   +3 +2 
0 = Absent    
1 = Mild:    
2 = Moderate:    
3 = Severe:    
 
 Grade 1  Grade 2  Grade 3  
 
III. LOWER RESPI[INVESTIGATOR_322234]:  
minimal # of grade 
increase  
 Alone  Associated  
A. Wheezing  (including cough due to bronchospasm)  +1 +1 
0 = Absent    
1 = Mild: expi[INVESTIGATOR_322235]    
2 = Moderate: dyspnea, inspi[INVESTIGATOR_318179]    
3 = Severe: dyspnea, use of accessory muscles, audible wheezing    
 
IV. GASTROINTESTINAL  
 Stoppi[INVESTIGATOR_004]:  
minimal # of grade 
increase  
 Alone  Associated  
A. Subjective Complaints  +3 +2 
0 = Absent    
1 = Mild: itchy mouth/throat, c/o nausea, abdominal pain, no change in activity    
2 = Moderate: frequent c/o nausea or abdominal pain, decreased activity    
3 = Severe: patient in bed; crying, notably distressed    
B. Objective Complaints  +1 +1 
0 = Absent    
1 = Mild: 1 epi[INVESTIGATOR_322236]* or diarrhea    
2 = Moderate: 2 -3 epi[INVESTIGATOR_322237]* or diarrhea or 1 of each    
3 = Severe: >3 epi[INVESTIGATOR_322237]* or diarrhea or 2 of each    
* Emesis to be differentiated from â€œspi[INVESTIGATOR_22940] -upâ€ due to food intolerance while feeding.  
  

Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 133 of 170 
 
V. CARDIOVASCULAR/NEUROLOGIC  
 Stoppi[INVESTIGATOR_004]:  
minimal # of grade 
increase  
 Alone  Associated  
Cardiovascular/neurologic  +1 +1 
0 = Normal: heart rate or BP for age/baseline    
1 = Mild: color change, subjective response (weak, dizzy), or tachycardia, 
mental status change, mild hypotension (weak rapid pulse and/or 10 -20% 
drop in blood pressure from baseline)    
2 = Moderate: drop in blood pressure >20% from baseline, significant change 
in mental status, light -headedness, feeling of â€œpending doomâ€    
3 = Severe: cardiovascular collapse, signs of impaired circulation, 
unconsciousness, bra dycardia, cardiac arrest.    
 
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 134 of 170 
14.3 Quality of Life Questionnaire Forms  
14.3.1  Food Allergy Quality of Life Questionnaire -Child Form  (FAQLQ -CF) 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 135 of 170 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAQLQ -CF 
Food Allergy  Quality of Life Questionnaire â€“  
Child Form (8 -12 years)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To cite this questionnaire:  
Flokstra -de Blok BMJ,  DunnGalvin A, Vlieg -Boerstra BJ, Oude Elberink JNG, Duiverman EJ, 
Hourihane JO, Dubois AEJ. Development and validation of a self -administered Food Allergy 
Quality of Life Questionnaire for children. Clin Exp Allergy 2009 Jan;39(1):127 -137.  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 136 of 170 
 
The questions are about the influence of your food allergy on your quality of life. It is 
important that you fill in the answers yourself. You may ask your parents for help, but 
they are not allowed to tell you which answer to give. Answer every question by [CONTACT_322285] â€˜xâ€™ in the proper box. You may choose from the following answers.  
       
not barely  a little bit  fairly  quite  very  extremely  
 
 
How troublesome  do you find it, because of your food 
allergy, that you â€¦         
[ADDRESS_397841] always watch what you eat?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
2 can eat fewer things?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
3 are limited in buying things you like?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397842] to read labels?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397843] to refuse food when you do things with others?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
6 can less easily stay for a meal with someone?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
7 can taste or try fewer things when eating out?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397844] to tell beforehand about what you are not allowed 
to eat when eating out?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397845] to check yourself whether you can eat something 
when eating out?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
10 hesitate eating certain foods when you donâ€™t know if it 
is safe?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397846] watch out when touching certain foods?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
12 donâ€™t get anything when someone is giving treats at 
school?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
  

Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 137 of 170 
       
not barely  a little bit  fairly  quite  very  extremely  
 
 
How troublesome  is it, because of your food allergy, â€¦         
13 that the ingredients of a food change?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
14 that the label states: â€œMay contain (traces of)â€¦.â€?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397847] a food allergy?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397848] a food 
allergy?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
17 that others can eat the food you are allergic to when you 
do things with other people?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
18 that you donâ€™t know how things taste which you canâ€™t 
eat?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
How frightened  are you because of your food allergy â€¦         
19 of an allergic reaction?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
20 of eating the wrong food by [CONTACT_21317]?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397849] never eaten before?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
Answer the following questions:         
22 How concerned  are you that you will never get rid of your 
food allergy?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
23 How disappointed  are you when people donâ€™t take your 
food allergy into account?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397850] a food 
allergy?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 

Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 138 of 170 
Food Allergy Independent Measure â€“ Child Form (8 -12 years)  
The following four questions are about the chance that you think you have of 
something happening to you because of your food allergy. Choose one of the answers. 
This is followed by [CONTACT_322286]. Answer every question 
by [CONTACT_81611] â€˜ xâ€™ in the box next to the p roper answer  
 
0 1 2 3 4 5 6 
never 
(0% chance)  very small 
chance  small 
chance  fair 
chance  big 
chance  very big 
chance  always 
(100%  chance)  
 
How big do you think the chance is that you â€¦  0 1  2  3  4  5 6  
1 will accidentally eat something to which you are allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397851] a severe reaction if you accidentally eat 
something to which you are allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
3 will die if you accidentally eat something to which you are 
allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
4 can not do the right things for your allergic reaction 
should you accidentally eat something to which you are 
allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
5. How many foods are you unable to 
eat because of your food allergy?  6. Everyone does things with other people, such as;  
- playing with friends,  
- going to a birthday party,  
- visiting,  
- staying over with someone for a meal or eating 
out. 
 
How much does your food allergy affect things you 
do with others?  
ï‚¨  almost none  
ï‚¨  very few  
ï‚¨  a few  
ï‚¨  some  
ï‚¨  many  
ï‚¨  very many  
ï‚¨  almost all  ï‚¨  so little I donâ€™t actually notice it  
ï‚¨  very little  
ï‚¨  little  
ï‚¨  moderately  
ï‚¨  a good deal  
ï‚¨  a great deal  
ï‚¨  a very great deal  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 139 of 170 
 
14.3.2  Food Allergy Quality of Life Questionnaire -Teenage r Form  (FAQLQ -TF) 
 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 140 of 170 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAQLQ -TF 
Food Allergy Quality of Life Questionnaire â€“  
Teenager Form (13 -17 years)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To cite this questionnaire:  
Flokstra -de Blok BMJ, DunnGalvin  A, Vlieg -Boerstra BJ, Oude Elberink JNG, Duiverman EJ, 
Hourihane JO, Dubois AEJ. Development and validation of the self -administered Food Allergy 
Quality of Life Questionnaire for adolescents. J Allergy Clin Immunol 2008 Jul;122(1):139 -
144.  
6SRQVRU'%97HFKQRORJLHV  
$PHQGPHQW0,/(6 )LQDO9HUVLRQ -XQH 
&RQILGHQWLDO 3DJHRI 
 
The following questions concern the influence your  food allergy has on your quality of life. 
Answer every question by [CONTACT_322287] e box with an â€˜xâ€™. You may choose from one 
of the following answers.  
0 1 2 3 4 5 6 
not barely slightly moderately quite very extremely 

How troublesome  do you find it, because of your food 
allergy, that you â€¦  [ADDRESS_397852] always be alert as to what you are eating? Â… Â… Â… Â… Â… Â… Â… 
2 are able to eat fewer products? Â… Â… Â… Â… Â… Â… Â… 
3 are limited as to the products you can buy? Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397853] read labels? Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397854] less control of what you eat when eating out?
 Â… Â… Â… Â… Â… Â… Â… 
6 are less able to spontaneously accept an invitation to stay for a meal?
 Â… Â… Â… Â… Â… Â… Â… 
7 are less able to taste or try various products when eating 
out?  Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397855] check yourself whether you can eat something 
when eating out?  Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397856] doubts about 
it? Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397857] refuse treats at school or work? Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397858] be careful about touching certain foods?  Â… Â… Â… Â… Â… Â… Â… 
[ADDRESS_397859] carry an epi[INVESTIGATOR_322238]  
? (If you donâ€™t have an epi[INVESTIGATOR_322239] â€˜xâ€™ here Â… ) Â… Â… Â… Â… Â… Â… Â… 

CCI
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 142 of 170 
0 1 2 3 4 5 6 
not barely  slightly  moderately  quite  very  extremely  
 
How troublesome  is it, because of your food allergy, â€¦  0 1 2 3 4 5 6 
13 that the ingredients of a food change?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
14 that the label states: â€œMay contain (traces of)â€¦.â€?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
15 that the labeling of the bulk packaging (for example box or 
bag) is different than the individual packages?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397860] a food allergy?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
17 that during social activities others can eat the food to 
which you are allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
18 that during social activities your food allergy is not taken 
into account enough?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
How frightened  are you because of your food allergy â€¦  0 1 2 3 4 5 6 
19 of an allergic reaction?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
20 of accidentally eating the wrong food?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397861] never eaten before?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
Answer the following questions:  0 1 2 3 4 5 6 
22 How discouraged  do you feel during an allergic reaction?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
23 How disappointed  are you when people donâ€™t take your 
food allergy into account?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 143 of 170 
Food Allergy Independent Measure â€“ Teenager  Form ( 13-17 years)  
The following four questions are about the chance that you think you have of something 
happening to you because of your food allergy. Choose one of the answers. This is followed by 
[CONTACT_322286]. Answer every question by [CONTACT_81611] â€˜xâ€™ in the 
box next to the proper answer.  
 
0 1 2 3 4 5 6 
never 
(0% chance)  very small 
chance  small 
chance  fair 
chance  great  
chance  very great  
chance  always 
(100%  chance)  
 
How great do you think the chance is that you â€¦  0 1  2  3  4  5 6  
1 will accidentally eat something to which you are 
allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
[ADDRESS_397862] a severe reaction if you accidentally eat 
something to which you are allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
3 will die if you accidentally eat something to which you 
are allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
4 can not effectively deal with an allergic reaction should 
you accidentally eat something to which you are 
allergic?  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
 5.  How many products must you avoid because 
of your food allergy?   6.  How great is the impact of your 
food allergy on your social life?  
 
ï‚¨  almost none  
ï‚¨  very few   
ï‚¨  negligibly small  
ï‚¨  very small  
ï‚¨  a few  ï‚¨  small  
ï‚¨  some  ï‚¨  moderate  
ï‚¨  many  ï‚¨  great  
ï‚¨  very many  ï‚¨  very great  
ï‚¨  almost all  ï‚¨  extremely great  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 144 of 170 
 
14.3.3  Food Allergy Quality of Life Questionnaire â€“ Parent Form for Children 
(FAQLQ -PF) 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 145 of 170 
 
  
 
 
 
 
 
 
FAQLQ -PF 
 
 
 
Food Allergy Qual ity of Life Questionnaire â€“  
Parent  Form ( 0-12 years)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To cite this questionnaire:  
DunnGalvin A, Flokstra -de Blok BMJ, Burks AW, Dubois AEJ, Hourihane JO. Food allergy QoL 
questionnaire for children aged 0 -12 years: content, c onstruct, and cross -cultural validity. Clin Exp 
Allergy 2008 Jun;38(6):977 -986. 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 146 of 170 
 
 
Food Allergy Quality of Life Questionnaire -Parent 
Form  
(FAQoL -PF) 
Children aged 0 -12 years  
 
 
 
 
Instructions to Parents  
 
â€¢ The following are scenarios that parents have told us affect childrenâ€™s quality of life because 
of food allergy.  
 
â€¢ Please indicate how much of an impact  each scenario has on  
your childâ€™s quality of life  by [CONTACT_1299] a tick  
or an x in one of the boxes numbered  0-6.   
 
 
 
 
 
 
All information given is completely confidential.  
This questionnaire will only be identified by a code number.  Response Options  
0 = not at all  
1= a little bit  
2 = slightly  
3 = moderately  
4 = quite a bit  
5 = very much  
6 = extremely  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 147 of 170 
 
â€¢ If your child is aged 0 to 3 years , please answer Section A . 
â€¢ If your child is aged 4 to 6 years , please answer Section A &  Section B . 
â€¢ If your child is aged 7 years and over , please answer Section A, Section B & Section  C. 
SECTION A  Not at all  Extremely  
Because of food allergy, my child feels â€¦ 0 1 2 3 4 5 6 
1 Anxious about food  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
2 Different from other children  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
3 Frustrated by [CONTACT_322288]  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
4 Afraid to try unfamiliar foods  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
5 Concerned that I am worried that he/she will have a 
reaction to food  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 Not at all  Extremely  
Because of food allergy, my child â€¦ 0 1 2 3 4 5 6 
6 Experiences physical distress  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
7 Experiences emotional distress  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
8 Has a lack of variety in his /her diet  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 Not at all  Extremely  
Because of food allergy, my child has been negatively 
affected by â€¦ 0 1 2 3 4 5 6 
9 Receiving more attention more attention than other children 
of his/her age  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
10 Having to grow up more quickly than other children of 
his/her age  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
11 His/her environment being more restricted than other 
children of his/her age  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 Not at all  Extremely  
 Not at all  Extremely  
 
â€¢ If your child is aged 0 to 3 years , please now go to Section D.  
â€¢ If your child is aged 4 to 12 years , please now answer  Section B.  Because of food allergy, my childâ€™s social environment 
is restricted because of limitations on â€¦ 0 1 2 3 4 5 6 
12 Restaurants we can safely go to as a family  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
13 Holiday destinations we can safely go to as a family  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
Because of food allergy, my childâ€™s ability to take part 
has been limited â€¦ 0 1 2 3 4 5 6 
14 In social activities in other peopleâ€™s houses ( sleepovers, 
parties, playtime )  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 148 of 170 
SECTION B  Not at all  Extremely  
 Not at all  Extremely  
Because of food allergy, my child feels â€¦ 0 1 2 3 4 5 6 
16 Anxious when going to new places  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
17 Concerned that he/she must always be cautious about food  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
18 â€˜Left outâ€™ in activities involving food  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
19 Upset that family social outings (eating out, celebrations, 
days out) have been limited by [CONTACT_322289]  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
20 Anxious about accidentally eating an ingredient to which 
he/she is allergic  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
21 Anxious when eating with unfamiliar adults/children  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
22 Frustrated by [CONTACT_322290]  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 Not at all  Extremely  
Because of food allergy, my child â€¦ 0 1 2 3 4 5 6 
23 Is more anxious in general than other children of his/her 
age ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
24 Is more cautious in general than other children of his/her 
age ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
25 Is not as confident as other children of his/her age in social 
situations  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
26 Wishes his/her food allergy would go away  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
 
â€¢ If your child is aged 6 years and under , please now go to Section D . 
â€¢ If your child is aged 7 years and older , please answer Section C . 
 
 
  Because of food allergy, my childâ€™s ability to take part 
has been limited â€¦ 0 1 2 3 4 5 6 
15 In preschool/school events involving food (class 
parties/treats/lunchtime)   ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 149 of 170 
SECTION C  Not at all  Extremely  
Because of food allergy, my child  feelsâ€¦  0 1 2 3 4 5 6 
27 Worried about his/her future  (opportunities, relationships)  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
28 That many people do not understand the serious nature of 
food allergy  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
29 Concerned  by [CONTACT_322291]  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
30 That food allergy limits his/her life in general  ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ ï‚¨ 
 
SECTION D   
 
 
Please answer the following questions with reference to the  
7-point scale on the right  
 
 
 
Q1. What chance do you think  your child has of â€¦.?  
 
 Question  7-point Scale  
0 1 2 3 4 5 6 
1 â€¦â€¦accidentally ingesting the food to which they are allergic?         
2 â€¦â€¦having a severe reaction if food is accidentally ingested?  
        
3 â€¦â€¦dying from his/her food allergy fo llowing ingestion in the 
future ?        
4 â€¦â€¦effectively treating him/herself, or receiving effective 
treatment from others (including Epi[INVESTIGATOR_322240]), if 
he/she accidentally ingests a food to which he/she is allergic?         
 
 
Q2. What chance does your child think  he/she has of â€¦â€¦?  
 
 Question  7-point Scale  
0 1 2 3 4 5 6 
1 â€¦â€¦accidentally ingesting the food to which they are allergic?   
       
2 â€¦â€¦having a severe reaction if food is accidentally ingested?  
        
3 â€¦â€¦dying from his/her food allergy fo llowing ingestion in the 
future ?  
       
4 â€¦â€¦effectively treating him/herself, or receiving effective 
treatment from others (including Epi[INVESTIGATOR_322240]), if 
he/she accidentally ingests a food to which he/she is allergic?         
 0 = extremely unlikely  
1 = very unlikely  
2 = somewhat unlikely  
3 = likely  
4 = quite likely  
5 = very likely  
6 = extremely likely  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 150 of 170 
 
14.3.4  Food Allergy Quality of Life Questionnaire â€“ Parent Form for Teenagers 
(FAQLQ -PFT) 
  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 151 of 170 
 
 
  
 
 
 
 
 
 
FAQLQ -PFT  
 
 
Food Allergy Quality of Life Questionnaire â€“ 
Parent Form â€“ Adolescents aged 13 -17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To cite the original English questionnaire:  
Knibb et al., unpublished  
 
To cite the Dutch translated questionnaire:  
van der Velde JL, Flokstra -de Blok BMJ, Hamp A, Knibb RC, Duiverman EJ, Dubois AEJ. Adolescent -parent disagreement on 
quality of life of food allergic adolescents; Who makes the difference? Allergy. 2011  
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 152 of 170 
 
 
  
 
 
      
     
   
          
         
 
           
             
       
            
             
           
    
  
    
   
   
   
    
   
   
      
          
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 153 of 170 
 
 
  
 
 
      
        
               
   
          
       
     
       
    
      
      
  
       
  
      
     
       
 
       
     
   
       
      
 
       
   
       
 
       
     
      
     
   
      
 
        
     
      
     
    
       
  
      
       
   
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 154 of 170 
 
 
  
 
 
        
  
  
          
                  
 
        
 
       
       
 
       
    
      
       
   
      
  
         
      
 
       
    
      
    
      
   
       
     
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 155 of 170 
Please answer these questions with reference to the 7 -point scale below.  
0 = extremely unlikely  
1 = very unlikely  
2 = somewhat unlikely  
3 = likely  
4 = quite likely  
5 = very likely  
6 = extremely likely  
 
 Question  7-point Scale  
0 1 2 3 4 5 6 
1. What chance do you think your teenager has of 
accidentally ingesting the food to which they are 
allergic?         
2. What chance do you think your teenager has of having 
a severe reaction if food is accidentally ingested?         
3. What chance do you think your teenager has of dying 
from his/her food allergy following ingestion in the 
future?         
4. What chance do you think your teenager has of 
effectively treating him/herself or receiving effective 
treatment from others (including Epi[INVESTIGATOR_322241]) if he/she accidentally ingests a food to 
which he/she is allergic?         
 
   
 
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 156 of 170 
 
14.4 Anaphylaxis Staging System  
Anaphylaxis is a generalized allergic reaction that is rapid in onset and may progress to 
death . The stages of severity for anaphylaxis reactions are presented below.  
Staging System of Severity of Anaphylaxis  
Stage  Defined By  
1. Mild (skin and subcutaneous tissues, 
Gastrointestinal , and/or mild 
respi[INVESTIGATOR_696])  Flushing, urticaria, periorbital or facial 
angioedema; mild dyspnea, wheeze or 
upper respi[INVESTIGATOR_1856]; mild 
abdominal pain and/or emesis . 
 
2. Moderate (mild symptoms + features 
suggesting moderate respi[INVESTIGATOR_696], 
cardiovascular or G astrointestinal  
symptoms)  Marked dysphagia, hoarseness, and/or 
stridor; shortness of breath, wheezing & 
retractions; crampy abdominal pain, 
recurrent vomiting and/or diarrhea; and/or 
mild dizziness . 
 
3. Severe (hypoxia, hypotension, or 
neurological compromise)  Cyanosis or SpO 2 <92% at any stage, 
hypotension, confusion, collapse, loss of 
consciousness; or incontinence . 
  
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 157 of 170 
14.5 Anaphylaxis Emergency Action Plan  
Example Form: ANAPHYLAXIS EMERGENCY ACTION PLAN  
 
 
  
 
 
  
  
        
     
    
    
       
    
     
    
      
      
             
         
   
           
  
           
         
   
      
      
      
      
 
         
      
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 161 of 170 
14.8 Declaration of Helsinki   
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 162 of 170 
 
 
 
     
     
  
            
    
        
         
        
             
         
           
  
            
           
         
 
            
            
        
               
           
             
            
        
  
              
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 163 of 170 
 
 
               
              
   
               
             
            
            
   
            
           
         
            
      
            
           
             
             
  
                
           
           
            
            
 
           
             
           
            
       
            
    
           
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 164 of 170 
 
 
          
            
          
           
      
           
               
             
              
       
            
        
    
            
  
           
             
            
             
             
        
            
        
             
              
  
              
           
      
    
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 165 of 170 
 
 
            
          
         
 
              
               
              
           
     
          
            
           
           
  
            
          
           
             
        
          
            
       
           
  
   
          
            
             
              
               
              
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 166 of 170 
 
 
               
        
            
          
             
             
              
    
   
             
       
  
            
             
            
            
           
            
            
            
             
               
              
            
            
           
           
            
           
 
            
         
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 167 of 170 
 
 
            
             
             
            
     
             
           
               
               
            
             
  
             
             
              
        
            
             
           
            
           
             
            
              
             
               
      
              
                
            
  
            
            
             
           
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 168 of 170 
 
 
             
        
   
             
            
 
             
  
          
                
            
            
               
             
           
  
            
            
              
        
       
 
             
        
          
             
              
            
            
             
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 169 of 170 
 
  
 
 
           
              
          
     
             
            
            
            
           
           
              
     
            
             
          
               
          
        
        
       
 
Sponsor: DBV Technologies    
Amendment 6: MILES  Final Version 6.0  24 June 2019  
Confidential  Page 170 of 170 
14.9 Reference Safety Information for  the Cowâ€™s Milk Food Challenge  in the MILES 
study  
In the context of DBV135 (Viaskin Milk) clinical development, a for mulated recipe of food 
challenge has been developed by [CONTACT_322292] -Blind Placebo -
Controlled Food Challenge (DBPCFC) procedure  in clinical trials .  
The food challenge kits, containing the low and high dose of cowâ€™s milk protein and 
placebo formulas, are provided to all sites participating in the Viaskin Milk clinical studies 
where DBPCFCs procedures are conducted according to a specific Manual of 
Procedure.  
The Food Challenge is  a non -authorized product  used to produce a physiological 
response that is relevant to the design of the clinical trial.  
All serious adverse events (SAE), including anaphylactic reaction s and allergic 
symptoms,  that occur during  the Food Challenge procedures, are elicited events to either 
diagnose the food allergy or to assess the efficacy of the corresponding Investigational 
Medicinal Product (Viaskin Milk). Therefore, they are considered as expected by 
[CONTACT_108].  
Only death occurring within the context of the DBPCFC procedure or any SAE with the 
outcome â€œDeathâ€ related to Food Challenge will be considered as unexpected and 
considered as suspected unexpected serious adverse reaction for expedited reporting 
purpose.  
 